

CITATION REPORT

List of articles citing

Comprehensive molecular portraits of human breast tumour

DOI: 10.1038/nature11412
Nature, 2012, 490, 61-70.

Source: <https://exaly.com/paper-pdf/53733520/citation-report.pdf>

Version: 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

| # | Paper | IF | Citations |
|------|-------------------------------------------------------------------------------------------------------------------------------------|----|-----------|
| 2277 | . | | |
| 2276 | Influence of Zero Locations on the Number of Extrema in the Step Response. 1991 , | | 27 |
| 2275 | Blank page [back cover]. 1994 , 9, c4-c4 | | |
| 2274 | Chapter 14: Cancer genome analysis. 2012 , 8, e1002824 | | 12 |
| 2273 | Climacteric Commentaries. 2012 , 16, 194-200 | | |
| 2272 | La formalisation de la GRH dans une PME comme enjeu d'une certification RSE. 2012 , 83, 20 | | 6 |
| 2271 | Tendon injuries of the hand in athletes. 2012 , 11, 201-213 | | 1 |
| 2270 | Running m(o)TOR with the brakes on leads to catastrophe at mitosis. 2012 , 11, 4494 | | 3 |
| 2269 | Micromanaging a large tumor suppressor. 2012 , 11, 4497 | | |
| 2268 | Mesenchymal traits and cancer stem cells in mammospheres: chicken or egg?. 2012 , 11, 4498 | | 1 |
| 2267 | Advances in Breast Cancer - Looking Back over the Year. 2012 , 72, 1117-1129 | | 16 |
| 2266 | The many roads to checkpoint activation. 2012 , 11, 4495 | | 3 |
| 2265 | Alteration/deficiency in activation 3 (ADA3): Regulator of DNA repair and genome stability. 2012 , 11, 4496 | | |
| 2264 | Kits herald new wave of genomics diagnostics for cancer. 2012 , 30, 1152-4 | | |
| 2263 | Field cancerization in mammary carcinogenesis - Implications for prevention and treatment of breast cancer. 2012 , 93, 391-8 | | 39 |
| 2262 | Molecular pathology of breast cancer: what a pathologist needs to know. 2012 , 138, 770-80 | | 66 |
| 2261 | Breakthroughs in genomics data integration for predicting clinical outcome. 2012 , 45, 1199-201 | | 12 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 2260 | Regulation of mRNA expression in breast cancer - a cis-tematic trans-action. 2012 , 14, 322 | 1 |
| 2259 | Genomic aberrations in normal tissue adjacent to HER2-amplified breast cancers: field cancerization or contaminating tumor cells?. 2012 , 136, 693-703 | 14 |
| 2258 | Frequent mutational activation of the PI3K-AKT pathway in trastuzumab-resistant breast cancer. 2012 , 18, 6784-91 | 138 |
| 2257 | SnapShot: breast cancer. 2012 , 22, 562-562.e1 | 54 |
| 2256 | ChIPing away at breast cancer. 2012 , 13, 1185-7 | 5 |
| 2255 | DriverNet: uncovering the impact of somatic driver mutations on transcriptional networks in cancer. 2012 , 13, R124 | 156 |
| 2254 | Molecular cytogenetics as a clinical test for prognostic and predictive biomarkers in newly diagnosed ovarian cancer. 2013 , 6, 2 | 6 |
| 2253 | Combinatorial targeting of FGF and ErbB receptors blocks growth and metastatic spread of breast cancer models. 2013 , 15, R8 | 56 |
| 2252 | Patchwork: allele-specific copy number analysis of whole-genome sequenced tumor tissue. 2013 , 14, R24 | 51 |
| 2251 | The T-box transcription factors TBX2 and TBX3 in mammary gland development and breast cancer. 2013 , 18, 143-7 | 49 |
| 2250 | Emerging Concepts in Breast Cancer Risk Prediction. 2013 , 2, 43-52 | 6 |
| 2249 | Systemic treatment after whole-brain radiotherapy may improve survival in RPA class II/III breast cancer patients with brain metastasis. 2013 , 114, 181-9 | 12 |
| 2248 | A conceptual and methodological framework for investigating etiologic heterogeneity. 2013 , 32, 5039-52 | 19 |
| 2247 | A meta-analysis of gene expression-based biomarkers predicting outcome after tamoxifen treatment in breast cancer. 2013 , 140, 219-32 | 140 |
| 2246 | A survey of immunohistochemical biomarkers for basal-like breast cancer against a gene expression profile gold standard. 2013 , 26, 1438-50 | 47 |
| 2245 | Role of ABL family kinases in cancer: from leukaemia to solid tumours. 2013 , 13, 559-71 | 280 |
| 2244 | An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. 2013 , 45, 970-6 | 774 |
| 2243 | Tumor growth dynamics: insights into evolutionary processes. 2013 , 28, 597-604 | 77 |

| | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 2242 | Relapsed triple-negative breast cancer: challenges and treatment strategies. 2013 , 73, 1257-65 | 34 |
| 2241 | Hsp90, an unlikely ally in the war on cancer. 2013 , 280, 1381-96 | 142 |
| 2240 | The emerging role of the molecular diagnostics laboratory in breast cancer personalized medicine. 2013 , 183, 1075-1083 | 28 |
| 2239 | Next generation sequencing in cancer research and clinical application. 2013 , 15, 4 | 76 |
| 2238 | Revealing selection in cancer using the predicted functional impact of cancer mutations. Application to nomination of cancer drivers. 2013 , 14 Suppl 3, S8 | 11 |
| 2237 | miRConnect 2.0: identification of oncogenic, antagonistic miRNA families in three human cancers. 2013 , 14, 179 | 16 |
| 2236 | Gene rearrangements in hormone receptor negative breast cancers revealed by mate pair sequencing. 2013 , 14, 165 | 28 |
| 2235 | Interplay between estrogen receptor and AKT in estradiol-induced alternative splicing. 2013 , 6, 21 | 19 |
| 2234 | Signaling pathway switch in breast cancer. 2013 , 13, 66 | 22 |
| 2233 | Luminal breast cancer: from biology to treatment. 2013 , 10, 494-506 | 123 |
| 2232 | Next generation analysis of breast cancer genomes for precision medicine. 2013 , 339, 1-7 | 19 |
| 2231 | Discovery of a Potent Anti-tumor Agent through Regioselective Mono--acylation of 7-Pyrrolo[3,2-]quinazoline-1,3-diamine. 2013 , 4, 1275-1282 | 9 |
| 2230 | A new genome-driven integrated classification of breast cancer and its implications. 2013 , 32, 617-28 | 212 |
| 2229 | Amplification of distant estrogen response elements deregulates target genes associated with tamoxifen resistance in breast cancer. 2013 , 24, 197-212 | 42 |
| 2228 | NF- κ B non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. 2013 , 4, 2299 | 131 |
| 2227 | MuPIT interactive: webserver for mapping variant positions to annotated, interactive 3D structures. 2013 , 132, 1235-43 | 56 |
| 2226 | The complex genetic landscape of familial breast cancer. 2013 , 132, 845-63 | 94 |
| 2225 | Evaluating the repair of DNA derived from formalin-fixed paraffin-embedded tissues prior to genomic profiling by SNP-CGH analysis. 2013 , 93, 701-10 | 21 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------|-----|
| 2224 | ROCK: a resource for integrative breast cancer data analysis. 2013 , 139, 907-21 | 27 |
| 2223 | Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype. 2013 , 139, 691-703 | 21 |
| 2222 | Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. 2013 , 14, 853-62 | 248 |
| 2221 | Finding the lost treasures in exome sequencing data. 2013 , 29, 593-9 | 105 |
| 2220 | The management of early-stage and metastatic triple-negative breast cancer: a review. 2013 , 27, 737-49, viii | 64 |
| 2219 | Next Generation Sequencing in Cancer Research. 2013 , | 4 |
| 2218 | Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. 2013 , 109, 827-35 | 79 |
| 2217 | The cell's nucleolus: an emerging target for chemotherapeutic intervention. 2013 , 8, 1441-9 | 41 |
| 2216 | Connecting the dots: applications of network medicine in pharmacology and disease. 2013 , 94, 659-69 | 23 |
| 2215 | The RasGAP gene, RASAL2, is a tumor and metastasis suppressor. 2013 , 24, 365-78 | 102 |
| 2214 | Individualised proteome profiling of human endometrial tumours improves detection of new prognostic markers. 2013 , 109, 704-13 | 11 |
| 2213 | Genexpressionssignaturen beim Mammakarzinom. 2013 , 19, 465-470 | |
| 2212 | Metastasiertes Mammakarzinom. 2013 , 19, 487-493 | |
| 2211 | Hoffnung aus der Grundlagenforschung. 2013 , 19, 66-68 | |
| 2210 | Identification of thresholds for dichotomizing DNA methylation data. 2013 , 2013, 8 | 8 |
| 2209 | Selection of bone metastasis seeds by mesenchymal signals in the primary tumor stroma. 2013 , 154, 1060-1073 | 296 |
| 2208 | Duration of trastuzumab for HER2-positive breast cancer. 2013 , 14, 678-9 | 3 |
| 2207 | Exploring novel targets of basal-like breast carcinoma by comparative gene profiling and mechanism analysis. 2013 , 141, 23-32 | 3 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 2206 | Deciphering and reversing tumor immune suppression. 2013 , 39, 61-73 | 392 |
| 2205 | Targeting caspases in cancer therapeutics. 2013 , 394, 831-43 | 109 |
| 2204 | Controversies regarding mammography, breast self-examination, and clinical breast examination. 2013 , 40, 413-27 | 12 |
| 2203 | Combined Wnt/ β -catenin, Met, and CXCL12/CXCR4 signals characterize basal breast cancer and predict disease outcome. 2013 , 5, 1214-27 | 57 |
| 2202 | Triple-negative breast cancer and the need for new therapeutic targets. 2013 , 183, 1064-1074 | 110 |
| 2201 | 27-Hydroxycholesterol promotes cell-autonomous, ER-positive breast cancer growth. 2013 , 5, 637-45 | 230 |
| 2200 | Endocrine resistance in breast cancer: focus on the phosphatidylinositol 3-kinase/akt/mammalian target of rapamycin signaling pathway. 2013 , 8, 248-55 | 32 |
| 2199 | Advances in molecular and clinical subtyping of breast cancer and their implications for therapy. 2013 , 22, 823-40 | 22 |
| 2198 | Beyond BRCA1/2: polygenic, 'polyfunctional' molecular circuitry model to predict breast cancer risk. 2013 , 7, 675-8 | 2 |
| 2197 | Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. 2013 , 14, 1183-92 | 268 |
| 2196 | Introduction to epidemiology of breast and ovarian cancers. 2013 , 24 Suppl 8, viii61-viii62 | 2 |
| 2195 | A gene signature for late distant metastasis in breast cancer identifies a potential mechanism of late recurrences. 2013 , 7, 987-99 | 29 |
| 2194 | Phosphatase and tensin homolog deficiency and resistance to trastuzumab and chemotherapy. 2013 , 31, 2073-5 | 10 |
| 2193 | Crossing the omic chasm: a time for omic ancillary systems. 2013 , 309, 1237-8 | 66 |
| 2192 | Mutational analysis of breast cancer: guiding personalized treatments. 2013 , 22 Suppl 2, S19-21 | 12 |
| 2191 | Differences that matter in cancer genomics. 2013 , 31, 892-3 | 2 |
| 2190 | Pattern Recognition in Bioinformatics. 2013 , | 1 |
| 2189 | DGIdb: mining the druggable genome. 2013 , 10, 1209-10 | 317 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 2188 | MicroRNA signatures in hereditary breast cancer. 2013 , 142, 19-30 | 28 |
| 2187 | MicroRNA-based molecular classification of non-BRCA1/2 hereditary breast tumours. 2013 , 109, 2724-34 | 22 |
| 2186 | Inferring tumour purity and stromal and immune cell admixture from expression data. 2013 , 4, 2612 | 2572 |
| 2185 | Photoacoustic and photothermal detection of circulating tumor cells, bacteria and nanoparticles in cerebrospinal fluid in vivo and ex vivo. 2013 , 6, 523-33 | 54 |
| 2184 | Optimal sequencing of anti-HER2 therapy throughout the continuum of HER2-positive breast cancer: evidence and clinical considerations. 2013 , 73, 1665-80 | 6 |
| 2183 | Cumulative haploinsufficiency and triplosensitivity drive aneuploidy patterns and shape the cancer genome. 2013 , 155, 948-62 | 478 |
| 2182 | Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. 2013 , 24, 2206-23 | 2048 |
| 2181 | Molecular pathways: PI3K pathway targets in triple-negative breast cancers. 2013 , 19, 3738-44 | 49 |
| 2180 | Cancer genome landscapes. 2013 , 339, 1546-58 | 5058 |
| 2179 | Identification of FDA-approved drugs targeting breast cancer stem cells along with biomarkers of sensitivity. 2013 , 3, 2530 | 49 |
| 2178 | Safety and efficacy of neratinib in combination with weekly paclitaxel and trastuzumab in women with metastatic HER2-positive breast cancer: an NSABP Foundation Research Program phase I study. 2013 , 72, 1205-12 | 52 |
| 2177 | ESR1 ligand-binding domain mutations in hormone-resistant breast cancer. 2013 , 45, 1439-45 | 754 |
| 2176 | Activating ESR1 mutations in hormone-resistant metastatic breast cancer. 2013 , 45, 1446-51 | 742 |
| 2175 | 'Rapid Learning health care in oncology' - an approach towards decision support systems enabling customised radiotherapy'. 2013 , 109, 159-64 | 147 |
| 2174 | Wip1 controls global heterochromatin silencing via ATM/BRCA1-dependent DNA methylation. 2013 , 24, 528-41 | 49 |
| 2173 | MAP3K1: Genomic Alterations in Cancer and Function in Promoting Cell Survival or Apoptosis. 2013 , 4, 419-26 | 70 |
| 2172 | The somatic genomic landscape of glioblastoma. 2013 , 155, 462-77 | 2900 |
| 2171 | Systems approaches to human autoimmune diseases. 2013 , 25, 598-605 | 9 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 2170 | Network medicine in disease analysis and therapeutics. 2013 , 94, 627-9 | 26 |
| 2169 | Profiles of Basal and stimulated receptor signaling networks predict drug response in breast cancer lines. 2013 , 6, ra84 | 75 |
| 2168 | Pan-cancer patterns of somatic copy number alteration. 2013 , 45, 1134-40 | 1198 |
| 2167 | Network-based stratification of tumor mutations. 2013 , 10, 1108-15 | 546 |
| 2166 | Impact and Challenges in Assessing Tumor Purity by Next-Generation Sequencing. 2013 , 359-371 | |
| 2165 | Noninvasive detection of HER2 amplification with plasma DNA digital PCR. 2013 , 19, 3276-84 | 137 |
| 2164 | Germline and somatic KLLN alterations in breast cancer dysregulate G2 arrest. 2013 , 22, 2451-61 | 14 |
| 2163 | Personalized reproductive medicine on the brink: progress, opportunities and challenges ahead. 2013 , 27, 611-23 | 9 |
| 2162 | Origins of metastatic traits. 2013 , 24, 410-21 | 367 |
| 2161 | Expression of polycomb targets predicts breast cancer prognosis. 2013 , 33, 3951-61 | 28 |
| 2160 | Mutational landscape and significance across 12 major cancer types. <i>Nature</i> , 2013 , 502, 333-339 | 50.4 2803 |
| 2159 | The search for ESR1 mutations in breast cancer. 2013 , 45, 1415-6 | 47 |
| 2158 | Combination of antibody that inhibits ligand-independent HER3 dimerization and a p110 α inhibitor potently blocks PI3K signaling and growth of HER2+ breast cancers. 2013 , 73, 6013-23 | 72 |
| 2157 | The molecular diversity of Luminal A breast tumors. 2013 , 141, 409-20 | 90 |
| 2156 | Molecular and cellular heterogeneity in breast cancer: challenges for personalized medicine. 2013 , 183, 1113-1124 | 157 |
| 2155 | Genetic susceptibility to triple-negative breast cancer. 2013 , 73, 2025-30 | 141 |
| 2154 | Targeted Sequencing Strategies in Cancer Research. 2013 , 137-163 | 2 |
| 2153 | Video Q&A: molecular profiling of breast cancer. 2013 , 11, 150 | |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 2152 | miR-21 coordinates tumor growth and modulates KRIT1 levels. 2013 , 438, 90-6 | 18 |
| 2151 | Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. 2013 , 105, 1332-4 | 31 |
| 2150 | Exploring the association between genetic variation in the SUMO isopeptidase gene USPL1 and breast cancer through integration of data from the population-based GENICA study and external genetic databases. 2013 , 133, 362-72 | 12 |
| 2149 | The Cancer Genome Atlas Pan-Cancer analysis project. 2013 , 45, 1113-20 | 3933 |
| 2148 | Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer. 2013 , 19, 6163-72 | 119 |
| 2147 | Virmid: accurate detection of somatic mutations with sample impurity inference. 2013 , 14, R90 | 50 |
| 2146 | PIK3CA mutations are frequently observed in BRCA1 but not BRCA2-associated male breast cancer. 2013 , 15, R69 | 18 |
| 2145 | Walking the interactome to identify human miRNA-disease associations through the functional link between miRNA targets and disease genes. 2013 , 7, 101 | 184 |
| 2144 | A simple consensus approach improves somatic mutation prediction accuracy. 2013 , 5, 90 | 29 |
| 2143 | PTPRO promoter methylation is predictive of poorer outcome for HER2-positive breast cancer: indication for personalized therapy. 2013 , 11, 245 | 23 |
| 2142 | BreakTrans: uncovering the genomic architecture of gene fusions. 2013 , 14, R87 | 18 |
| 2141 | Hereditary breast cancer: ever more pieces to the polygenic puzzle. 2013 , 11, 12 | 38 |
| 2140 | Presence of anaplastic lymphoma kinase in inflammatory breast cancer. 2013 , 2, 497 | 36 |
| 2139 | HER-2 gene amplification in human breast cancer without concurrent HER-2 over-expression. 2013 , 2, 386 | 16 |
| 2138 | Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. 2013 , 15, R92 | 248 |
| 2137 | Sister chromatid cohesion defects are associated with chromosome instability in Hodgkin lymphoma cells. 2013 , 13, 391 | 14 |
| 2136 | Characterization of aberrant pathways across human cancers. 2013 , 7 Suppl 1, S1 | 8 |
| 2135 | Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation. 2013 , 15, R55 | 70 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 2134 | REACTIN: regulatory activity inference of transcription factors underlying human diseases with application to breast cancer. 2013 , 14, 504 | 17 |
| 2133 | Prognostic relevance of Ki-67 in the primary tumor for survival after a diagnosis of distant metastasis. 2013 , 138, 899-908 | 18 |
| 2132 | Evaluation of ultra-deep targeted sequencing for personalized breast cancer care. 2013 , 15, R115 | 14 |
| 2131 | Microrna-124 targets flotillin-1 to regulate proliferation and migration in breast cancer. 2013 , 12, 163 | 87 |
| 2130 | PGC-1 β supports glutamine metabolism in breast cancer. 2013 , 1, 22 | 108 |
| 2129 | Relative impact of multi-layered genomic data on gene expression phenotypes in serous ovarian tumors. 2013 , 7 Suppl 6, S9 | 17 |
| 2128 | CGPredictor: a systematic integrated analytic tool for mining and examining genome-scale cancer independent prognostic epigenetic marker panels. 2013 , 7 Suppl 6, S10 | |
| 2127 | Molecular pathway identification using biological network-regularized logistic models. 2013 , 14 Suppl 8, S7 | 52 |
| 2126 | Transcriptomic classification of genetically engineered mouse models of breast cancer identifies human subtype counterparts. 2013 , 14, R125 | 120 |
| 2125 | A relative ordering-based predictor for tamoxifen-treated estrogen receptor-positive breast cancer patients: multi-laboratory cohort validation. 2013 , 142, 505-14 | 15 |
| 2124 | Systems biology of cancer: entropy, disorder, and selection-driven evolution to independence, invasion and "swarm intelligence". 2013 , 32, 403-21 | 33 |
| 2123 | Differential methylation relative to breast cancer subtype and matched normal tissue reveals distinct patterns. 2013 , 142, 365-80 | 26 |
| 2122 | Genomic profiling of histological special types of breast cancer. 2013 , 142, 257-69 | 55 |
| 2121 | Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers. 2013 , 5, 91 | 125 |
| 2120 | Preemptive tumor profiling for biomarker-stratified early clinical drug development in metastatic breast cancer patients. 2013 , 142, 81-8 | 3 |
| 2119 | Emerging patterns of somatic mutations in cancer. 2013 , 14, 703-18 | 366 |
| 2118 | Genetically engineered mouse models of PI3K signaling in breast cancer. 2013 , 7, 146-64 | 28 |
| 2117 | High-resolution imaging mass spectrometry reveals detailed spatial distribution of phosphatidylinositols in human breast cancer. 2013 , 104, 1372-9 | 50 |

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 2116 | Integration of cancer genomics with treatment selection: from the genome to predictive biomarkers. 2013 , 119, 3914-28 | 13 |
| 2115 | Defining biomarkers to predict sensitivity to PI3K/Akt/mTOR pathway inhibitors in breast cancer. 2013 , 39, 313-20 | 67 |
| 2114 | Tumour angiogenesis regulation by the miR-200 family. 2013 , 4, 2427 | 295 |
| 2113 | Constitutive activation of RANK disrupts mammary cell fate leading to tumorigenesis. 2013 , 31, 1954-65 | 31 |
| 2112 | Dissecting cancer heterogeneity--an unsupervised classification approach. 2013 , 45, 2574-9 | 18 |
| 2111 | Epigenetic modifications in breast cancer and their role in personalized medicine. 2013 , 183, 1052-1063 | 58 |
| 2110 | Targeting the PI3-kinase/Akt/mTOR signaling pathway. 2013 , 22, 641-64 | 116 |
| 2109 | The landscape of somatic mutations in Down syndrome-related myeloid disorders. 2013 , 45, 1293-9 | 244 |
| 2108 | Dysregulation of the epigenome in triple-negative breast cancers: basal-like and claudin-low breast cancers express aberrant DNA hypermethylation. 2013 , 95, 276-87 | 45 |
| 2107 | Crosstalk between microRNAs and Epigenetics: From the Nutritional Perspective. 2013 , 319-341 | |
| 2106 | Biology and therapeutic potential of PI3K signaling in ER+/HER2-negative breast cancer. 2013 , 22 Suppl 2, S12-8 | 65 |
| 2105 | The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. 2013 , 39, 11-26 | 554 |
| 2104 | Emerging landscape of oncogenic signatures across human cancers. 2013 , 45, 1127-33 | 889 |
| 2103 | CYP2D6 genotype should not be used to determine endocrine therapy in postmenopausal breast cancer patients. 2013 , 94, 183-5 | 12 |
| 2102 | Combined targeting of mTOR and AKT is an effective strategy for basal-like breast cancer in patient-derived xenograft models. 2013 , 12, 1665-75 | 37 |
| 2101 | Somatic mutation of CDKN1B in small intestine neuroendocrine tumors. 2013 , 45, 1483-6 | 219 |
| 2100 | Reverse-phase protein microarray highlights HER2 signaling activation in immunohistochemistry/FISH/HER2-negative breast cancers. 2013 , 10, 223-6 | 5 |
| 2099 | The classification of invasive carcinoma of the breast. 2013 , 13, 941-54 | 9 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 2098 | The FGF/FGFR axis as a therapeutic target in breast cancer. 2013 , 8, 391-402 | 34 |
| 2097 | TACE-dependent TGF β shedding drives triple-negative breast cancer cell invasion. 2013 , 133, 2587-95 | 25 |
| 2096 | Tumor subtype identification with weighted sparse non-negative matrix factorization for multiple heterogeneous data integration. 2013 , | 0 |
| 2095 | Bridging paradigms: hybrid mechanistic-discriminative predictive models. 2013 , 60, 735-42 | 10 |
| 2094 | Molecular fingerprinting catches responders to therapeutic agents. 2013 , 14, 135 | |
| 2093 | Needles in a haystack: finding recurrent genomic changes in breast cancer. 2013 , 14, 304 | 2 |
| 2092 | Activating mutations and senescence secretome: new insights into HER2 activation, drug sensitivity and metastatic progression. 2013 , 15, 309 | 1 |
| 2091 | The genomic map of breast cancer: which roads lead to better targeted therapies?. 2013 , 15, 209 | 10 |
| 2090 | Sox4, EMT programs, and the metastatic progression of breast cancers: mastering the masters of EMT. 2013 , 15, R72 | 48 |
| 2089 | Identifying cancer biomarkers through a network regularized Cox model. 2013 , | 4 |
| 2088 | Diagnostic SOX10 gene signatures in salivary adenoid cystic and breast basal-like carcinomas. 2013 , 109, 444-51 | 64 |
| 2087 | Discovering causal pathways linking genomic events to transcriptional states using Tied Diffusion Through Interacting Events (TieDIE). 2013 , 29, 2757-64 | 128 |
| 2086 | Discoidin domain receptors: unique receptor tyrosine kinases in collagen-mediated signaling. 2013 , 288, 7430-7437 | 140 |
| 2085 | Pattern discovery and cancer gene identification in integrated cancer genomic data. 2013 , 110, 4245-50 | 250 |
| 2084 | SF3B1 mutations in chronic lymphocytic leukemia. 2013 , 121, 4627-34 | 82 |
| 2083 | Integrated analysis of genome-wide DNA methylation and gene expression profiles in molecular subtypes of breast cancer. 2013 , 41, 8464-74 | 47 |
| 2082 | Ki67 and proliferation in breast cancer. 2013 , 66, 512-6 | 139 |
| 2081 | A Local Poisson Graphical Model for inferring networks from sequencing data. 2013 , 12, 189-98 | 40 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 2080 | A Nonparametric Bayesian Model for Local Clustering with Application to Proteomics. 2013 , 108, | 16 |
| 2079 | Activating HER2 mutations in HER2 gene amplification negative breast cancer. 2013 , 3, 224-37 | 561 |
| 2078 | Genome and transcriptome sequencing in prospective metastatic triple-negative breast cancer uncovers therapeutic vulnerabilities. 2013 , 12, 104-16 | 170 |
| 2077 | Breast cancer in 2012: New drugs, new knowledge, new targets. 2013 , 10, 75-6 | 9 |
| 2076 | The genomic landscape of breast cancer as a therapeutic roadmap. 2013 , 3, 27-34 | 161 |
| 2075 | Effect of HER2 status on distant recurrence in early stage breast cancer. 2013 , 137, 449-55 | 31 |
| 2074 | A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. 2013 , 137, 483-92 | 82 |
| 2073 | Breast cancer biomarker measurements and standards. 2013 , 7, 17-29 | 30 |
| 2072 | Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. 2013 , 4, 1116-30 | 447 |
| 2071 | Agreement of self-reported hormone receptor status with cancer registry data in young breast cancer patients. 2013 , 37, 601-5 | 5 |
| 2070 | Targeted therapy for breast cancer. 2013 , 183, 1096-1112 | 83 |
| 2069 | Nursing genomics: practice implications every nurse should know. 2013 , 48, 499-522 | 16 |
| 2068 | A comprehensive nuclear receptor network for breast cancer cells. 2013 , 3, 538-51 | 61 |
| 2067 | Tight junction proteins: from barrier to tumorigenesis. 2013 , 337, 41-8 | 136 |
| 2066 | Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer. 2013 , 73, 6346-58 | 94 |
| 2065 | Acquired mutations that affect pre-mRNA splicing in hematologic malignancies and solid tumors. 2013 , 105, 1540-9 | 60 |
| 2064 | Tackling the diversity of triple-negative breast cancer. 2013 , 19, 6380-8 | 120 |
| 2063 | Familial rhabdoid tumour 'avant la lettre'--from pathology review to exome sequencing and back again. 2013 , 231, 35-43 | 49 |

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| 2062 | A Three-Gene Model to Robustly Identify Breast Cancer Molecular Subtypes: Haibe-Kains B, Desmedt C, Loi S, et al (Dana-Farber Cancer Inst, Boston, MA; UniversitLibre de Bruxelles, Brussels, Belgium) <i>J Natl Cancer Inst</i> 104:311-325, 2012. 2013 , 24, 36-38 | |
| 2061 | Signaling network assessment of mutations and copy number variations predict breast cancer subtype-specific drug targets. 2013 , 5, 216-23 | 95 |
| 2060 | Searching for the answer to cancer: new perspective may help to resolve an ageless conundrum. 2013 , 31, 721-6 | 1 |
| 2059 | Statin induces inhibition of triple negative breast cancer (TNBC) cells via PI3K pathway. 2013 , 439, 275-9 | 40 |
| 2058 | Modeling the estrogen receptor to growth factor receptor signaling switch in human breast cancer cells. 2013 , 587, 3327-34 | 20 |
| 2057 | Activation of NFkB is a novel mechanism of pro-survival activity of glucocorticoids in breast cancer cells. 2013 , 337, 90-5 | 33 |
| 2056 | SPARCL1 suppresses metastasis in prostate cancer. 2013 , 7, 1019-30 | 23 |
| 2055 | Feasibility of preemptive biomarker profiling for personalised early clinical drug development at a Comprehensive Cancer Center. 2013 , 49, 3076-82 | 25 |
| 2054 | Human Pol E dependent replication errors and the influence of mismatch repair on their correction. 2013 , 12, 954-63 | 17 |
| 2053 | Activating mutations in HER2: neu opportunities and neu challenges. 2013 , 3, 145-7 | 22 |
| 2052 | Evolutionary foundations for cancer biology. 2013 , 6, 144-59 | 124 |
| 2051 | The PGC-1/ERR signaling axis in cancer. 2013 , 32, 3483-90 | 117 |
| 2050 | Analysis of circulating tumor DNA to monitor metastatic breast cancer. 2013 , 368, 1199-209 | 1560 |
| 2049 | Promise of rapalogues versus mTOR kinase inhibitors in subset specific breast cancer: old targets new hope. 2013 , 39, 403-12 | 30 |
| 2048 | Pharmacogenetics and pharmacogenomics: a bridge to individualized cancer therapy. 2013 , 14, 315-24 | 66 |
| 2047 | APOBEC3B is an enzymatic source of mutation in breast cancer. <i>Nature</i> , 2013 , 494, 366-70 | 50.4 563 |
| 2046 | Therapeutic targets in triple negative breast cancer. 2013 , 66, 530-42 | 104 |
| 2045 | Translating metastasis-related biomarkers to the clinic--progress and pitfalls. 2013 , 10, 169-79 | 35 |

| | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 2044 | Emerging targeted agents in metastatic breast cancer. 2013 , 10, 191-210 | 138 |
| 2043 | Alterations of EGFR, p53 and PTEN that mimic changes found in basal-like breast cancer promote transformation of human mammary epithelial cells. 2013 , 14, 246-53 | 25 |
| 2042 | FOXA1 mutations in hormone-dependent cancers. 2013 , 3, 20 | 42 |
| 2041 | Interplay between the cancer genome and epigenome. 2013 , 153, 38-55 | 588 |
| 2040 | Lessons from the cancer genome. 2013 , 153, 17-37 | 912 |
| 2039 | The future of epigenetic therapy in solid tumours--lessons from the past. 2013 , 10, 256-66 | 262 |
| 2038 | The war on cancer: are we winning?. 2013 , 34, 1275-84 | 36 |
| 2037 | Computational solutions for omics data. 2013 , 14, 333-46 | 218 |
| 2036 | Epigenetic therapy: use of agents targeting deacetylation and methylation in cancer management. 2013 , 6, 223-32 | 30 |
| 2035 | Using MEMo to discover mutual exclusivity modules in cancer. 2013 , Chapter 8, Unit 8.17 | 26 |
| 2034 | GATA3 suppresses metastasis and modulates the tumour microenvironment by regulating microRNA-29b expression. 2013 , 15, 201-13 | 274 |
| 2033 | Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers. 2013 , 108, 2172-7 | 153 |
| 2032 | The role of intratumoral and systemic IL-6 in breast cancer. 2013 , 138, 657-64 | 229 |
| 2031 | Hotspot mutations in PIK3CA associate with first-line treatment outcome for aromatase inhibitors but not for tamoxifen. 2013 , 139, 39-49 | 41 |
| 2030 | Integrated genomic characterization of endometrial carcinoma. <i>Nature</i> , 2013 , 497, 67-73 | 50.4 2800 |
| 2029 | Understanding genomic alterations in cancer genomes using an integrative network approach. 2013 , 340, 261-9 | 49 |
| 2028 | The shaping and functional consequences of the microRNA landscape in breast cancer. <i>Nature</i> , 2013 , 497, 378-82 | 50.4 321 |
| 2027 | Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer. 2013 , 39, 935-46 | 259 |

| | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 2026 | Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. 2013 , 6, pl1 | 7715 |
| 2025 | The new sequencer on the block: comparison of Life Technology's Proton sequencer to an Illumina HiSeq for whole-exome sequencing. 2013 , 132, 1153-63 | 60 |
| 2024 | Applying systems biology in drug discovery and development. 2013 , 28, 67-78 | 8 |
| 2023 | Use of pharmacogenetics for predicting cancer prognosis and treatment exposure, response and toxicity. 2013 , 58, 346-52 | 48 |
| 2022 | Oncogenic ERBB3 mutations in human cancers. 2013 , 23, 603-17 | 277 |
| 2021 | Progesterone signalling in breast cancer: a neglected hormone coming into the limelight. 2013 , 13, 385-96 | 171 |
| 2020 | Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. 2013 , 45, 592-601 | 765 |
| 2019 | Circulating tumour cells and cell-free DNA as tools for managing breast cancer. 2013 , 10, 377-89 | 146 |
| 2018 | Do mutator mutations fuel tumorigenesis?. 2013 , 32, 353-61 | 44 |
| 2017 | Latest research and treatment of advanced-stage epithelial ovarian cancer. 2013 , 10, 211-24 | 365 |
| 2016 | Cancer systems biology in the genome sequencing era: part 1, dissecting and modeling of tumor clones and their networks. 2013 , 23, 279-85 | 61 |
| 2015 | Cancer systems biology in the genome sequencing era: part 2, evolutionary dynamics of tumor clonal networks and drug resistance. 2013 , 23, 286-92 | 57 |
| 2014 | Forkhead box proteins: tuning forks for transcriptional harmony. 2013 , 13, 482-95 | 417 |
| 2013 | Biopsies: next-generation biospecimens for tailoring therapy. 2013 , 10, 437-50 | 86 |
| 2012 | Genetic heterogeneity in breast cancer: the road to personalized medicine?. 2013 , 11, 151 | 42 |
| 2011 | Poised chromatin at the ZEB1 promoter enables breast cancer cell plasticity and enhances tumorigenicity. 2013 , 154, 61-74 | 608 |
| 2010 | Molecular cytogenetics: recent developments and applications in cancer. 2013 , 84, 315-25 | 24 |
| 2009 | Targeting BCL-2 with the BH3 mimetic ABT-199 in estrogen receptor-positive breast cancer. 2013 , 24, 120-9 | 211 |

| | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| 2008 | Diverse mechanisms of somatic structural variations in human cancer genomes. 2013 , 153, 919-29 | 238 |
| 2007 | Lipid biology of breast cancer. 2013 , 1831, 1509-17 | 59 |
| 2006 | MicroRNA-30c inhibits human breast tumour chemotherapy resistance by regulating TWF1 and IL-11. 2013 , 4, 1393 | 184 |
| 2005 | Translational utility of next-generation sequencing. 2013 , 102, 137-9 | 29 |
| 2004 | Cancer networks and beyond: interpreting mutations using the human interactome and protein structure. 2013 , 23, 219-26 | 19 |
| 2003 | Toward a systems biology of mood disorder. 2013 , 73, 107-8 | 7 |
| 2002 | High-throughput gene expression and mutation profiling: current methods and future perspectives. 2013 , 8, 401-6 | 11 |
| 2001 | DNA repair gene patterns as prognostic and predictive factors in molecular breast cancer subtypes. 2013 , 18, 1063-73 | 64 |
| 2000 | [Breast cancer. Individualized therapy concepts]. 2013 , 54, 194-9 | 4 |
| 1999 | Isogenic human mammary epithelial cell lines: novel tools for target identification and validation. Comprehensive characterization of an isogenic human mammary epithelial cell model provides evidence for epithelial-mesenchymal transition. 2013 , 138, 437-56 | 2 |
| 1998 | Multiple variants aggregate in the neuregulin signaling pathway in a subset of schizophrenia patients. 2013 , 3, e264 | 31 |
| 1997 | Genomic profiling in triple-negative breast cancer. 2013 , 8, 408-13 | 20 |
| 1996 | SF3B1 mutations are associated with alternative splicing in uveal melanoma. 2013 , 3, 1122-1129 | 282 |
| 1995 | Tumour heterogeneity in the clinic. <i>Nature</i> , 2013 , 501, 355-64 | 50.4 770 |
| 1994 | APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. 2013 , 73, 7222-31 | 123 |
| 1993 | Progress in breast cancer: overview. 2013 , 19, 6353-9 | 6 |
| 1992 | BCL-2 hypermethylation is a potential biomarker of sensitivity to antimitotic chemotherapy in endocrine-resistant breast cancer. 2013 , 12, 1874-85 | 36 |
| 1991 | Correlating transcriptional networks to breast cancer survival: a large-scale coexpression analysis. 2013 , 34, 2300-8 | 228 |

| | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1990 | Thrombospondin-4 expression is activated during the stromal response to invasive breast cancer. 2013 , 463, 535-45 | 44 |
| 1989 | Role of hypoxia-inducible factors in breast cancer metastasis. 2013 , 9, 1623-36 | 173 |
| 1988 | Metasignatures identify two major subtypes of breast cancer. 2013 , 2, e35 | 13 |
| 1987 | Notch3 functions as a tumor suppressor by controlling cellular senescence. 2013 , 73, 3451-9 | 75 |
| 1986 | A targeted RNAi screen of the breast cancer genome identifies KIF14 and TLN1 as genes that modulate docetaxel chemosensitivity in triple-negative breast cancer. 2013 , 19, 2061-70 | 46 |
| 1985 | A new view of invasive lobular breast cancer. 2013 , 19, 3331-3 | 5 |
| 1984 | Research resource: global identification of estrogen receptor β target genes in triple negative breast cancer cells. 2013 , 27, 1762-75 | 42 |
| 1983 | Harnessing massively parallel DNA sequencing for the personalization of cancer management. 2013 , 10, 183-190 | 2 |
| 1982 | Exploring and exploiting the aberrant DNA methylation profile of endocrine-resistant breast cancer. 2013 , 5, 595-8 | 6 |
| 1981 | Regulator of G protein signaling 6 is a novel suppressor of breast tumor initiation and progression. 2013 , 34, 1747-55 | 27 |
| 1980 | Ontology-aware classification of tissue and cell-type signals in gene expression profiles across platforms and technologies. 2013 , 29, 3036-44 | 21 |
| 1979 | [Breast cancer: tumor biology-based concepts for surgical and drug treatment]. 2013 , 138, 180-2 | 0 |
| 1978 | Master regulators of FGFR2 signalling and breast cancer risk. 2013 , 4, 2464 | 128 |
| 1977 | Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility. 2013 , 73, 932-940 | 46 |
| 1976 | [Personalized medicine and breast cancer: anticipatory medicine, prognostic evaluation and therapeutic targeting]. 2013 , 100, 1295-310 | 3 |
| 1975 | Population and target considerations for triple-negative breast cancer clinical trials. 2013 , 7, 11-21 | 9 |
| 1974 | How variability in clinical phenotypes should guide research into disease mechanisms in asthma. 2013 , 10 Suppl, S109-17 | 31 |
| 1973 | Meta-analysis of Genomic and Proteomic Features to Predict Synthetic Lethality of Yeast and Human Cancer. 2013 , | 4 |

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1972 | Joint analysis of expression profiles from multiple cancers improves the identification of microRNA-gene interactions. 2013 , 29, 2137-45 | 29 |
| 1971 | ANTXR1, a stem cell-enriched functional biomarker, connects collagen signaling to cancer stem-like cells and metastasis in breast cancer. 2013 , 73, 5821-33 | 81 |
| 1970 | C-Terminal Binding Protein: A Molecular Link between Metabolic Imbalance and Epigenetic Regulation in Breast Cancer. 2013 , 2013, 647975 | 30 |
| 1969 | Controversies in the management of brain metastases. 2013 , 4, S231-5 | 6 |
| 1968 | Bayesian consensus clustering. 2013 , 29, 2610-6 | 136 |
| 1967 | Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications. 2013 , 24, 2715-24 | 84 |
| 1966 | Identifying breast cancer subtype related miRNAs from two constructed miRNAs interaction networks in silico method. 2013 , 2013, 798912 | 5 |
| 1965 | Bringing precision medicine to the clinic: from genomic profiling to the power of clinical observation. 2013 , 24, 1956-7 | 17 |
| 1964 | Integrative analysis of cancer-related signaling pathways. 2013 , 4, 124 | 9 |
| 1963 | Overview of diagnostic/targeted treatment combinations in personalized medicine for breast cancer patients. 2013 , 7, 1-19 | 8 |
| 1962 | A case report and genetic characterization of a massive acinic cell carcinoma of the parotid with delayed distant metastases. 2013 , 2013, 270362 | 4 |
| 1961 | Obesity, metabolism and the microenvironment: Links to cancer. 2013 , 12, 19 | 71 |
| 1960 | Pituitary tumor-transforming gene 1 is expressed in primary ductal breast carcinoma, lymph node infiltration, and distant metastases. 2013 , 35, 267-72 | 7 |
| 1959 | A multiplexed luciferase-based screening platform for interrogating cancer-associated signal transduction in cultured cells. 2013 , e50369 | 5 |
| 1958 | The gene desert mammary carcinoma susceptibility locus Mcs1a regulates Nr2f1 modifying mammary epithelial cell differentiation and proliferation. 2013 , 9, e1003549 | 17 |
| 1957 | Integrative analysis of deep sequencing data identifies estrogen receptor early response genes and links ATAD3B to poor survival in breast cancer. 2013 , 9, e1003100 | 8 |
| 1956 | RUNX1: A microRNA hub in normal and malignant hematopoiesis. 2013 , 14, 1566-88 | 32 |
| 1955 | Simultaneous identification of multiple driver pathways in cancer. 2013 , 9, e1003054 | 163 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1954 | Significance analysis of prognostic signatures. 2013 , 9, e1002875 | 22 |
| 1953 | Prognostic discrimination using a 70-gene signature among patients with estrogen receptor-positive breast cancer and an intermediate 21-gene recurrence score. 2013 , 14, 23685-99 | 13 |
| 1952 | Reply to A.-S. Dieudonné et al and J.M. Rae et al. 2013 , 31, 2755-6 | 3 |
| 1951 | CYP2D6 genotype should not be used for deciding about tamoxifen therapy in postmenopausal breast cancer. 2013 , 31, 2753-5 | 6 |
| 1950 | Updates in the treatment of basal/triple-negative breast cancer. 2013 , 25, 40-8 | 32 |
| 1949 | Bibliography. Head and neck. Current world literature. 2013 , 25, 325-30 | |
| 1948 | Frequent PIK3CA mutations in radial scars. 2013 , 22, 210-4 | 17 |
| 1947 | Ductal carcinoma in situ: morphology-based knowledge and molecular advances. 2013 , 20, 205-16 | 14 |
| 1946 | Pilot studies for personalized cancer medicine: focusing on the patient for treatment selection. 2013 , 18, 1180-8 | 19 |
| 1945 | Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling. 2013 , 73, 4075-85 | 19 |
| 1944 | Personalized medicine for metastatic breast cancer. 2013 , 25, 615-24 | 4 |
| 1943 | Targeting receptor tyrosine kinases in HER2-negative breast cancer. 2013 , 25, 594-601 | 9 |
| 1942 | Low-copy piggyBac transposon mutagenesis in mice identifies genes driving melanoma. 2013 , 110, E3640-9 | 24 |
| 1941 | Role of inhibitors of mammalian target of rapamycin in the treatment of luminal breast cancer. 2013 , 24, 769-80 | 10 |
| 1940 | Procollagen lysyl hydroxylase 2 is essential for hypoxia-induced breast cancer metastasis. 2013 , 11, 456-66 | 175 |
| 1939 | Targeted therapies of solid cancers: new options, new challenges. 2013 , 25, 296-304 | 17 |
| 1938 | Carboxyl group footprinting mass spectrometry and molecular dynamics identify key interactions in the HER2-HER3 receptor tyrosine kinase interface. 2013 , 288, 25254-25264 | 25 |
| 1937 | DETECTING STATISTICAL INTERACTION BETWEEN SOMATIC MUTATIONAL EVENTS AND GERMLINE VARIATION FROM NEXT-GENERATION SEQUENCE DATA. 2013 , | |

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1936 | Revealing targeted therapeutic opportunities in triple-negative breast cancers: a new strategy. 2013 , 12, 2705-6 | 10 |
| 1935 | PIK3CA and AKT1 mutations have distinct effects on sensitivity to targeted pathway inhibitors in an isogenic luminal breast cancer model system. 2013 , 19, 5413-22 | 67 |
| 1934 | A novel link between p53 and ROS. 2013 , 12, 201-2 | 17 |
| 1933 | p53 continues to surprise: high levels of p53 can suppress apoptosis. 2013 , 12, 203 | |
| 1932 | HER2-directed T-cell receptor-mimicking antibody: a "Me Too" or an example of novel antitumor aggressive mimicry?. 2013 , 105, 161-3 | 1 |
| 1931 | MYC phosphorylation at novel regulatory regions suppresses transforming activity. 2013 , 73, 6504-15 | 22 |
| 1930 | DNA co-methylation analysis suggests novel functional associations between gene pairs in breast cancer samples. 2013 , 22, 3016-22 | 24 |
| 1929 | Dual human epidermal growth factor receptor 2 (HER2) blockade and hormonal therapy for the treatment of primary HER2-positive breast cancer: one more step toward chemotherapy-free therapy. 2013 , 31, 1703-6 | 21 |
| 1928 | COHCAP: an integrative genomic pipeline for single-nucleotide resolution DNA methylation analysis. 2013 , 41, e117 | 71 |
| 1927 | Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. 2013 , 105, 960-7 | 112 |
| 1926 | Minireview: the molecular and genomic basis for prostate cancer health disparities. 2013 , 27, 879-91 | 51 |
| 1925 | [Triple-negative breast cancer: histoclinical and molecular features, therapeutic management and perspectives]. 2013 , 100, 453-64 | 14 |
| 1924 | Risk factors for specific histopathological types of postmenopausal breast cancer in the NIH-AARP Diet and Health Study. 2013 , 178, 359-71 | 17 |
| 1923 | DEXUS: identifying differential expression in RNA-Seq studies with unknown conditions. 2013 , 41, e198 | 20 |
| 1922 | A molecular signature predictive of indolent prostate cancer. 2013 , 5, 202ra122 | 98 |
| 1921 | Clinical phenotypes of psychosis in the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP). 2013 , 170, 1263-74 | 217 |
| 1920 | Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. 2013 , 110, 11982-7 | 398 |
| 1919 | Does microenvironment contribute to the etiology of estrogen receptor-negative breast cancer?. 2013 , 19, 541-8 | 24 |

| | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1918 | Molecular characterization of basal-like and non-basal-like triple-negative breast cancer. 2013 , 18, 123-33 | 376 |
| 1917 | The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. 2013 , 14, r106 | 78 |
| 1916 | Envisioning Watson as a rapid-learning system for oncology. 2013 , 9, 155-7 | 31 |
| 1915 | Connecting genomic alterations to cancer biology with proteomics: the NCI Clinical Proteomic Tumor Analysis Consortium. 2013 , 3, 1108-12 | 162 |
| 1914 | Impact of molecular breast cancer portraits on new treatment strategies for gynecologic malignancies. 2013 , 25, 38-9 | 2 |
| 1913 | STOP gene Phactr4 is a tumor suppressor. 2013 , 110, E407-14 | 11 |
| 1912 | GATA3 acts upstream of FOXA1 in mediating ESR1 binding by shaping enhancer accessibility. 2013 , 23, 12-22 | 241 |
| 1911 | Combination of gene expression and genome copy number alteration has a prognostic value for breast cancer. 2013 , 2013, 608-11 | 15 |
| 1910 | MicroRNA 9-3p targets β 1 integrin to sensitize claudin-low breast cancer cells to MEK inhibition. 2013 , 33, 2260-74 | 41 |
| 1909 | Phenotypic and Molecular Characterization of MCF10DCIS and SUM Breast Cancer Cell Lines. 2013 , 2013, 872743 | 47 |
| 1908 | Review of biological network data and its applications. 2013 , 11, 200-10 | 57 |
| 1907 | GLI1 regulates a novel neuropilin-2/ β 1 integrin based autocrine pathway that contributes to breast cancer initiation. 2013 , 5, 488-508 | 108 |
| 1906 | Lessons from postgenome-wide association studies: functional analysis of cancer predisposition loci. 2013 , 274, 414-24 | 19 |
| 1905 | Genomic profiling in luminal breast cancer. 2013 , 8, 414-22 | 10 |
| 1904 | Growth of triple-negative breast cancer cells relies upon coordinate autocrine expression of the proinflammatory cytokines IL-6 and IL-8. 2013 , 73, 3470-80 | 289 |
| 1903 | The current and future role of sequence-based analysis in prostate cancer treatment. 2013 , 10, 257-273 | |
| 1902 | Complexity in cancer biology: is systems biology the answer?. 2013 , 2, 164-77 | 26 |
| 1901 | Collagen prolyl hydroxylases are essential for breast cancer metastasis. 2013 , 73, 3285-96 | 198 |

1900 . **2013**,

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1899 | Identifying survival associated morphological features of triple negative breast cancer using multiple datasets. 2013 , 20, 680-7 | 29 |
| 1898 | The fragile X protein binds mRNAs involved in cancer progression and modulates metastasis formation. 2013 , 5, 1523-36 | 78 |
| 1897 | Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. 2013 , 231, 63-76 | 270 |
| 1896 | When everyone is an orphan: against adopting a U.S.-styled orphan drug policy in Canada. 2013 , 20, 227-69 | 15 |
| 1895 | Bisected, complex N-glycans and galectins in mouse mammary tumor progression and human breast cancer. 2013 , 23, 1477-90 | 23 |
| 1894 | Transforming epidemiology for 21st century medicine and public health. 2013 , 22, 508-16 | 83 |
| 1893 | MicroRNA-24 suppression of N-deacetylase/N-sulfotransferase-1 (NDST1) reduces endothelial cell responsiveness to vascular endothelial growth factor A (VEGFA). 2013 , 288, 25956-25963 | 23 |
| 1892 | From photomorphogenesis to cancer: a CSN journey. 2013 , 12, 205-6 | 5 |
| 1891 | Clinical cancer advances 2012: annual report on progress against cancer from the american society of clinical oncology. 2013 , 31, 131-61 | 35 |
| 1890 | Impact of bioinformatic procedures in the development and translation of high-throughput molecular classifiers in oncology. 2013 , 19, 4315-25 | 27 |
| 1889 | Differential chemotherapeutic sensitivity for breast tumors with "BRCAness": a review. 2013 , 18, 909-16 | 46 |
| 1888 | Mutant PIK3CA accelerates HER2-driven transgenic mammary tumors and induces resistance to combinations of anti-HER2 therapies. 2013 , 110, 14372-7 | 137 |
| 1887 | Recurrent patterns of DNA methylation in the ZNF154, CASP8, and VHL promoters across a wide spectrum of human solid epithelial tumors and cancer cell lines. 2013 , 8, 1355-72 | 40 |
| 1886 | The mutational landscape of phosphorylation signaling in cancer. 2013 , 3, 2651 | 116 |
| 1885 | Research Highlights. 2013 , 31, 893-893 | |
| 1884 | Expression of PIK3CA mutant E545K in the mammary gland induces heterogeneous tumors but is less potent than mutant H1047R. 2013 , 2, e74 | 42 |
| 1883 | Specific plasma autoantibody reactivity in myelodysplastic syndromes. 2013 , 3, 3311 | 8 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1882 | Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas. 2013 , 45, 1121-6 | 82 |
| 1881 | Triple-negative breast cancer: molecular characterization and targeted therapies. 2013 , 2, 417-430 | 1 |
| 1880 | Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2. 2013 , 19, 5390-401 | 56 |
| 1879 | Prognostic microRNA/mRNA signature from the integrated analysis of patients with invasive breast cancer. 2013 , 110, 7413-7 | 128 |
| 1878 | Incorporating genomics into breast cancer clinical trials and care. 2013 , 19, 6371-9 | 14 |
| 1877 | Development of a prognostic model for breast cancer survival in an open challenge environment. 2013 , 5, 181ra50 | 91 |
| 1876 | Common gene pathways and families altered by DNA methylation in breast and prostate cancers. 2013 , 20, R215-32 | 18 |
| 1875 | Metastatic castration-resistant prostate cancer reveals inpatient similarity and interpatient heterogeneity of therapeutic kinase targets. 2013 , 110, E4762-9 | 82 |
| 1874 | Improving endocrine therapy for breast cancer: it's not that simple. 2013 , 31, 171-3 | 28 |
| 1873 | Tumors and their stroma: mitochondria at the crossroad. 2013 , 12, 204-5 | 3 |
| 1872 | Linking JNK-STAT3-Akt signaling axis to EZH2 phosphorylation: a novel pathway of carcinogenesis. 2013 , 12, 202-3 | 14 |
| 1871 | Genomic analyses across six cancer types identify basal-like breast cancer as a unique molecular entity. 2013 , 3, 3544 | 42 |
| 1870 | Estrogen receptor negative/progesterone receptor positive breast cancer is not a reproducible subtype. 2013 , 15, R68 | 92 |
| 1869 | Comprehensive whole-genome sequencing of an early-stage primary myelofibrosis patient defines low mutational burden and non-recurrent candidate genes. 2013 , 98, 1689-96 | 9 |
| 1868 | Variation at 10p12.2 and 10p14 influences risk of childhood B-cell acute lymphoblastic leukemia and phenotype. 2013 , 122, 3298-307 | 119 |
| 1867 | PIK3R1 underexpression is an independent prognostic marker in breast cancer. 2013 , 13, 545 | 71 |
| 1866 | Evaluation of factors related to late recurrence--later than 10 years after the initial treatment--in primary breast cancer. 2013 , 85, 100-10 | 42 |
| 1865 | Monitoring of technical variation in quantitative high-throughput datasets. 2013 , 12, 193-201 | 40 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1864 | Clinical application of high-throughput genomic technologies for treatment selection in breast cancer. 2013 , 15, R97 | 13 |
| 1863 | Using multigene tests to select treatment for early-stage breast cancer. 2013 , 11, 174-82; quiz 182 | 37 |
| 1862 | ATHENA: Identifying interactions between different levels of genomic data associated with cancer clinical outcomes using grammatical evolution neural network. 2013 , 6, 23 | 44 |
| 1861 | General mechanism for halting cancer progression found?. 2013 , 10, 182-182 | |
| 1860 | Genetics and genomics nursing has arrived!. 2013 , 40, 20-1 | 2 |
| 1859 | The phosphoinositide-3-kinase-Akt-mTOR pathway as a therapeutic target in breast cancer. 2013 , 11, 670-8 | 81 |
| 1858 | Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control. 2013 , 14, 643 | 68 |
| 1857 | Development of targeted therapies for triple-negative breast cancer: can we harness tumor heterogeneity to improve patient outcomes?. 2013 , 2, 175-178 | |
| 1856 | Computation as the mechanistic bridge between precision medicine and systems therapeutics. 2013 , 93, 117-28 | 30 |
| 1855 | Massively parallel sequencing for diagnosing clinically and genetically heterogeneous disorders. 2013 , 10, 613-619 | |
| 1854 | Euphol arrests breast cancer cells at the G1 phase through the modulation of cyclin D1, p21 and p27 expression. 2013 , 8, 1279-85 | 43 |
| 1853 | Comprehensive molecular portraits of human breast tumours. 2013 , 2013, 286-288 | 1 |
| 1852 | Murine microenvironment metaprofiles associate with human cancer etiology and intrinsic subtypes. 2013 , 19, 1353-62 | 20 |
| 1851 | Intertumoral and intratumoral heterogeneity as a barrier for effective treatment of medulloblastoma. 2013 , 60 Suppl 1, 57-63 | 12 |
| 1850 | Listening to the brain: new techniques in intraoperative brain mapping. 2013 , 60 Suppl 1, 64-9 | 5 |
| 1849 | Lobular neoplasia of the breast revisited with emphasis on the role of E-cadherin immunohistochemistry. 2013 , 37, e1-11 | 109 |
| 1848 | The role of epithelial-mesenchymal transition programming in invasion and metastasis: a clinical perspective. 2013 , 5, 187-95 | 102 |
| 1847 | Downregulation of BMP6 enhances cell proliferation and chemoresistance via activation of the ERK signaling pathway in breast cancer. 2013 , 30, 193-200 | 23 |

| | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1846 | Modeling precision treatment of breast cancer. 2013 , 14, R110 | 204 |
| 1845 | Breast cancer in adolescents and young adults: a review with a focus on biology. 2013 , 11, 1060-9 | 43 |
| 1844 | The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells. 2013 , 6, ra66 | 196 |
| 1843 | The Interactions of microRNA and Epigenetic Modifications in Prostate Cancer. 2013 , 5, 998-1019 | 25 |
| 1842 | Gene regulation, modulation, and their applications in gene expression data analysis. 2013 , 2013, 360678 | 19 |
| 1841 | Gene Expression Meta-Analysis Identifies Cytokine Pathways and 5q Aberrations Involved in Metastasis of ERBB2 Amplified and Basal Breast Cancer. 2013 , 12, 203-19 | 2 |
| 1840 | Aberrantly methylated DNA as a biomarker in breast cancer. 2013 , 28, 141-50 | 7 |
| 1839 | Household income is associated with the p53 mutation frequency in human breast tumors. 2013 , 8, e57361 | 7 |
| 1838 | Real-time motion analysis reveals cell directionality as an indicator of breast cancer progression. 2013 , 8, e58859 | 40 |
| 1837 | Whole genome and transcriptome sequencing of a B3 thymoma. 2013 , 8, e60572 | 21 |
| 1836 | Prolactin-induced protein (PIP) regulates proliferation of luminal A type breast cancer cells in an estrogen-independent manner. 2014 , 8, e62361 | 25 |
| 1835 | Age-specific gene expression signatures for breast tumors and cross-species conserved potential cancer progression markers in young women. 2013 , 8, e63204 | 80 |
| 1834 | Oncogenic Actions of the Nuclear Receptor Corepressor (NCOR1) in a Mouse Model of Thyroid Cancer. 2013 , 8, e67954 | 14 |
| 1833 | Simple and versatile molecular method of copy-number measurement using cloned competitors. 2013 , 8, e69414 | 7 |
| 1832 | Molecular phenotypes in triple negative breast cancer from African American patients suggest targets for therapy. 2013 , 8, e71915 | 49 |
| 1831 | Genetic background may contribute to PAM50 gene expression breast cancer subtype assignments. 2013 , 8, e72287 | 12 |
| 1830 | Genomic interaction profiles in breast cancer reveal altered chromatin architecture. 2013 , 8, e73974 | 30 |
| 1829 | Next-generation sequence analysis of cancer xenograft models. 2013 , 8, e74432 | 23 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1828 | Performance comparison of digital microRNA profiling technologies applied on human breast cancer cell lines. 2013 , 8, e75813 | 23 |
| 1827 | An integrated model of the transcriptome of HER2-positive breast cancer. 2013 , 8, e79298 | 16 |
| 1826 | Gli activity is critical at multiple stages of embryonic mammary and nipple development. 2013 , 8, e79845 | 13 |
| 1825 | SurvExpress: an online biomarker validation tool and database for cancer gene expression data using survival analysis. 2013 , 8, e74250 | 510 |
| 1824 | Synthetic genetic targeting of genome instability in cancer. 2013 , 5, 739-61 | 24 |
| 1823 | Using aptamers for cancer biomarker discovery. 2013 , 2013, 817350 | 43 |
| 1822 | Computational and bioinformatics frameworks for next-generation whole exome and genome sequencing. 2013 , 2013, 730210 | 31 |
| 1821 | Neoadjuvant therapy in operable breast cancer: application to triple negative breast cancer. 2013 , 2013, 219869 | 12 |
| 1820 | An Introduction to The Cancer Genome Atlas. 31-53 | 1 |
| 1819 | Personalised treatment aim for project to sequence genomes of cancer patients. 2013 , 11, 8-10 | |
| 1818 | Engine Emissions Measurement Handbook. 2013 , | 2 |
| 1817 | Profiling and targeting HER2-positive breast cancer using trastuzumab emtansine. 2014 , 7, 329-38 | 9 |
| 1816 | Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. 2014 , 9, e88401 | 27 |
| 1815 | Metabotropic glutamate receptor-1 contributes to progression in triple negative breast cancer. 2014 , 9, e81126 | 33 |
| 1814 | Candidate luminal B breast cancer genes identified by genome, gene expression and DNA methylation profiling. 2014 , 9, e81843 | 42 |
| 1813 | A pan-cancer analysis of transcriptome changes associated with somatic mutations in U2AF1 reveals commonly altered splicing events. 2014 , 9, e87361 | 112 |
| 1812 | Gasdermin-B promotes invasion and metastasis in breast cancer cells. 2014 , 9, e90099 | 67 |
| 1811 | Phenotypic diversity of breast cancer-related mutations in metalloproteinase-disintegrin ADAM12. 2014 , 9, e92536 | 11 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1810 | S-score: a scoring system for the identification and prioritization of predicted cancer genes. 2014 , 9, e94147 | 7 |
| 1809 | Integration of mRNA expression profile, copy number alterations, and microRNA expression levels in breast cancer to improve grade definition. 2014 , 9, e97681 | 46 |
| 1808 | Identification of druggable cancer driver genes amplified across TCGA datasets. 2014 , 9, e98293 | 88 |
| 1807 | Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. 2014 , 9, e100759 | 54 |
| 1806 | Remodeling of the methylation landscape in breast cancer metastasis. 2014 , 9, e103896 | 25 |
| 1805 | Do breast cancer cell lines provide a relevant model of the patient tumor methylome?. 2014 , 9, e105545 | 15 |
| 1804 | Highly adaptable triple-negative breast cancer cells as a functional model for testing anticancer agents. 2014 , 9, e109487 | 14 |
| 1803 | Mg ²⁺ effect on argonaute and RNA duplex by molecular dynamics and bioinformatics implications. 2014 , 9, e109745 | 9 |
| 1802 | MicroRNA related polymorphisms and breast cancer risk. 2014 , 9, e109973 | 37 |
| 1801 | Obesity-mediated regulation of HGF/c-Met is associated with reduced basal-like breast cancer latency in parous mice. 2014 , 9, e111394 | 12 |
| 1800 | Human breast progenitor cell numbers are regulated by WNT and TBX3. 2014 , 9, e111442 | 17 |
| 1799 | RADIA: RNA and DNA integrated analysis for somatic mutation detection. 2014 , 9, e111516 | 59 |
| 1798 | Somatic mutations favorable to patient survival are predominant in ovarian carcinomas. 2014 , 9, e112561 | 3 |
| 1797 | Mesothelin expression in triple negative breast carcinomas correlates significantly with basal-like phenotype, distant metastases and decreased survival. 2014 , 9, e114900 | 48 |
| 1796 | CREB targets define the gene expression signature of malignancies having reduced levels of the tumor suppressor tristetraprolin. 2014 , 9, e115517 | 24 |
| 1795 | Biomarkers in women's cancers, gynecology, and obstetrics. 2014 , 2014, 602340 | 1 |
| 1794 | Targeting the NF κ B signaling pathways for breast cancer prevention and therapy. 2015 , 22, 264-89 | 111 |
| 1793 | MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. 2014 , 3, e01763 | 75 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1792 | Multi-omic network signatures of disease. 2014 , 4, 309 | 17 |
| 1791 | The gene regulatory network for breast cancer: integrated regulatory landscape of cancer hallmarks. 2014 , 5, 15 | 42 |
| 1790 | Toward a systematic understanding of cancers: a survey of the pan-cancer study. 2014 , 5, 194 | 19 |
| 1789 | Evidence for a Functional Link between Chromosomal Breakpoints and Aberrant DNA Methylation in Cancer. 2014 , 4, 46 | 4 |
| 1788 | RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells. 2014 , 3, e03881 | 62 |
| 1787 | Loss of the multifunctional RNA-binding protein RBM47 as a source of selectable metastatic traits in breast cancer. 2014 , 3, | 79 |
| 1786 | Overcoming endocrine resistance in metastatic breast cancer: Current evidence and future directions. 2014 , 5, 990-1001 | 73 |
| 1785 | Targeting autophagy in breast cancer. 2014 , 5, 224-40 | 46 |
| 1784 | Computational prognostic indicators for breast cancer. 2014 , 6, 301-12 | 7 |
| 1783 | cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. 2014 , 5, 745-53 | 32 |
| 1782 | Subtype classification for prediction of prognosis of breast cancer from a biomarker panel: correlations and indications. 2014 , 9, 1039-48 | 12 |
| 1781 | Patterns and Biologic Features of p53 Mutation Types in Korean Breast Cancer Patients. 2014 , 17, 1-7 | 10 |
| 1780 | Potential of antibody-drug conjugates and novel therapeutics in breast cancer management. 2014 , 7, 491-500 | 17 |
| 1779 | Assessment of subnetwork detection methods for breast cancer. 2014 , 13, 15-23 | 8 |
| 1778 | Molecular and immunohistochemical profiling of invasive micropapillary carcinoma of the breast. 2014 , 33 | |
| 1777 | Expression of DNA Cytosine Deaminase APOBEC3 Proteins, a Potential Source for Producing Mutations, in Gastric, Colorectal and Prostate Cancers. 2014 , 100, e112-e117 | 8 |
| 1776 | Long-term survival analysis of korean breast cancer patients at a single center: improving outcome over time. 2014 , 55, 1187-95 | 9 |
| 1775 | Novel treatment strategies in triple-negative breast cancer: specific role of poly(adenosine diphosphate-ribose) polymerase inhibition. 2014 , 7, 307-16 | 19 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1774 | Hypoxia-inducible factor 1 mediates TAZ expression and nuclear localization to induce the breast cancer stem cell phenotype. 2014 , 5, 12509-27 | 83 |
| 1773 | MYC-driven accumulation of 2-hydroxyglutarate is associated with breast cancer prognosis. 2014 , 124, 398-412 | 281 |
| 1772 | Radiation-induced immunogenic modulation of tumor enhances antigen processing and calreticulin exposure, resulting in enhanced T-cell killing. 2014 , 5, 403-16 | 260 |
| 1771 | Cooperative interactions between p53 and NFB enhance cell plasticity. 2014 , 5, 12111-25 | 22 |
| 1770 | Epithelial ovarian cancer: An overview. 2014 , 3, 1-8 | 72 |
| 1769 | miR-142 regulates the tumorigenicity of human breast cancer stem cells through the canonical WNT signaling pathway. 2014 , 3, | 128 |
| 1768 | The horizon of precision medicine in breast cancer: fragmentation, alliance, or reunification?. 2014 , e5-10 | 3 |
| 1767 | Implications of functional proteomics in breast cancer. 2014 , 19, 328-35 | 14 |
| 1766 | HER2-positive endometrial cancer subtype carries poor prognosis. 2014 , 7, 482-8 | 16 |
| 1765 | Subtyping of breast cancer using reverse phase protein arrays. 2014 , 11, 757-70 | 13 |
| 1764 | PIK3CA mutations in Peruvian patients with HER2-amplified and triple negative non-metastatic breast cancers. 2014 , 7, 142-8 | 13 |
| 1763 | Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors. 2014 , 25, 552-563 | 242 |
| 1762 | Prediction of individualized therapeutic vulnerabilities in cancer from genomic profiles. 2014 , 30, 2051-9 | 28 |
| 1761 | Molecular breast cancer subtypes and therapies in a public hospital of northeastern Brazil. 2014 , 14, 110 | 22 |
| 1760 | STAT3-mediated autophagy dependence identifies subtypes of breast cancer where autophagy inhibition can be efficacious. 2014 , 74, 2579-90 | 117 |
| 1759 | Compact variant-rich customized sequence database and a fast and sensitive database search for efficient proteogenomic analyses. 2014 , 14, 2742-9 | 19 |
| 1758 | Tapping microRNA regulation networks through integrated analysis of microRNA-mRNA high-throughput profiles. 2014 , 1182, 279-88 | |
| 1757 | Mislocalization of the cell polarity protein scribble promotes mammary tumorigenesis and is associated with basal breast cancer. 2014 , 74, 3180-94 | 76 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1756 | Personalized Cancer Therapy. 2014 , 671-824 | 1 |
| 1755 | Genome-based risk prediction for early stage breast cancer. 2014 , 19, 1019-27 | 4 |
| 1754 | Hallmarks of triple negative breast cancer emerging at last?. 2014 , 24, 904-5 | 39 |
| 1753 | Intrinsic subtypes from PAM50 gene expression assay in a population-based breast cancer cohort: differences by age, race, and tumor characteristics. 2014 , 23, 714-24 | 84 |
| 1752 | FOXC1 is a critical mediator of EGFR function in human basal-like breast cancer. 2014 , 21 Suppl 4, S758-66 | 31 |
| 1751 | BSSV: Bayesian based somatic structural variation identification with whole genome DNA-seq data. 2014 , 2014, 3937-40 | 1 |
| 1750 | The KDM5 family of histone demethylases as targets in oncology drug discovery. 2014 , 6, 277-86 | 78 |
| 1749 | The emerging roles of ARID1A in tumor suppression. 2014 , 15, 655-64 | 148 |
| 1748 | Transcriptional CCND1 expression as a predictor of poor response to neoadjuvant chemotherapy with trastuzumab in HER2-positive/ER-positive breast cancer. 2014 , 147, 513-25 | 12 |
| 1747 | A general framework for analyzing tumor subclonality using SNP array and DNA sequencing data. 2014 , 15, 473 | 52 |
| 1746 | L1CAM is expressed in triple-negative breast cancers and is inversely correlated with androgen receptor. 2014 , 14, 958 | 22 |
| 1745 | Meta-analysis of the global gene expression profile of triple-negative breast cancer identifies genes for the prognostication and treatment of aggressive breast cancer. 2014 , 3, e100 | 45 |
| 1744 | Invasive Breast Carcinoma. 2014 , 934-951 | 3 |
| 1743 | Gene therapy for cancer: present status and future perspective. 2014 , 2, 27 | 135 |
| 1742 | Luminal breast cancer metastases and tumor arousal from dormancy are promoted by direct actions of estradiol and progesterone on the malignant cells. 2014 , 16, 489 | 41 |
| 1741 | Combined image and genomic analysis of high-grade serous ovarian cancer reveals PTEN loss as a common driver event and prognostic classifier. 2014 , 15, 526 | 74 |
| 1740 | Characterization of age signatures of DNA methylation in normal and cancer tissues from multiple studies. 2014 , 15, 997 | 16 |
| 1739 | Genome-driven integrated classification of breast cancer validated in over 7,500 samples. 2014 , 15, 431 | 130 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1738 | Smoking status impacts microRNA mediated prognosis and lung adenocarcinoma biology. 2014 , 14, 778 | 34 |
| 1737 | A four-long non-coding RNA signature in predicting breast cancer survival. 2014 , 33, 84 | 122 |
| 1736 | Epigenetic deregulation in pediatric acute lymphoblastic leukemia. 2014 , 9, 459-67 | 32 |
| 1735 | NUSAP1 influences the DNA damage response by controlling BRCA1 protein levels. 2014 , 15, 533-43 | 23 |
| 1734 | PI3K pathway activation in high-grade ductal carcinoma in situ—implications for progression to invasive breast carcinoma. 2014 , 20, 2326-37 | 37 |
| 1733 | PIK3CA activating mutations: a discordant role in early versus advanced hormone-dependent estrogen receptor-positive breast cancer?. 2014 , 32, 2932-4 | 29 |
| 1732 | Optimising parallel R correlation matrix calculations on gene expression data using MapReduce. 2014 , 15, 351 | 14 |
| 1731 | Statistical measures of transcriptional diversity capture genomic heterogeneity of cancer. 2014 , 15, 876 | 19 |
| 1730 | BADGE: a novel Bayesian model for accurate abundance quantification and differential analysis of RNA-Seq data. 2014 , 15 Suppl 9, S6 | 7 |
| 1729 | Distinct luminal-type mammary carcinomas arise from orthotopic Trp53-null mammary transplantation of juvenile versus adult mice. 2014 , 74, 7149-58 | 1 |
| 1728 | Genome-based approaches for the diagnosis of breast cancer: a review with perspective. 2014 , 3, 173-193 | |
| 1727 | Cancer-relevant splicing factor CAPER engages the essential splicing factor SF3b155 in a specific ternary complex. 2014 , 289, 17325-37 | 30 |
| 1726 | Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinase. 2014 , 16, 430 | 55 |
| 1725 | Bioinformatics in otolaryngology research. Part two: other high-throughput platforms in genomics and epigenetics. 2014 , 128, 942-7 | 0 |
| 1724 | Effect of estrogen receptor binding on functional DNA methylation in breast cancer. 2014 , 9, 523-32 | 26 |
| 1723 | PRMT2 and ROR expression are associated with breast cancer survival outcomes. 2014 , 28, 1166-85 | 36 |
| 1722 | Mammary gland-specific ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation. 2014 , 110, 2747-55 | 11 |
| 1721 | HER2-positive advanced breast cancer: optimizing patient outcomes and opportunities for drug development. 2014 , 111, 1888-98 | 83 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1720 | Brain somatic mutations: the dark matter of psychiatric genetics?. 2014 , 19, 156-8 | 43 |
| 1719 | The AURORA initiative for metastatic breast cancer. 2014 , 111, 1881-7 | 68 |
| 1718 | Frequent phosphatidylinositol-3-kinase mutations in proliferative breast lesions. 2014 , 27, 740-50 | 36 |
| 1717 | Membranous Nectin-4 expression is a risk factor for distant relapse of T1-T2, N0 luminal-A early breast cancer. 2014 , 3, e118 | 24 |
| 1716 | MMTV-Espl1 transgenic mice develop aneuploid, estrogen receptor alpha (ER) positive mammary adenocarcinomas. 2014 , 33, 5511-5522 | 47 |
| 1715 | TraceRNA: a web application for competing endogenous RNA exploration. 2014 , 7, 548-57 | 2 |
| 1714 | Dual targeting of hypoxia and homologous recombination repair dysfunction in triple-negative breast cancer. 2014 , 13, 2501-14 | 34 |
| 1713 | Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer. 2014 , 19, 135-50 | 43 |
| 1712 | Retinoblastoma pathway deregulatory mechanisms determine clinical outcome in high-grade serous ovarian carcinoma. 2014 , 27, 991-1001 | 29 |
| 1711 | A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress. 2014 , 5, e1194 | 71 |
| 1710 | Unfolding triple-negative breast cancer. 2014 , 7, 421-421 | |
| 1709 | Kinome-wide screening of HER2+ breast cancer cells for molecules that mediate cell proliferation or sensitize cells to trastuzumab therapy. 2014 , 3, e133 | 13 |
| 1708 | Taspase1 cleaves MLL1 to activate cyclin E for HER2/neu breast tumorigenesis. 2014 , 24, 1354-66 | 23 |
| 1707 | Involvement of polypyrimidine tract-binding protein (PTBP1) in maintaining breast cancer cell growth and malignant properties. 2014 , 3, e84 | 68 |
| 1706 | The atypical ubiquitin ligase RNF31 stabilizes estrogen receptor and modulates estrogen-stimulated breast cancer cell proliferation. 2014 , 33, 4340-51 | 65 |
| 1705 | PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies. 2014 , 25, 32-40 | 234 |
| 1704 | MicroRNA Expression Profiling and Its Clinical Impact in Breast Cancer. 2014 , 355-367 | 2 |
| 1703 | Proteomic analysis of phosphorylation in cancer. 2014 , 11, 259-67 | 36 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1702 | Identifying Cancer Subtypes based on Somatic Mutation Profile. 2014 , | 3 |
| 1701 | Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. 2014 , 24, 743-50 | 440 |
| 1700 | Herbal extract SH003 suppresses tumor growth and metastasis of MDA-MB-231 breast cancer cells by inhibiting STAT3-IL-6 signaling. 2014 , 2014, 492173 | 30 |
| 1699 | Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. 2014 , 7, ra114 | 79 |
| 1698 | A novel model to combine clinical and pathway-based transcriptomic information for the prognosis prediction of breast cancer. 2014 , 10, e1003851 | 58 |
| 1697 | miR-100 induces epithelial-mesenchymal transition but suppresses tumorigenesis, migration and invasion. 2014 , 10, e1004177 | 88 |
| 1696 | Characterization of the usage of the serine metabolic network in human cancer. 2014 , 9, 1507-19 | 94 |
| 1695 | SciClone: inferring clonal architecture and tracking the spatial and temporal patterns of tumor evolution. 2014 , 10, e1003665 | 301 |
| 1694 | Molecular biology of brain metastasis. 2014 , 15, 9519-30 | 30 |
| 1693 | Genetic predisposition to in situ and invasive lobular carcinoma of the breast. 2014 , 10, e1004285 | 38 |
| 1692 | Advanced heat map and clustering analysis using heatmap3. 2014 , 2014, 986048 | 150 |
| 1691 | Retired self-proteins as vaccine targets for primary immunoprevention of adult-onset cancers. 2014 , 13, 1447-62 | 11 |
| 1690 | Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. 2014 , 7, 203-15 | 69 |
| 1689 | AKT-induced tamoxifen resistance is overturned by RRM2 inhibition. 2014 , 12, 394-407 | 36 |
| 1688 | MiR-155 at the heart of oncogenic pathways. 2014 , 33, 677-8 | 44 |
| 1687 | Membrane domain formation-a key factor for targeted intracellular drug delivery. 2014 , 5, 462 | 1 |
| 1686 | Tug of war between survival and death: exploring ATM function in cancer. 2014 , 15, 5388-409 | 23 |
| 1685 | Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. 2014 , 10, e1003409 | 35 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1684 | A supervised network analysis on gene expression profiles of breast tumors predicts a 41-gene prognostic signature of the transcription factor MYB across molecular subtypes. 2014 , 2014, 813067 | 13 |
| 1683 | Targeted H3R26 deimination specifically facilitates estrogen receptor binding by modifying nucleosome structure. 2014 , 10, e1004613 | 31 |
| 1682 | Abnormal dosage of ultraconserved elements is highly disfavored in healthy cells but not cancer cells. 2014 , 10, e1004646 | 15 |
| 1681 | Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry. 2014 , 25, 773-780 | 5 |
| 1680 | MODMatcher: multi-omics data matcher for integrative genomic analysis. 2014 , 10, e1003790 | 25 |
| 1679 | Hydroxymethylated cytosines are associated with elevated C to G transversion rates. 2014 , 10, e1004585 | 28 |
| 1678 | Standard of care and promising new agents for triple negative metastatic breast cancer. 2014 , 6, 2187-223 | 32 |
| 1677 | Identification of drivers from cancer genome diversity in hepatocellular carcinoma. 2014 , 15, 11142-60 | 35 |
| 1676 | RidgeRace: ridge regression for continuous ancestral character estimation on phylogenetic trees. 2014 , 30, i527-33 | 18 |
| 1675 | Molecular markers for breast cancer: prediction on tumor behavior. 2014 , 2014, 513158 | 104 |
| 1674 | Tumour-associated mutations of PA-TM-RING ubiquitin ligases RNF167/RNF13 identify the PA domain as a determinant for endosomal localization. 2014 , 459, 27-36 | 12 |
| 1673 | Predictive factors for response to neoadjuvant therapy in breast cancer. 2014 , 37, 563-8 | 17 |
| 1672 | Microbial contamination in next generation sequencing: implications for sequence-based analysis of clinical samples. 2014 , 10, e1004437 | 118 |
| 1671 | Pathway-driven discovery of rare mutational impact on cancer. 2014 , 2014, 171892 | 3 |
| 1670 | OmicCircos: A Simple-to-Use R Package for the Circular Visualization of Multidimensional Omics Data. 2014 , 13, 13-20 | 111 |
| 1669 | The oncogenic potential of human cytomegalovirus and breast cancer. 2014 , 4, 230 | 40 |
| 1668 | Regulation of Ras localization and cell transformation by evolutionarily conserved palmitoyltransferases. 2014 , 34, 374-85 | 21 |
| 1667 | BRCA and Early Events in the Development of Serous Ovarian Cancer. 2014 , 4, 5 | 43 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1666 | Predictive value of phosphorylated mammalian target of rapamycin for disease-free survival in breast cancer patients receiving neoadjuvant chemotherapy. 2014 , 8, 2642-2648 | 1 |
| 1665 | Emerging understanding of multiscale tumor heterogeneity. 2014 , 4, 366 | 73 |
| 1664 | A new method for predicting patient survivorship using efficient bayesian network learning. 2014 , 13, 47-57 | 10 |
| 1663 | Bionimbus: a cloud for managing, analyzing and sharing large genomics datasets. 2014 , 21, 969-75 | 56 |
| 1662 | Targeting PI3K/mTOR overcomes resistance to HER2-targeted therapy independent of feedback activation of AKT. 2014 , 20, 3507-20 | 83 |
| 1661 | SLIT/ROBO2 signaling promotes mammary stem cell senescence by inhibiting Wnt signaling. 2014 , 3, 385-93 | 19 |
| 1660 | Mitochondrial dysfunction in some triple-negative breast cancer cell lines: role of mTOR pathway and therapeutic potential. 2014 , 16, 434 | 111 |
| 1659 | World Endometriosis Research Foundation Endometriosis Phenome and Biobanking Harmonisation Project: IV. Tissue collection, processing, and storage in endometriosis research. 2014 , 102, 1244-53 | 100 |
| 1658 | In vivo multiplexed interrogation of amplified genes identifies GAB2 as an ovarian cancer oncogene. 2014 , 111, 1102-7 | 35 |
| 1657 | Molecular mechanisms regulating the hormone sensitivity of breast cancer. 2014 , 105, 1377-83 | 24 |
| 1656 | What do the changes in the aging genome mean for pharmacogenomics?. 2014 , 15, 1725-1728 | |
| 1655 | Using molecular profiled human tissue to accelerate drug discovery. 2014 , 9, 1383-7 | 1 |
| 1654 | Systems consequences of amplicon formation in human breast cancer. 2014 , 24, 1559-71 | 21 |
| 1653 | Autocrine Activation of the Wnt/ β Catenin Pathway by CUX1 and GLIS1 in Breast Cancers. 2014 , 3, 937-46 | 32 |
| 1652 | Estrogen receptor mutations in breast cancer-an anticipated "rediscovery?". 2014 , 28, 427-8 | 4 |
| 1651 | Detecting independent and recurrent copy number aberrations using interval graphs. 2014 , 30, i195-203 | 20 |
| 1650 | Transcriptional specialization of human dendritic cell subsets in response to microbial vaccines. 2014 , 5, 5283 | 41 |
| 1649 | Targeting SH2 domains in breast cancer. 2014 , 6, 1909-26 | 45 |

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| 1648 | Linking signaling pathways to transcriptional programs in breast cancer. 2014 , 24, 1869-80 | 44 |
| 1647 | The oncogenic STP axis promotes triple-negative breast cancer via degradation of the REST tumor suppressor. 2014 , 9, 1318-32 | 15 |
| 1646 | Multigene Assays for Classification, Prognosis, and Prediction in Breast Cancer: a Critical Review on the Background and Clinical Utility. 2014 , 11, 153-161 | |
| 1645 | Molecular Markers as Prognostic Factors in DCIS and Small Invasive Breast Cancers. 2014 , 74, 1016-1022 | 9 |
| 1644 | Conditional knockout mouse models of cancer. 2014 , 2014, 1217-33 | 18 |
| 1643 | Pluripotent stem cell miRNAs and metastasis in invasive breast cancer. 2014 , 106, | 25 |
| 1642 | Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. 2014 , 26, 623-37 | 513 |
| 1641 | Single-cell Western blotting after whole-cell imaging to assess cancer chemotherapeutic response. 2014 , 86, 10429-36 | 76 |
| 1640 | RARRES3 suppresses breast cancer lung metastasis by regulating adhesion and differentiation. 2014 , 6, 865-81 | 51 |
| 1639 | Molecular features and survival outcomes of the intrinsic subtypes within HER2-positive breast cancer. 2014 , 106, | 132 |
| 1638 | High expression of LMTK3 is an independent factor indicating a poor prognosis in estrogen receptor β -positive breast cancer patients. 2014 , 44, 889-97 | 4 |
| 1637 | Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets. 2014 , 4, 232-45 | 310 |
| 1636 | Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer \square 2014 , 25, 1122-7 | 76 |
| 1635 | Combined deletion of Pten and p53 in mammary epithelium accelerates triple-negative breast cancer with dependency on eEF2K. 2014 , 6, 1542-60 | 80 |
| 1634 | TRIM37 is a new histone H2A ubiquitin ligase and breast cancer oncoprotein. <i>Nature</i> , 2014 , 516, 116-20 | 50.4 112 |
| 1633 | Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer. 2014 , 32, 3848-57 | 58 |
| 1632 | The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. 2014 , 26, 923-937 | 562 |
| 1631 | Reply to: Comparative analysis of GATA3 mutation profiles between Asian and Western patients with breast cancer. Is there really a difference?. 2014 , 120, 2779-80 | |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 1630 | Cancer beyond organ and tissue specificity: next-generation-sequencing gene mutation data reveal complex genetic similarities across major cancers. 2014 , 135, 2362-9 | 30 |
| 1629 | Extrachromosomal driver mutations in glioblastoma and low-grade glioma. 2014 , 5, 5690 | 45 |
| 1628 | Integration of genomic data enables selective discovery of breast cancer drivers. 2014 , 159, 1461-75 | 67 |
| 1627 | Chemogenetic evaluation of the mitotic kinesin CENP-E reveals a critical role in triple-negative breast cancer. 2014 , 13, 2104-15 | 41 |
| 1626 | Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry. 2014 , 15, e625-e634 | 141 |
| 1625 | Stromal expression of miR-21 identifies high-risk group in triple-negative breast cancer. 2014 , 184, 3217-25 | 35 |
| 1624 | Axes of differentiation in breast cancer: untangling stemness, lineage identity, and the epithelial to mesenchymal transition. 2014 , 6, 93-106 | 12 |
| 1623 | Integrated genomic characterization of papillary thyroid carcinoma. 2014 , 159, 676-90 | 1660 |
| 1622 | Proteogenomic strategies for identification of aberrant cancer peptides using large-scale next-generation sequencing data. 2014 , 14, 2719-30 | 47 |
| 1621 | The lipid-transfer protein Nir2 enhances epithelial-mesenchymal transition and facilitates breast cancer metastasis. 2014 , 127, 4740-9 | 20 |
| 1620 | Oncogenic activity of the regulatory subunit p85 β of phosphatidylinositol 3-kinase (PI3K). 2014 , 111, 16826-9 | 27 |
| 1619 | Antitumor activity of the glutaminase inhibitor CB-839 in triple-negative breast cancer. 2014 , 13, 890-901 | 573 |
| 1618 | Emerging research and clinical development trends of liposome and lipid nanoparticle drug delivery systems. 2014 , 103, 29-52 | 334 |
| 1617 | Lessons learned from the intrinsic subtypes of breast cancer in the quest for precision therapy. 2014 , 101, 925-38 | 30 |
| 1616 | GATA3 mutations define a unique subtype of luminal-like breast cancer with improved survival. 2014 , 120, 1329-37 | 48 |
| 1615 | Insights into wild-type and mutant p53 functions provided by genetically engineered mice. 2014 , 35, 715-27 | 25 |
| 1614 | Effects of TP53 mutational status on gene expression patterns across 10 human cancer types. 2014 , 232, 522-33 | 52 |
| 1613 | Induction of entosis by epithelial cadherin expression. 2014 , 24, 1288-98 | 82 |

| | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1612 | Copy number gain of hsa-miR-569 at 3q26.2 leads to loss of TP53INP1 and aggressiveness of epithelial cancers. 2014 , 26, 863-879 | 34 |
| 1611 | Next-Generation Sequencing: How Close Are We to Clinical Application?. 2014 , 25, 296-299 | |
| 1610 | A novel reannotation strategy for dissecting DNA methylation patterns of human long intergenic non-coding RNAs in cancers. 2014 , 42, 8258-70 | 34 |
| 1609 | Hypoxia-inducible factors are required for chemotherapy resistance of breast cancer stem cells. 2014 , 111, E5429-38 | 349 |
| 1608 | Mutational profiling of familial male breast cancers reveals similarities with luminal A female breast cancer with rare TP53 mutations. 2014 , 111, 2351-60 | 17 |
| 1607 | The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers. 2014 , 6, 154-66 | 251 |
| 1606 | TPD52 represents a survival factor in ERBB2-amplified breast cancer cells. 2014 , 53, 807-19 | 25 |
| 1605 | Growing indication for FNA to study and analyze tumor heterogeneity at metastatic sites. 2014 , 122, 504-11 | 15 |
| 1604 | Morgana acts as a proto-oncogene through inhibition of a ROCK-PTEN pathway. 2014 , 234, 152-63 | 19 |
| 1603 | Polymalic acid-based nano biopolymers for targeting of multiple tumor markers: an opportunity for personalized medicine?. 2014 , | 14 |
| 1602 | Relationship of PIK3CA mutation and pathway activity with antiproliferative response to aromatase inhibition. 2014 , 16, R68 | 20 |
| 1601 | MicroRNA-18a inhibits hypoxia-inducible factor 1 activity and lung metastasis in basal breast cancers. 2014 , 16, R78 | 75 |
| 1600 | Polarity gene alterations in pure invasive micropapillary carcinomas of the breast. 2014 , 16, R46 | 30 |
| 1599 | DOTS-Finder: a comprehensive tool for assessing driver genes in cancer genomes. 2014 , 6, 44 | 21 |
| 1598 | Receptor-interacting protein kinase 2 promotes triple-negative breast cancer cell migration and invasion via activation of nuclear factor-kappaB and c-Jun N-terminal kinase pathways. 2014 , 16, R28 | 31 |
| 1597 | Identification of distinct miRNA target regulation between breast cancer molecular subtypes using AGO2-PAR-CLIP and patient datasets. 2014 , 15, R9 | 51 |
| 1596 | Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells. 2014 , 16, 504 | 11 |
| 1595 | EGFR as a potential therapeutic target for a subset of muscle-invasive bladder cancers presenting a basal-like phenotype. 2014 , 6, 244ra91 | 202 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1594 | Reptation-induced coalescence of tunnels and cavities in Escherichia Coli Xyle transporter conformers accounts for facilitated diffusion. 2014 , 247, 1161-79 | 8 |
| 1593 | Anti-nicestrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells. 2014 , 148, 455-62 | 18 |
| 1592 | Understanding the Paradigm Challenges Posed by Multiplex Panel Testing for Cancer Susceptibility. 2014 , 2, 250-254 | |
| 1591 | Population dynamics inside cancer biomass driven by repeated hypoxia-reoxygenation cycles. 2014 , 2, 85-99 | 7 |
| 1590 | A fine-scale dissection of the DNA double-strand break repair machinery and its implications for breast cancer therapy. 2014 , 42, 6106-27 | 53 |
| 1589 | Tumor subtype-specific cancer-testis antigens as potential biomarkers and immunotherapeutic targets for cancers. 2014 , 2, 371-9 | 64 |
| 1588 | iGPSe: a visual analytic system for integrative genomic based cancer patient stratification. 2014 , 15, 203 | 16 |
| 1587 | Estrogen independent gene expression defines clinically relevant subgroups of estrogen receptor positive breast cancer. 2014 , 14, 871 | 2 |
| 1586 | Claudin-low breast cancers: clinical, pathological, molecular and prognostic characterization. 2014 , 13, 228 | 73 |
| 1585 | Combining functional genomics strategies identifies modular heterogeneity of breast cancer intrinsic subtypes. 2014 , 7, 27 | 2 |
| 1584 | Semi-automated literature mining to identify putative biomarkers of disease from multiple biofluids. 2014 , 4, 13 | 6 |
| 1583 | Triple-negative vimentin-positive heterogeneous feline mammary carcinomas as a potential comparative model for breast cancer. 2014 , 10, 185 | 25 |
| 1582 | Integrative network analysis of TCGA data for ovarian cancer. 2014 , 8, 1338 | 52 |
| 1581 | Onco-STS: a web-based laboratory information management system for sample and analysis tracking in oncogenomic experiments. 2014 , 9, 25 | 3 |
| 1580 | Methylation profiling of ductal carcinoma in situ and its relationship to histopathological features. 2014 , 16, 423 | 16 |
| 1579 | Significance of glioma-associated oncogene homolog 1 (GLI1) expression in claudin-low breast cancer and crosstalk with the nuclear factor kappa-light-chain-enhancer of activated B cells (NF κ B) pathway. 2014 , 16, 444 | 49 |
| 1578 | DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival. 2014 , 16, 450 | 64 |
| 1577 | New concepts in breast cancer genomics and genetics. 2014 , 16, 460 | 23 |

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1576 | Shift in GATA3 functions, and GATA3 mutations, control progression and clinical presentation in breast cancer. 2014 , 16, 464 | 26 |
| 1575 | Identification by array comparative genomic hybridization of a new amplicon on chromosome 17q highly recurrent in BRCA1 mutated triple negative breast cancer. 2014 , 16, 466 | 24 |
| 1574 | Progesterone receptor activation downregulates GATA3 by transcriptional repression and increased protein turnover promoting breast tumor growth. 2014 , 16, 491 | 24 |
| 1573 | Estrogen receptor mutations and their role in breast cancer progression. 2014 , 16, 494 | 69 |
| 1572 | Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. 2014 , 16, 3417 | 14 |
| 1571 | Toca-1 is suppressed by p53 to limit breast cancer cell invasion and tumor metastasis. 2014 , 16, 3413 | 11 |
| 1570 | Genome-wide DNA methylation profiles in progression to in situ and invasive carcinoma of the breast with impact on gene transcription and prognosis. 2014 , 15, 435 | 108 |
| 1569 | Cancer progression modeling using static sample data. 2014 , 15, 440 | 18 |
| 1568 | A multi-gene signature predicts outcome in patients with pancreatic ductal adenocarcinoma. 2014 , 6, 105 | 76 |
| 1567 | Evaluation of efficacy of a new MEK inhibitor, RO4987655, in human tumor xenografts by [(18)F] FDG-PET imaging combined with proteomic approaches. 2014 , 4, 34 | 8 |
| 1566 | Phosphoprotein secretome of tumor cells as a source of candidates for breast cancer biomarkers in plasma. 2014 , 13, 1034-49 | 35 |
| 1565 | BRCA1 and BRCA2 Cancer Syndromes and Clinical Significance. 2014 , 19, 43-48 | |
| 1564 | State of the art of genetic alterations in thymic epithelial tumors. 2014 , 9, S131-6 | 40 |
| 1563 | Therapeutic priority of the PI3K/AKT/mTOR pathway in small cell lung cancers as revealed by a comprehensive genomic analysis. 2014 , 9, 1324-31 | 120 |
| 1562 | Expression of HER-2 in rectal cancers treated with preoperative radiotherapy: a potential biomarker predictive of metastasis. 2014 , 57, 602-7 | 21 |
| 1561 | Triple-negative breast cancer: molecular subtypes and targeted therapy. 2014 , 26, 34-40 | 26 |
| 1560 | Realizing the promise of reverse phase protein arrays for clinical, translational, and basic research: a workshop report: the RPPA (Reverse Phase Protein Array) society. 2014 , 13, 1625-43 | 117 |
| 1559 | miR-221/222 control luminal breast cancer progression by regulating different targets. 2014 , 13, 1811-26 | 30 |

| | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1558 | Cyclin-dependent kinase 4/6 inhibitors in breast cancer therapy. 2014 , 26, 568-75 | 28 |
| 1557 | Sequencing efforts help to refine the molecular classification of breast cancer. 2014 , 26, 18-20 | |
| 1556 | TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance. 2014 , 20, 3569-80 | 167 |
| 1555 | Kinetochore genes are coordinately up-regulated in human tumors as part of a FoxM1-related cell division program. 2014 , 25, 1983-94 | 36 |
| 1554 | Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer. 2014 , 20, 413-24 | 46 |
| 1553 | Functional genetic approach identifies MET, HER3, IGF1R, INSR pathways as determinants of lapatinib unresponsiveness in HER2-positive gastric cancer. 2014 , 20, 4559-73 | 53 |
| 1552 | Gene co-expression modules as clinically relevant hallmarks of breast cancer diversity. 2014 , 9, e88309 | 63 |
| 1551 | NCG 4.0: the network of cancer genes in the era of massive mutational screenings of cancer genomes. 2014 , 2014, bau015 | 47 |
| 1550 | Normal cell phenotypes of breast epithelial cells provide the foundation of a breast cancer taxonomy. 2014 , 14, 1385-9 | 11 |
| 1549 | PDGF receptors in tumor biology: prognostic and predictive potential. 2014 , 10, 1695-708 | 68 |
| 1548 | IL15RA drives antagonistic mechanisms of cancer development and immune control in lymphocyte-enriched triple-negative breast cancers. 2014 , 74, 4908-21 | 25 |
| 1547 | Taxonomy of breast cancer based on normal cell phenotype predicts outcome. 2014 , 124, 859-70 | 134 |
| 1546 | The eSNV-detect: a computational system to identify expressed single nucleotide variants from transcriptome sequencing data. 2014 , 42, e172 | 26 |
| 1545 | Rapid induction of apoptosis by PI3K inhibitors is dependent upon their transient inhibition of RAS-ERK signaling. 2014 , 4, 334-47 | 133 |
| 1544 | Chromosomal instability selects gene copy-number variants encoding core regulators of proliferation in ER+ breast cancer. 2014 , 74, 4853-4863 | 42 |
| 1543 | Complexities of androgen receptor signalling in breast cancer. 2014 , 21, T161-81 | 95 |
| 1542 | Favorable prognostic impact in loss of TP53 and PIK3CA mutations after neoadjuvant chemotherapy in breast cancer. 2014 , 74, 3399-407 | 31 |
| 1541 | Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence. 2014 , 74, 2340-50 | 204 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1540 | DNA replication error-induced extinction of diploid yeast. 2014 , 196, 677-91 | 36 |
| 1539 | Changing the paradigm: circulating tumor DNA as a "liquid biopsy" for clinical biomarker assessments. 2014 , 4, 1083-1093 | 1 |
| 1538 | Age-related DNA methylation in normal breast tissue and its relationship with invasive breast tumor methylation. 2014 , 9, 268-75 | 47 |
| 1537 | Frequent promoter hypermethylation and expression reduction of the glucocorticoid receptor gene in breast tumors. 2014 , 9, 851-9 | 30 |
| 1536 | Theranostic and molecular classification of breast cancer. 2014 , 138, 44-56 | 35 |
| 1535 | Association of H3K9me3 and H3K27me3 repressive histone marks with breast cancer subtypes in the Nurses' Health Study. 2014 , 147, 639-51 | 37 |
| 1534 | Lapatinib-associated mucocutaneous toxicities are clinical predictors of improved progression-free survival in patients with human epidermal growth factor receptor (HER2)-positive advanced breast cancer. 2014 , 148, 197-209 | 6 |
| 1533 | Application of Theranostics to Measure and Treat Cell Heterogeneity in Cancer. 2014 , 493-516 | 1 |
| 1532 | Oncoproteomics. 2014 , 63-85 | |
| 1531 | Omics Approaches in Breast Cancer. 2014 , | 8 |
| 1530 | Breast Cancer Genomics. 2014 , 53-103 | |
| 1529 | Clinical application of whole-genome sequencing: proceed with care. 2014 , 311, 1017-9 | 45 |
| 1528 | PI3K/Akt-mediated regulation of p53 in cancer. 2014 , 42, 798-803 | 117 |
| 1527 | MarvelD3 couples tight junctions to the MEK1-JNK pathway to regulate cell behavior and survival. 2014 , 204, 821-38 | 50 |
| 1526 | PARP-1 inhibitors and radiotherapy sensitivity: future prospects for therapy?. 2014 , 3, 281-296 | 2 |
| 1525 | The impact of vitamin D in breast cancer: genomics, pathways, metabolism. 2014 , 5, 213 | 77 |
| 1524 | Cancer evolution is associated with pervasive positive selection on globally expressed genes. 2014 , 10, e1004239 | 72 |
| 1523 | Microarray R-based analysis of complex lysate experiments with MIRACLE. 2014 , 30, i631-8 | 8 |

| | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1522 | Human breast cancer metastases to the brain display GABAergic properties in the neural niche. 2014 , 111, 984-9 | 185 |
| 1521 | Genetic risk signatures of opioid-induced respiratory depression following pediatric tonsillectomy. 2014 , 15, 1749-1762 | 20 |
| 1520 | Mining genome sequencing data to identify the genomic features linked to breast cancer histopathology. 2014 , 5, 3 | 19 |
| 1519 | A Novel Subset of Human Tumors That Simultaneously Overexpress Multiple E2F-responsive Genes Found in Breast, Ovarian, and Prostate Cancers. 2014 , 13, 89-100 | 13 |
| 1518 | The PTEN/PI3K/AKT Pathway in vivo, Cancer Mouse Models. 2014 , 4, 252 | 126 |
| 1517 | BRCA 1/2-Mutation Related and Sporadic Breast and Ovarian Cancers: More Alike than Different. 2014 , 4, 19 | 31 |
| 1516 | Age-specific changes in intrinsic breast cancer subtypes: a focus on older women. 2014 , 19, 1076-83 | 85 |
| 1515 | Whole exome sequencing for cancer – is there evidence of clinical utility?. 2014 , 115 | 2 |
| 1514 | Multidrug-resistant breast cancer: current perspectives. 2014 , 6, 1-13 | 61 |
| 1513 | Emerging role of cell polarity proteins in breast cancer progression and metastasis. 2014 , 6, 15-27 | 17 |
| 1512 | Palbociclib: an evidence-based review of its potential in the treatment of breast cancer. 2014 , 6, 123-33 | 50 |
| 1511 | PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data. 2014 , 16, 201 | 75 |
| 1510 | Patient-derived xenografts of triple-negative breast cancer reproduce molecular features of patient tumors and respond to mTOR inhibition. 2014 , 16, R36 | 55 |
| 1509 | Using high-density DNA methylation arrays to profile copy number alterations. 2014 , 15, R30 | 79 |
| 1508 | Mutational analysis of PI3K/AKT signaling pathway in tamoxifen exemestane adjuvant multinational pathology study. 2014 , 32, 2951-8 | 85 |
| 1507 | Whole-genome sequencing of asian lung cancers: second-hand smoke unlikely to be responsible for higher incidence of lung cancer among Asian never-smokers. 2014 , 74, 6071-81 | 35 |
| 1506 | Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. 2014 , 20, 3818-29 | 168 |
| 1505 | Clinical value of isoform-specific detection and targeting of AKT1, AKT2 and AKT3 in breast cancer. 2014 , 3, 409-421 | 3 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1504 | Thyroid hormone receptor interacting protein 13 (TRIP13) AAA-ATPase is a novel mitotic checkpoint-silencing protein. 2014 , 289, 23928-37 | 101 |
| 1503 | Structure-based predictions broadly link transcription factor mutations to gene expression changes in cancers. 2014 , 42, 12973-83 | 3 |
| 1502 | Using molecular profiles to tailor treatment in breast cancer: are they ready for prime time?. 2014 , 26, 21-6 | 1 |
| 1501 | A fast multilocus test with adaptive SNP selection for large-scale genetic-association studies. 2014 , 22, 696-702 | 17 |
| 1500 | STAT signaling in different breast cancer sub-types. 2014 , 382, 612-615 | 46 |
| 1499 | Prediction of tamoxifen outcome by genetic variation of CYP2D6 in post-menopausal women with early breast cancer. 2014 , 77, 695-703 | 38 |
| 1498 | Individualizing breast cancer treatment-The dawn of personalized medicine. 2014 , 320, 1-11 | 24 |
| 1497 | c-Myc and Her2 cooperate to drive a stem-like phenotype with poor prognosis in breast cancer. 2014 , 33, 3992-4002 | 71 |
| 1496 | p70S6 kinase mediates breast cancer cell survival in response to surgical wound fluid stimulation. 2014 , 8, 766-80 | 24 |
| 1495 | OPG and PgR show similar cohort specific effects as prognostic factors in ER positive breast cancer. 2014 , 8, 1196-207 | 17 |
| 1494 | Role of aldo-keto reductase family 1 (AKR1) enzymes in human steroid metabolism. 2014 , 79, 49-63 | 117 |
| 1493 | Inference of tumor evolution during chemotherapy by computational modeling and in situ analysis of genetic and phenotypic cellular diversity. 2014 , 6, 514-27 | 194 |
| 1492 | CTCF haploinsufficiency destabilizes DNA methylation and predisposes to cancer. 2014 , 7, 1020-9 | 113 |
| 1491 | A Comprehensive Analysis of CXCL12 Isoforms in Breast Cancer. 2014 , 7, 429-429 | 30 |
| 1490 | TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. 2014 , 8, 508-19 | 49 |
| 1489 | The flavoprotein FOXRED2 reductively activates nitro-chloromethylbenzindolines and other hypoxia-targeting prodrugs. 2014 , 89, 224-35 | 18 |
| 1488 | Signaling through cyclin D-dependent kinases. 2014 , 33, 1890-903 | 203 |
| 1487 | The '-omics' revolution and oesophageal adenocarcinoma. 2014 , 11, 19-27 | 25 |

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1486 | Omics-based nanomedicine: the future of personalized oncology. 2014 , 352, 126-36 | 55 |
| 1485 | Opportunities and hurdles in the treatment of BRCA1-related breast cancer. 2014 , 33, 3753-63 | 24 |
| 1484 | A phase II study of combined fulvestrant and everolimus in patients with metastatic estrogen receptor (ER)-positive breast cancer after aromatase inhibitor (AI) failure. 2014 , 143, 325-32 | 43 |
| 1483 | Mutations in EGFR, BRAF and RAS are rare in triple-negative and basal-like breast cancers from Caucasian women. 2014 , 143, 385-92 | 43 |
| 1482 | Characterizing the heterogeneity of triple-negative breast cancers using microdissected normal ductal epithelium and RNA-sequencing. 2014 , 143, 57-68 | 25 |
| 1481 | The Fibroblast Growth Factor Receptor: A New Potential Target for the Treatment of Breast Cancer. 2014 , 6, 51-58 | 2 |
| 1480 | Tissue mechanics modulate microRNA-dependent PTEN expression to regulate malignant progression. 2014 , 20, 360-7 | 291 |
| 1479 | Tumor heterogeneity confounds and illuminates: a case for Darwinian tumor evolution. 2014 , 20, 344-6 | 51 |
| 1478 | E-cadherin acts as a tumour suppressor in E-cadherin-negative basal-like breast cancer by inhibiting NF- κ B signalling. 2014 , 16, 245-54 | 58 |
| 1477 | Emergence of constitutively active estrogen receptor- β mutations in pretreated advanced estrogen receptor-positive breast cancer. 2014 , 20, 1757-1767 | 415 |
| 1476 | Cancer Systems Biology: a peek into the future of patient care?. 2014 , 11, 167-76 | 120 |
| 1475 | Gene co-expression network analysis reveals common system-level properties of prognostic genes across cancer types. 2014 , 5, 3231 | 250 |
| 1474 | Aberrant DNA methylation of microRNA genes in human breast cancer - a critical appraisal. 2014 , 356, 657-64 | 20 |
| 1473 | Detection of a recurrent DNAJB1-PRKACA chimeric transcript in fibrolamellar hepatocellular carcinoma. 2014 , 343, 1010-4 | 281 |
| 1472 | Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer. 2014 , 144, 249-61 | 37 |
| 1471 | Wnt modulates MCL1 to control cell survival in triple negative breast cancer. 2014 , 14, 124 | 44 |
| 1470 | Tripelnegatives Mammakarzinom. 2014 , 9, 6-10 | |
| 1469 | Evaluation of histidine-rich glycoprotein tissue RNA and serum protein as novel markers for breast cancer. 2014 , 31, 897 | 7 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----------|
| 1468 | Molecular determinants of context-dependent progesterone receptor action in breast cancer. 2014 , 12, 32 | 52 |
| 1467 | PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer. 2014 , 117, 7-13 | 13 |
| 1466 | Direct inhibition of PI3K in combination with dual HER2 inhibitors is required for optimal antitumor activity in HER2+ breast cancer cells. 2014 , 16, R9 | 60 |
| 1465 | Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatment. 2014 , 16, R6 | 34 |
| 1464 | A network-assisted co-clustering algorithm to discover cancer subtypes based on gene expression. 2014 , 15, 37 | 55 |
| 1463 | Deregulation of the phosphatase, PP2A is a common event in breast cancer, predicting sensitivity to FTY720. 2014 , 5, 3 | 36 |
| 1462 | Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes. 2014 , 32, 14-24 | 37 |
| 1461 | Molecular tests as prognostic factors in breast cancer. 2014 , 464, 283-91 | 30 |
| 1460 | NBS1 Glu185Gln polymorphism and cancer risk: update on current evidence. 2014 , 35, 675-87 | 5 |
| 1459 | Identification of cellular and genetic drivers of breast cancer heterogeneity in genetically engineered mouse tumour models. 2014 , 233, 124-37 | 36 |
| 1458 | Integrated analysis of high-resolution DNA methylation profiles, gene expression, germline genotypes and clinical end points in breast cancer patients. 2014 , 134, 2615-25 | 32 |
| 1457 | XBP1 promotes triple-negative breast cancer by controlling the HIF1 α pathway. <i>Nature</i> , 2014 , 508, 103-107.4 | 512 |
| 1456 | Systems biology in drug discovery and development. 2014 , 19, 113-25 | 62 |
| 1455 | Comprehensive molecular characterization of urothelial bladder carcinoma. <i>Nature</i> , 2014 , 507, 315-22 | 50.4 1963 |
| 1454 | Epigenomic alterations define lethal CIMP-positive ependymomas of infancy. <i>Nature</i> , 2014 , 506, 445-50 | 50.4 434 |
| 1453 | Estrogen receptor mutations in breast cancer--new focus on an old target. 2014 , 20, 1724-6 | 33 |
| 1452 | Epistatic interactions and drug response. 2014 , 232, 255-63 | 19 |
| 1451 | Novel role of Engrailed 1 as a prosurvival transcription factor in basal-like breast cancer and engineering of interference peptides block its oncogenic function. 2014 , 33, 4767-77 | 51 |

| | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1450 | p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. 2014 , 105, 81-8 | 49 |
| 1449 | Principles and methods of integrative genomic analyses in cancer. 2014 , 14, 299-313 | 245 |
| 1448 | ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. 2014 , 25, 282-303 | 631 |
| 1447 | The challenge of intratumour heterogeneity in precision medicine. 2014 , 276, 41-51 | 50 |
| 1446 | Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer. 2014 , 20, 2516-22 | 89 |
| 1445 | Current approaches to the treatment of metastatic brain tumours. 2014 , 11, 203-22 | 174 |
| 1444 | Li-Fraumeni syndrome: cancer risk assessment and clinical management. 2014 , 11, 260-71 | 162 |
| 1443 | ATM down-regulation is associated with poor prognosis in sporadic breast carcinomas. 2014 , 25, 69-75 | 42 |
| 1442 | A personalized committee classification approach to improving prediction of breast cancer metastasis. 2014 , 30, 1858-66 | 21 |
| 1441 | Priorities for the primary prevention of breast cancer. 2014 , 64, 186-94 | 144 |
| 1440 | Molecular Testing in Cancer. 2014 , | 1 |
| 1439 | Pharmacogenomics and Personalized Medicines in Cancer Treatment. 2014 , 55-90 | |
| 1438 | Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. 2014 , 232, 553-65 | 75 |
| 1437 | Akt-ing up on SRPK1: oncogene or tumor suppressor?. 2014 , 54, 329-30 | 14 |
| 1436 | Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. 2014 , 46, 613-7 | 165 |
| 1435 | Somatic retrotransposition in human cancer revealed by whole-genome and exome sequencing. 2014 , 24, 1053-63 | 147 |
| 1434 | Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment. 2014 , 111, E2120-9 | 133 |
| 1433 | Angiopoietin-2 mediates blood-brain barrier impairment and colonization of triple-negative breast cancer cells in brain. 2014 , 232, 369-81 | 80 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1432 | Detection of cancer DNA in plasma of patients with early-stage breast cancer. 2014 , 20, 2643-2650 | 280 |
| 1431 | Molecular profiling of patient-matched brain and extracranial melanoma metastases implicates the PI3K pathway as a therapeutic target. 2014 , 20, 5537-46 | 115 |
| 1430 | The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. 2014 , 15, 681-700 | 40 |
| 1429 | Metastatic progression of breast cancer: insights from 50 years of autopsies. 2014 , 232, 23-31 | 112 |
| 1428 | Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing. 2014 , 145, 707-14 | 110 |
| 1427 | Tumor protein D52 (TPD52) and cancer-oncogene understudy or understudied oncogene?. 2014 , 35, 7369-82 | 40 |
| 1426 | In situ proliferation contributes to accumulation of tumor-associated macrophages in spontaneous mammary tumors. 2014 , 44, 2247-62 | 81 |
| 1425 | Mutational landscape of the essential autophagy gene BECN1 in human cancers. 2014 , 12, 485-90 | 139 |
| 1424 | Mutational patterns in the breast cancer mitochondrial genome, with clinical correlates. 2014 , 35, 1046-54 | 49 |
| 1423 | Addressing overdiagnosis and overtreatment in cancer: a prescription for change. 2014 , 15, e234-42 | 313 |
| 1422 | Genome-wide profiling of AP-1-regulated transcription provides insights into the invasiveness of triple-negative breast cancer. 2014 , 74, 3983-94 | 77 |
| 1421 | Three-stage quality control strategies for DNA re-sequencing data. 2014 , 15, 879-89 | 106 |
| 1420 | Triple-negative breast cancer: bridging the gap from cancer genomics to predictive biomarkers. 2014 , 6, 88-100 | 29 |
| 1419 | Biomarkers of drugs targeting HER-family signalling in cancer. 2014 , 232, 219-29 | 47 |
| 1418 | ClearCode34: A prognostic risk predictor for localized clear cell renal cell carcinoma. 2014 , 66, 77-84 | 169 |
| 1417 | Targeting Akt3 signaling in triple-negative breast cancer. 2014 , 74, 964-73 | 109 |
| 1416 | Two histopathologically different diseases: hormone receptor-positive and hormone receptor-negative tumors in HER2-positive breast cancer. 2014 , 145, 615-23 | 39 |
| 1415 | Comparative epigenetic analyses reveal distinct patterns of oncogenic pathways activation in breast cancer subtypes. 2014 , 23, 5378-93 | 27 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1414 | Integrative gene set analysis of multi-platform data with sample heterogeneity. 2014 , 30, 1501-7 | 8 |
| 1413 | DNA sequencing of cancer: what have we learned?. 2014 , 65, 63-79 | 37 |
| 1412 | Demonstrating the feasibility of large-scale development of standardized assays to quantify human proteins. 2014 , 11, 149-55 | 145 |
| 1411 | Revitalizing psychiatric therapeutics. 2014 , 39, 220-9 | 61 |
| 1410 | PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy. 2014 , 464, 85-93 | 12 |
| 1409 | Hypoxia-inducible factors mediate coordinated RhoA-ROCK1 expression and signaling in breast cancer cells. 2014 , 111, E384-93 | 139 |
| 1408 | Validation and implementation of targeted capture and sequencing for the detection of actionable mutation, copy number variation, and gene rearrangement in clinical cancer specimens. 2014 , 16, 56-67 | 203 |
| 1407 | Using Genome Query Language to uncover genetic variation. 2014 , 30, 1-8 | 82 |
| 1406 | Signaling events mediated by $\beta 1$ integrin are essential for mammary tumorigenesis. 2014 , 33, 4286-95 | 39 |
| 1405 | Investigation of molecular alterations of AKT-3 in triple-negative breast cancer. 2014 , 64, 660-70 | 19 |
| 1404 | The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. 2014 , 69-70, 42-51 | 234 |
| 1403 | Integrated analysis of germline and somatic variants in ovarian cancer. 2014 , 5, 3156 | 199 |
| 1402 | Mining cancer methylomes: prospects and challenges. 2014 , 30, 75-84 | 146 |
| 1401 | Stress signaling and the shaping of the mammary tissue in development and cancer. 2014 , 33, 5483-90 | 25 |
| 1400 | Therapeutic targeting of platelet-derived growth factor receptors in solid tumors. 2014 , 23, 211-26 | 30 |
| 1399 | Lobular breast cancer: pathology, biology, and options for clinical intervention. 2014 , 62, 7-21 | 15 |
| 1398 | Detection and prognostic significance of circulating tumour cells in patients with metastatic breast cancer according to immunohistochemical subtypes. 2014 , 110, 375-83 | 51 |
| 1397 | Tracking progesterone receptor-mediated actions in breast cancer. 2014 , 142, 114-25 | 51 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------|
| 1396 | Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer. 2014 , 92, 151-64 | 75 |
| 1395 | Mitigating overdiagnosis and overtreatment in breast cancer: what is the role of the pathologist?. 2014 , 138, 1428-31 | 6 |
| 1394 | Targeting multiple pathways in breast cancer. 2014 , 3, 87-101 | 0 |
| 1393 | ABRA: improved coding indel detection via assembly-based realignment. 2014 , 30, 2813-5 | 107 |
| 1392 | A targeted next-generation sequencing assay detects a high frequency of therapeutically targetable alterations in primary and metastatic breast cancers: implications for clinical practice. 2014 , 19, 453-8 | 49 |
| 1391 | GATA2 deficiency: a protean disorder of hematopoiesis, lymphatics, and immunity. 2014 , 123, 809-21 | 459 |
| 1390 | Unbiased approaches to biomarker discovery in neurodegenerative diseases. 2014 , 84, 594-607 | 40 |
| 1389 | SGK3 mediates INPP4B-dependent PI3K signaling in breast cancer. 2014 , 56, 595-607 | 105 |
| 1388 | MSC-regulated microRNAs converge on the transcription factor FOXP2 and promote breast cancer metastasis. 2014 , 15, 762-74 | 128 |
| 1387 | Molecular subtyping of bladder cancer using Kohonen self-organizing maps. 2014 , 3, 1225-34 | 14 |
| 1386 | Widespread genetic epistasis among cancer genes. 2014 , 5, 4828 | 45 |
| 1385 | Molecular homology and difference between spontaneous canine mammary cancer and human breast cancer. 2014 , 74, 5045-56 | 77 |
| 1384 | Targeting DNA damage response in cancer therapy. 2014 , 105, 370-88 | 198 |
| 1383 | Identification and use of biomarkers in treatment strategies for triple-negative breast cancer subtypes. 2014 , 232, 142-50 | 267 |
| 1382 | PTEN/PIK3CA genes are frequently mutated in spontaneous and medroxyprogesterone acetate-accelerated 7,12-dimethylbenz(a)anthracene-induced mammary tumours of tree shrews. 2014 , 50, 3230-42 | 19 |
| 1381 | Comparative analysis of GATA3 mutation profiles between Asian and Western patients with breast cancer. Is there really a difference?. 2014 , 120, 2778-9 | |
| 1380 | Deconstructing breast cancer heterogeneity: clinical implications for women with Basal-like tumors. 2014 , 41, 639-46 | 4 |
| 1379 | Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis. <i>Nature</i> , 2014 , 515, 130-3 | 50.4 420 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1378 | Hypoxia promotes stem cell phenotypes and poor prognosis through epigenetic regulation of DICER. 2014 , 5, 5203 | 164 |
| 1377 | MicroRNAs 206 and 21 cooperate to promote RAS-extracellular signal-regulated kinase signaling by suppressing the translation of RASA1 and SPRED1. 2014 , 34, 4143-64 | 48 |
| 1376 | Downregulation of microRNAs 145-3p and 145-5p is a long-term predictor of postmenopausal breast cancer risk: The ORDET prospective study. 2014 , 23, 2471-81 | 22 |
| 1375 | IndividualizedPath: identifying genetic alterations contributing to the dysfunctional pathways in glioblastoma individuals. 2014 , 10, 2031-42 | 7 |
| 1374 | Synthesis and biological evaluation of imidazo[1,5-a]pyridine-benzimidazole hybrids as inhibitors of both tubulin polymerization and PI3K/Akt pathway. 2014 , 12, 9864-80 | 28 |
| 1373 | Deciphering global signal features of high-throughput array data from cancers. 2014 , 10, 1549-56 | 6 |
| 1372 | Bioinformatic analysis reveals a pattern of STAT3-associated gene expression specific to basal-like breast cancers in human tumors. 2014 , 111, 12787-92 | 41 |
| 1371 | Loss-of-function RNAi screens in breast cancer cells identify AURKB, PLK1, PIK3R1, MAPK12, PRKD2, and PTK6 as sensitizing targets of rapamycin activity. 2014 , 354, 336-47 | 18 |
| 1370 | Pan-cancer patterns of DNA methylation. 2014 , 6, 66 | 107 |
| 1369 | Invasive lobular breast cancer and its variants: how special are they for systemic therapy decisions?. 2014 , 92, 235-57 | 51 |
| 1368 | Strategies to Overcome Resistance to Hormonal Therapy. 2014 , 25, 117-119 | 2 |
| 1367 | Antiangiogenesis therapy for breast cancer: an update and perspectives from clinical trials. 2014 , 44, 197-207 | 45 |
| 1366 | Genome-wide association study of breast cancer in Latinas identifies novel protective variants on 6q25. 2014 , 5, 5260 | 89 |
| 1365 | MEK inhibition in non-small cell lung cancer. 2014 , 86, 121-5 | 47 |
| 1364 | Outsmarting cancer: the power of hybrid genomic/proteomic biomarkers to predict drug response. 2014 , 16, 303 | 2 |
| 1363 | Retinoblastoma tumor suppressor pathway in breast cancer: prognosis, precision medicine, and therapeutic interventions. 2014 , 16, 207 | 74 |
| 1362 | CARM1 and BAF155: an example of how chromatin remodeling factors can be relocalized and contribute to cancer. 2014 , 16, 307 | 1 |
| 1361 | Targeting TopBP1 at a convergent point of multiple oncogenic pathways for cancer therapy. 2014 , 5, 5476 | 29 |

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1360 | Metabolic isoenzyme shifts in cancer as potential novel therapeutic targets. 2014 , 148, 477-88 | 3 |
| 1359 | Identifying driver mutations in sequenced cancer genomes: computational approaches to enable precision medicine. 2014 , 6, 5 | 127 |
| 1358 | Advancing clinical oncology through genome biology and technology. 2014 , 15, 427 | 5 |
| 1357 | MicroRNAs: Key Regulators of Oncogenesis. 2014 , | 10 |
| 1356 | RhoC upregulation is correlated with reduced E-cadherin in human breast cancer specimens after chemotherapy and in human breast cancer MCF-7 cells. 2014 , 5, 414-23 | 12 |
| 1355 | Radiogenomic analysis of breast cancer: luminal B molecular subtype is associated with enhancement dynamics at MR imaging. 2014 , 273, 365-72 | 166 |
| 1354 | Breast cancer intra-tumor heterogeneity. 2014 , 16, 210 | 188 |
| 1353 | On integrating multi-experiment microarray data. 2014 , 372, 20130136 | 5 |
| 1352 | RNF43 is frequently mutated in colorectal and endometrial cancers. 2014 , 46, 1264-6 | 287 |
| 1351 | Genome-wide association study identifies multiple loci associated with both mammographic density and breast cancer risk. 2014 , 5, 5303 | 84 |
| 1350 | Functional annotation of colon cancer risk SNPs. 2014 , 5, 5114 | 85 |
| 1349 | Genetically engineered mice as experimental tools to dissect the critical events in breast cancer. 2014 , 121, 331-382 | 22 |
| 1348 | Approaches to integrating germline and tumor genomic data in cancer research. 2014 , 35, 2157-63 | 9 |
| 1347 | NF- κ B activation-induced anti-apoptosis renders HER2-positive cells drug resistant and accelerates tumor growth. 2014 , 12, 408-420 | 35 |
| 1346 | Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancer. 2014 , 25, 1959-1965 | 181 |
| 1345 | Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. 2014 , 11, 400-10 | 189 |
| 1344 | Breast cancer subtypes and previously established genetic risk factors: a bayesian approach. 2014 , 23, 84-97 | 29 |
| 1343 | B-cell lymphoma mutations: improving diagnostics and enabling targeted therapies. 2014 , 99, 222-31 | 43 |

| | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1342 | Sequencing of captive target transcripts identifies the network of regulated genes and functions of primate-specific miR-522. 2014 , 8, 1225-39 | 44 |
| 1341 | Differences in gene and protein expression and the effects of race/ethnicity on breast cancer subtypes. 2014 , 23, 316-23 | 16 |
| 1340 | Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors. 2014 , 32, 68-75 | 147 |
| 1339 | Targeted radionuclide therapy: proceedings of a joint workshop hosted by the National Cancer Institute and the Society of Nuclear Medicine and Molecular Imaging. 2014 , 55, 337-48 | 17 |
| 1338 | Cancer therapy. Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility. 2014 , 345, 216-20 | 670 |
| 1337 | BRCA1 suppresses epithelial-to-mesenchymal transition and stem cell dedifferentiation during mammary and tumor development. 2014 , 74, 6161-72 | 43 |
| 1336 | Functional ex vivo assay to select homologous recombination-deficient breast tumors for PARP inhibitor treatment. 2014 , 20, 4816-26 | 111 |
| 1335 | Septin 9 amplification and isoform-specific expression in peritumoral and tumor breast tissue. 2014 , 395, 157-67 | 26 |
| 1334 | p66ShcA promotes breast cancer plasticity by inducing an epithelial-to-mesenchymal transition. 2014 , 34, 3689-701 | 15 |
| 1333 | Protective role of miR-155 in breast cancer through RAD51 targeting impairs homologous recombination after irradiation. 2014 , 111, 4536-41 | 144 |
| 1332 | Overexpression of miR-146a in basal-like breast cancer cells confers enhanced tumorigenic potential in association with altered p53 status. 2014 , 35, 2567-75 | 37 |
| 1331 | Luminal B breast cancer: molecular characterization, clinical management, and future perspectives. 2014 , 32, 2794-803 | 197 |
| 1330 | Similarity network fusion for aggregating data types on a genomic scale. 2014 , 11, 333-7 | 849 |
| 1329 | Lean Big Data integration in systems biology and systems pharmacology. 2014 , 35, 450-60 | 67 |
| 1328 | DegPack: a web package using a non-parametric and information theoretic algorithm to identify differentially expressed genes in multiclass RNA-seq samples. 2014 , 69, 306-14 | 3 |
| 1327 | Seminal plasma as a diagnostic fluid for male reproductive system disorders. 2014 , 11, 278-88 | 112 |
| 1326 | Elevated APOBEC3B correlates with poor outcomes for estrogen-receptor-positive breast cancers. 2014 , 5, 405-13 | 99 |
| 1325 | Inflammatory bowel disease as a model for translating the microbiome. 2014 , 40, 843-54 | 237 |

| | | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|-----|
| 1324 | Proteogenomic characterization of human colon and rectal cancer. <i>Nature</i> , 2014 , 513, 382-7 | 50.4 | 900 |
| 1323 | Exome sequencing identifies highly recurrent MED12 somatic mutations in breast fibroadenoma. 2014 , 46, 877-80 | | 138 |
| 1322 | Clonal evolution in breast cancer revealed by single nucleus genome sequencing. <i>Nature</i> , 2014 , 512, 155-60 | 50.4 | 730 |
| 1321 | Integrating germline and somatic data towards a personalized cancer medicine. 2014 , 20, 413-5 | | 9 |
| 1320 | Cancer-specific defects in DNA repair pathways as targets for personalized therapeutic approaches. 2014 , 30, 326-39 | | 179 |
| 1319 | An update on the medical management of breast cancer. 2014 , 348, g3608 | | 46 |
| 1318 | The somatic genomic landscape of chromophobe renal cell carcinoma. 2014 , 26, 319-330 | | 521 |
| 1317 | Phosphorylation of myofibrillogenesis regulator-1 activates the MAPK signaling pathway and induces proliferation and migration in human breast cancer MCF7 cells. 2014 , 588, 2903-10 | | 12 |
| 1316 | Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. 2014 , 13, 1690-704 | | 239 |
| 1315 | Unbiased analysis of potential targets of breast cancer susceptibility loci by Capture Hi-C. 2014 , 24, 1854-68 | | 168 |
| 1314 | WWOX at the crossroads of cancer, metabolic syndrome related traits and CNS pathologies. 2014 , 1846, 188-200 | | 57 |
| 1313 | Role of DNA damage response pathways in preventing carcinogenesis caused by intrinsic replication stress. 2014 , 33, 3688-95 | | 18 |
| 1312 | Genome-wide association analysis in East Asians identifies breast cancer susceptibility loci at 1q32.1, 5q14.3 and 15q26.1. 2014 , 46, 886-90 | | 110 |
| 1311 | FAK in cancer: mechanistic findings and clinical applications. 2014 , 14, 598-610 | | 764 |
| 1310 | Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. 2014 , 158, 929-944 | | 935 |
| 1309 | Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. 2014 , 5, 4577 | | 88 |
| 1308 | RNA Mapping. 2014 , | | 1 |
| 1307 | Loss of the tyrosine phosphatase PTPRD leads to aberrant STAT3 activation and promotes gliomagenesis. 2014 , 111, 8149-54 | | 57 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1306 | Cancer genomics and inherited risk. 2014 , 32, 687-98 | 100 |
| 1305 | A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma. 2014 , 13, 2738-50 | 62 |
| 1304 | Progress and opportunities in molecular pathological epidemiology of colorectal premalignant lesions. 2014 , 109, 1205-14 | 42 |
| 1303 | shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer. 2014 , 74, 2119-30 | 26 |
| 1302 | Molecular pathways: PI3K pathway phosphatases as biomarkers for cancer prognosis and therapy. 2014 , 20, 3057-63 | 22 |
| 1301 | Rare breast cancer subtypes: histological, molecular, and clinical peculiarities. 2014 , 19, 805-13 | 93 |
| 1300 | PIK3CA mutations are associated with lower rates of pathologic complete response to anti-human epidermal growth factor receptor 2 (her2) therapy in primary HER2-overexpressing breast cancer. 2014 , 32, 3212-20 | 189 |
| 1299 | Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses. 2014 , 20, 4827-36 | 150 |
| 1298 | Comparison of RNA-Seq by poly (A) capture, ribosomal RNA depletion, and DNA microarray for expression profiling. 2014 , 15, 419 | 204 |
| 1297 | Identification of collaborative driver pathways in breast cancer. 2014 , 15, 605 | 10 |
| 1296 | Transcriptome instability as a molecular pan-cancer characteristic of carcinomas. 2014 , 15, 672 | 13 |
| 1295 | Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow. 2014 , 14, 456 | 81 |
| 1294 | Family-specific, novel, deleterious germline variants provide a rich resource to identify genetic predispositions for BRCAx familial breast cancer. 2014 , 14, 470 | 14 |
| 1293 | Association of TRPS1 gene with different EMT markers in ER ⁺ positive and ER ⁻ negative breast cancer. 2014 , 9, 119 | 14 |
| 1292 | Functional characterization of breast cancer using pathway profiles. 2014 , 7, 45 | 8 |
| 1291 | Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines. 2014 , 3, 417 | 23 |
| 1290 | C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. 2014 , 16, R54 | 73 |
| 1289 | A shared transcriptional program in early breast neoplasias despite genetic and clinical distinctions. 2014 , 15, R71 | 25 |

| | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1288 | hsa-mir-30c promotes the invasive phenotype of metastatic breast cancer cells by targeting NOV/CCN3. 2014 , 14, 73 | 37 |
| 1287 | Association of phosphatase and tensin homolog low and phosphatidylinositol 3-kinase catalytic subunit alpha gene mutations on outcome in human epidermal growth factor receptor 2-positive metastatic breast cancer patients treated with first-line lapatinib plus paclitaxel or paclitaxel alone. 2014 , 16, 405 | 20 |
| 1286 | PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. 2014 , 16, 406 | 199 |
| 1285 | A joint analysis of metabolomics and genetics of breast cancer. 2014 , 16, 415 | 116 |
| 1284 | Modeling luminal breast cancer heterogeneity: combination therapy to suppress a hormone receptor-negative, cytokeratin 5-positive subpopulation in luminal disease. 2014 , 16, 418 | 10 |
| 1283 | Transcriptome sequencing reveals altered long intergenic non-coding RNAs in lung cancer. 2014 , 15, 429 | 157 |
| 1282 | DawnRank: discovering personalized driver genes in cancer. 2014 , 6, 56 | 126 |
| 1281 | The 'dnet' approach promotes emerging research on cancer patient survival. 2014 , 6, 64 | 38 |
| 1280 | Long non-coding RNAs in colorectal cancer: implications for pathogenesis and clinical application. 2014 , 27, 1310-20 | 81 |
| 1279 | p63 promotes stem cell activity in mammary gland development and basal-like breast cancer by enhancing Fzd7 expression and Wnt signalling. 2014 , 16, 1004-15, 1-13 | 137 |
| 1278 | Personalized medicine approaches for colon cancer driven by genomics and systems biology: OncoTrack. 2014 , 9, 1104-14 | 36 |
| 1277 | Contribution of p53 to metastasis. 2014 , 4, 405-14 | 212 |
| 1276 | Next-generation sequencing technologies: breaking the sound barrier of human genetics. 2014 , 29, 303-10 | 80 |
| 1275 | Genome-wide analysis of noncoding regulatory mutations in cancer. 2014 , 46, 1160-5 | 367 |
| 1274 | Association study of susceptibility loci with specific breast cancer subtypes in Chinese women. 2014 , 146, 503-14 | 19 |
| 1273 | Molecular features of the basal-like breast cancer subtype based on BRCA1 mutation status. 2014 , 147, 185-91 | 33 |
| 1272 | ESPL1 is a candidate oncogene of luminal B breast cancers. 2014 , 147, 51-9 | 31 |
| 1271 | Changes in PIK3CA mutation status are not associated with recurrence, metastatic disease or progression in endocrine-treated breast cancer. 2014 , 147, 211-9 | 31 |

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1270 | Aromatase inhibitors for metastatic male breast cancer: molecular, endocrine, and clinical considerations. 2014 , 147, 227-35 | 16 |
| 1269 | High NR2F2 transcript level is associated with increased survival and its expression inhibits TGF- β -dependent epithelial-mesenchymal transition in breast cancer. 2014 , 147, 265-81 | 23 |
| 1268 | How many etiological subtypes of breast cancer: two, three, four, or more?. 2014 , 106, | 142 |
| 1267 | Male breast cancer: a rare disease that might uncover underlying pathways of breast cancer. 2014 , 14, 643 | 29 |
| 1266 | Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. 2014 , 159, 402-14 | 126 |
| 1265 | Therapeutic targeting of ERBB2 in breast cancer: understanding resistance in the laboratory and combating it in the clinic. 2014 , 92, 681-95 | 13 |
| 1264 | The role of HIF1 β in renal cell carcinoma tumorigenesis. 2014 , 92, 825-36 | 55 |
| 1263 | Microsatellite genotyping reveals a signature in breast cancer exomes. 2014 , 145, 791-8 | 22 |
| 1262 | Hypomethylation of the MMP7 promoter and increased expression of MMP7 distinguishes the basal-like breast cancer subtype from other triple-negative tumors. 2014 , 146, 25-40 | 20 |
| 1261 | Somatic mutation load of estrogen receptor-positive breast tumors predicts overall survival: an analysis of genome sequence data. 2014 , 146, 211-20 | 67 |
| 1260 | Breast cancer risk accumulation starts early: prevention must also. 2014 , 145, 567-79 | 82 |
| 1259 | Reverse phase protein array: a tool for signaling pathway profiling in the era of genome resequencing. 2014 , 59, 895-6 | 1 |
| 1258 | Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors. 2014 , 32, 670-81 | 147 |
| 1257 | PD-L1 expression in triple-negative breast cancer. 2014 , 2, 361-70 | 698 |
| 1256 | Nuclear CSPP1 expression defined subtypes of basal-like breast cancer. 2014 , 111, 326-38 | 7 |
| 1255 | Characterizing cancer subtypes using dual analysis in Caleydo StratomeX. 2014 , 34, 38-47 | 15 |
| 1254 | Where cancer genomics should go next: a clinician's perspective. 2014 , 23, R69-75 | 12 |
| 1253 | PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patients. 2014 , 16, R13 | 49 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1252 | In silico analysis of microRNA-510 as a potential oncomir in human breast cancer. 2014 , 16, 403 | 3 |
| 1251 | Serine-arginine protein kinase 1 is associated with breast cancer progression and poor patient survival. 2014 , 31, 83 | 14 |
| 1250 | JARID1B is a luminal lineage-driving oncogene in breast cancer. 2014 , 25, 762-77 | 131 |
| 1249 | Inferring primary tumor sites from mutation spectra: a meta-analysis of histology-specific aberrations in cancer-derived cell lines. 2014 , 23, 1527-37 | 13 |
| 1248 | Cancer affects microRNA expression, release, and function in cardiac and skeletal muscle. 2014 , 74, 4270-81 | 35 |
| 1247 | The Pan-Cancer analysis of pseudogene expression reveals biologically and clinically relevant tumour subtypes. 2014 , 5, 3963 | 99 |
| 1246 | Expanding the computational toolbox for mining cancer genomes. 2014 , 15, 556-70 | 146 |
| 1245 | Statistical Analysis of Next Generation Sequencing Data. 2014 , | 11 |
| 1244 | Breast cancer risk after radiotherapy for heritable and non-heritable retinoblastoma: a US-UK study. 2014 , 110, 2623-32 | 17 |
| 1243 | Activity of trabectedin in germline BRCA1/2-mutated metastatic breast cancer: results of an international first-in-class phase II study. 2014 , 25, 1152-8 | 31 |
| 1242 | Systematic analysis of metastasis-associated genes identifies miR-17-5p as a metastatic suppressor of basal-like breast cancer. 2014 , 146, 487-502 | 38 |
| 1241 | Epigenome-wide association studies without the need for cell-type composition. 2014 , 11, 309-11 | 171 |
| 1240 | Progesterone receptor-cyclin D1 complexes induce cell cycle-dependent transcriptional programs in breast cancer cells. 2014 , 28, 442-57 | 34 |
| 1239 | A single nucleotide polymorphism in PIK3CA gene is inversely associated with P53 protein expression in breast cancer. 2014 , 31, 30 | 9 |
| 1238 | Molecular Heterogeneity of Triple Negative Breast Cancer. 2014 , 6, 154-158 | 43 |
| 1237 | Astrocyte elevated gene-1: a novel independent prognostic biomarker for metastatic ovarian tumors. 2014 , 35, 3079-85 | 16 |
| 1236 | Heterogeneity in the expression of receptors in the human breast cancer metastasized to the brain. 2014 , 35, 7267-73 | 4 |
| 1235 | Effective filtering strategies to improve data quality from population-based whole exome sequencing studies. 2014 , 15, 125 | 67 |

| | | |
|------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1234 | A multivariate approach to the integration of multi-omics datasets. 2014 , 15, 162 | 161 |
| 1233 | Comparison of somatic mutation calling methods in amplicon and whole exome sequence data. 2014 , 15, 244 | 110 |
| 1232 | EgoNet: identification of human disease ego-network modules. 2014 , 15, 314 | 19 |
| 1231 | Nucleosome positioning and histone modifications define relationships between regulatory elements and nearby gene expression in breast epithelial cells. 2014 , 15, 331 | 33 |
| 1230 | Hereditary breast and ovarian cancer: assessment of point mutations and copy number variations in Brazilian patients. 2014 , 15, 55 | 42 |
| 1229 | Phospho-aspirin (MDC-22) inhibits breast cancer in preclinical animal models: an effect mediated by EGFR inhibition, p53 acetylation and oxidative stress. 2014 , 14, 141 | 19 |
| 1228 | Breast tumor specific mutation in GATA3 affects physiological mechanisms regulating transcription factor turnover. 2014 , 14, 278 | 38 |
| 1227 | Genome instability in blood cells of a BRCA1+ breast cancer family. 2014 , 14, 342 | 6 |
| 1226 | Analysis of growth factor signaling in genetically diverse breast cancer lines. 2014 , 12, 20 | 29 |
| 1225 | Patterns and processes of somatic mutations in nine major cancers. 2014 , 7, 11 | 47 |
| 1224 | Derivative component analysis for mass spectral serum proteomic profiles. 2014 , 7 Suppl 1, S5 | 11 |
| 1223 | MicroRNA expression signatures for the prediction of BRCA1/2 mutation-associated hereditary breast cancer in paraffin-embedded formalin-fixed breast tumors. 2015 , 136, 593-602 | 32 |
| 1222 | E2F activators signal and maintain centrosome amplification in breast cancer cells. 2014 , 34, 2581-99 | 38 |
| 1221 | Definition of PKC- ζ CDK6, and MET as therapeutic targets in triple-negative breast cancer. 2014 , 74, 4822-35 | 48 |
| 1220 | Past, present, and future challenges in breast cancer treatment. 2014 , 32, 1979-86 | 142 |
| 1219 | Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis. 2014 , 111, E3234-42 | 307 |
| 1218 | Advances in the approach to novel drug clinical development for breast cancer. 2014 , 9, 647-68 | 5 |
| 1217 | Detection of ErbB2: nanotechnological solutions for clinical diagnostics. 2014 , 4, 3422-3442 | 17 |

| | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1216 | Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. 2014 , 8, 1588-602 | 38 |
| 1215 | Impact of estrogen receptor (ER) and human epidermal growth factor receptor-2 (HER2) co-expression on breast cancer disease characteristics: implications for tumor biology and research. 2014 , 148, 437-44 | 29 |
| 1214 | Endometriosis. 2014 , | 4 |
| 1213 | An integrated genomics approach identifies drivers of proliferation in luminal-subtype human breast cancer. 2014 , 46, 1051-9 | 158 |
| 1212 | Is the differentiation into molecular subtypes of breast cancer important for staging, local and systemic therapy, and follow up?. 2014 , 40, 1089-95 | 19 |
| 1211 | Metastatic breast cancer subtypes and central nervous system metastases. 2014 , 23, 623-8 | 64 |
| 1210 | Quantifying tumor heterogeneity in whole-genome and whole-exome sequencing data. 2014 , 30, 3532-40 | 95 |
| 1209 | Phosphorylated RPA recruits PALB2 to stalled DNA replication forks to facilitate fork recovery. 2014 , 206, 493-507 | 73 |
| 1208 | TGF β induces "BRCAness" and sensitivity to PARP inhibition in breast cancer by regulating DNA-repair genes. 2014 , 12, 1597-609 | 38 |
| 1207 | Cancer Bioinformatics. 2014 , | 4 |
| 1206 | Influence of biospecimen variables on proteomic biomarkers in breast cancer. 2014 , 20, 3870-83 | 41 |
| 1205 | Validation of DNA methylation biomarkers for diagnosis of acute lymphoblastic leukemia. 2014 , 60, 995-1003 | 18 |
| 1204 | The 41st David A. Karnofsky Memorial Award Lecture: Academic research worldwide--quo vadis?. 2014 , 32, 347-54 | 31 |
| 1203 | Co-overexpression of HER2/HER3 is a predictor of impaired survival in breast cancer patients. 2014 , 23, 637-43 | 41 |
| 1202 | Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. 2014 , 20, 511-21 | 143 |
| 1201 | Endometrial Carcinoma Recurrence Score (ECARS) validates to identify aggressive disease and associates with markers of epithelial-mesenchymal transition and PI3K alterations. 2014 , 134, 599-606 | 8 |
| 1200 | Cancer mouse models: past, present and future. 2014 , 27, 54-60 | 37 |
| 1199 | IRP2 regulates breast tumor growth. 2014 , 74, 497-507 | 77 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1198 | A community effort to assess and improve drug sensitivity prediction algorithms. 2014 , 32, 1202-12 | 447 |
| 1197 | An epigenomic approach to therapy for tamoxifen-resistant breast cancer. 2014 , 24, 809-19 | 132 |
| 1196 | Thymoquinone, a bioactive component of black caraway seeds, causes G1 phase cell cycle arrest and apoptosis in triple-negative breast cancer cells with mutant p53. 2014 , 66, 408-18 | 43 |
| 1195 | A pan-cancer proteomic perspective on The Cancer Genome Atlas. 2014 , 5, 3887 | 324 |
| 1194 | Multicolor two-photon light-sheet microscopy. 2014 , 11, 600-1 | 87 |
| 1193 | Chk1 as a new therapeutic target in triple-negative breast cancer. 2014 , 23, 250-8 | 37 |
| 1192 | Inhibition of Wnt/ β -catenin pathway by niclosamide: a therapeutic target for ovarian cancer. 2014 , 134, 112-20 | 118 |
| 1191 | Breast tumor PDXs are genetically plastic and correspond to a subset of aggressive cancers prone to relapse. 2014 , 8, 431-43 | 36 |
| 1190 | Noninfectious pneumonitis with the use of mTOR inhibitors in breast cancer. 2014 , 40, 320-6 | 17 |
| 1189 | Stratification and delineation of gastric cancer signaling by in vitro transcription factor activity profiling and integrative genomics. 2014 , 26, 880-94 | 10 |
| 1188 | Regulation of mammary epithelial cell homeostasis by lncRNAs. 2014 , 54, 318-30 | 19 |
| 1187 | A marker of endocrine receptor-positive cells, CEACAM6, is shared by two major classes of breast cancer: luminal and HER2-enriched. 2014 , 184, 1198-208 | 14 |
| 1186 | SV40 TAg mouse models of cancer. 2014 , 27, 61-73 | 19 |
| 1185 | Transcriptional coexpression network reveals the involvement of varying stem cell features with different dysregulations in different gastric cancer subtypes. 2014 , 8, 1306-25 | 16 |
| 1184 | nab-Paclitaxel for the treatment of aggressive metastatic breast cancer. 2014 , 14, 221-7 | 28 |
| 1183 | An expanding role for RAS GTPase activating proteins (RAS GAPs) in cancer. 2014 , 55, 1-14 | 103 |
| 1182 | Breast cancer patient stratification using a molecular regularized consensus clustering method. 2014 , 67, 304-12 | 29 |
| 1181 | Lobular neoplasia. 2014 , 23, 487-503 | 19 |

| | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1180 | From biomarker development towards implementation of multidimensional biomarker panels in a clinical setting. 2014 , 8, 781-2 | 2 |
| 1179 | Chromatin and epigenetic determinants of estrogen receptor alpha (ESR1) signaling. 2014 , 382, 633-641 | 41 |
| 1178 | Incorporating inter-relationships between different levels of genomic data into cancer clinical outcome prediction. 2014 , 67, 344-53 | 23 |
| 1177 | Breast cancer stem cells transition between epithelial and mesenchymal states reflective of their normal counterparts. 2014 , 2, 78-91 | 656 |
| 1176 | Pathological T0 following radical cystectomy with or without neoadjuvant chemotherapy: a useful surrogate. 2014 , 191, 898-906 | 38 |
| 1175 | Collection, integration and analysis of cancer genomic profiles: from data to insight. 2014 , 24, 92-8 | 17 |
| 1174 | Personalized medicine: present and future of breast cancer management. 2014 , 91, 223-33 | 40 |
| 1173 | Modeling vitamin D actions in triple negative/basal-like breast cancer. 2014 , 144 Pt A, 65-73 | 34 |
| 1172 | Histopathological characteristics of breast cancer and evaluation of ER alpha and Her-2neu using immunohistochemical and RT-PCR techniquesPeer review under responsibility of Alexandria University Faculty of Medicine.View all notesAvailable online 31 March 2014View all notes. 2014 , 50, 275-282 | 4 |
| 1171 | KIF14 promotes AKT phosphorylation and contributes to chemoresistance in triple-negative breast cancer. 2014 , 16, 247-56, 256.e2 | 54 |
| 1170 | 3,3'-diindolylmethane ameliorates experimental autoimmune encephalomyelitis by promoting cell cycle arrest and apoptosis in activated T cells through microRNA signaling pathways. 2014 , 350, 341-52 | 32 |
| 1169 | Ganetespib and HSP90: translating preclinical hypotheses into clinical promise. 2014 , 74, 1294-300 | 89 |
| 1168 | Big data bioinformatics. 2014 , 229, 1896-900 | 109 |
| 1167 | The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis. 2014 , 87, 20140065 | 28 |
| 1166 | The omics of triple-negative breast cancers. 2014 , 60, 122-33 | 44 |
| 1165 | High-throughput sequencing in mitochondrial DNA research. 2014 , 17, 157-63 | 65 |
| 1164 | Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. 2014 , 111, 3110-5 | 537 |
| 1163 | Tumor microenvironment of metastasis and risk of distant metastasis of breast cancer. 2014 , 106, | 125 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1162 | TCGA-assembler: open-source software for retrieving and processing TCGA data. 2014 , 11, 599-600 | 284 |
| 1161 | Prolactin cooperates with loss of p53 to promote claudin-low mammary carcinomas. 2014 , 33, 3075-82 | 12 |
| 1160 | Family matters: sibling rivalry and bonding between p53 and p63 in cancer. 2014 , 23, 238-9 | 5 |
| 1159 | The molecular balancing act of p16(INK4a) in cancer and aging. 2014 , 12, 167-83 | 162 |
| 1158 | The structural basis of PI3K cancer mutations: from mechanism to therapy. 2014 , 74, 641-6 | 39 |
| 1157 | VGLL1 expression is associated with a triple-negative basal-like phenotype in breast cancer. 2014 , 21, 587-99 | 43 |
| 1156 | HITS-CLIP reveals key regulators of nuclear receptor signaling in breast cancer. 2014 , 146, 85-97 | 55 |
| 1155 | Absence of estrogen receptor alpha (ESR1) gene amplification in a series of breast cancers in Taiwan. 2014 , 464, 689-99 | 12 |
| 1154 | BRCA1 gene promoter methylation status in high-grade serous ovarian cancer patients--a study of the tumour Bank ovarian cancer (TOC) and ovarian cancer diagnosis consortium (OVCAD). 2014 , 50, 2090-8 | 61 |
| 1153 | DNA replication and oncogene-induced replicative stress. 2014 , 24, R435-44 | 247 |
| 1152 | Adaptive reprogramming of the breast cancer kinome. 2014 , 95, 413-5 | 21 |
| 1151 | Mosaic partial deletion of the PTEN gene in a patient with Cowden syndrome. 2014 , 13, 459-67 | 12 |
| 1150 | Molecular classification of breast cancer. 2014 , 465, 1-14 | 106 |
| 1149 | Age-related dysfunction in mechanotransduction impairs differentiation of human mammary epithelial progenitors. 2014 , 7, 1926-39 | 58 |
| 1148 | Drug resistance to targeted therapies: dīvu all over again. 2014 , 8, 1067-83 | 137 |
| 1147 | Molecular profiling of male breast cancer - lost in translation?. 2014 , 53, 526-35 | 28 |
| 1146 | APOBEC-mediated cytosine deamination links PIK3CA helical domain mutations to human papillomavirus-driven tumor development. 2014 , 7, 1833-41 | 235 |
| 1145 | O-GlcNAcylation regulates cancer metabolism and survival stress signaling via regulation of the HIF-1 pathway. 2014 , 54, 820-31 | 222 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1144 | Reverse phase protein array based tumor profiling identifies a biomarker signature for risk classification of hormone receptor-positive breast cancer. 2014 , 2, 52-59 | 16 |
| 1143 | Doubling down on the PI3K-AKT-mTOR pathway enhances the antitumor efficacy of PARP inhibitor in triple negative breast cancer model beyond BRCA-ness. 2014 , 16, 43-72 | 81 |
| 1142 | The Hippo transducer TAZ interacts with the SWI/SNF complex to regulate breast epithelial lineage commitment. 2014 , 6, 1059-1072 | 109 |
| 1141 | PELO negatively regulates HER receptor signalling and metastasis. 2014 , 33, 1190-7 | 6 |
| 1140 | Characterizing DNA methylation alterations from The Cancer Genome Atlas. 2014 , 124, 17-23 | 128 |
| 1139 | Use of mTOR inhibitors in the treatment of breast cancer: an evaluation of factors that influence patient outcomes. 2014 , 6, 43-57 | 20 |
| 1138 | Harnessing the potential of epigenetic therapy to target solid tumors. 2014 , 124, 56-63 | 106 |
| 1137 | Bacteroides fragilis subverts mucosal biology: from symbiont to colon carcinogenesis. 2014 , 124, 4166-72 | 173 |
| 1136 | Far beyond the usual biomarkers in breast cancer: a review. 2014 , 5, 559-71 | 39 |
| 1135 | Integrated genomic and epigenomic analysis of breast cancer brain metastasis. 2014 , 9, e85448 | 77 |
| 1134 | An integrative analysis of PIK3CA mutation, PTEN, and INPP4B expression in terms of trastuzumab efficacy in HER2-positive breast cancer. 2014 , 9, e116054 | 24 |
| 1133 | Validation of predicted mRNA splicing mutations using high-throughput transcriptome data. 2014 , 3, 8 | 10 |
| 1132 | Kinetic competition during the transcription cycle results in stochastic RNA processing. 2014 , 3, | 122 |
| 1131 | Profiling the tyrosine phosphoproteome of different mouse mammary tumour models reveals distinct, model-specific signalling networks and conserved oncogenic pathways. 2014 , 16, 437 | 10 |
| 1130 | Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. 2014 , 12, 71-80 | 27 |
| 1129 | Exploring breast carcinogenesis through integrative genomics and epigenomics analyses. 2014 , 45, 1959-68 | 7 |
| 1128 | Surveying Recent Themes in Translational Bioinformatics: Big Data in EHRs, Omics for Drugs, and Personal Genomics. 2014 , 9, 199-205 | 15 |
| 1127 | Characterizing Cancer-Specific Networks by Integrating TCGA Data. 2014 , 13, 125-31 | 4 |

| | | |
|------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1126 | Multivariate Boosting for Integrative Analysis of High-Dimensional Cancer Genomic Data. 2015 , 13, 123-31 | 2 |
| 1125 | Sequencing of breast cancer stem cell populations indicates a dynamic conversion between differentiation states in vivo. 2014 , 16, R72 | 47 |
| 1124 | Joint estimation of multiple related biological networks. 2014 , 8, | 11 |
| 1123 | A Statistical Learning Theory Framework for Supervised Pattern Discovery. 2014 , | 1 |
| 1122 | FOXA1 Promotes Tumor Cell Proliferation through AR Involving the Notch Pathway in Endometrial Cancer. 2014 , 145-180 | |
| 1121 | Direct Inhibition of PI3K in Combination with Dual HER2 Inhibitors is Required for Optimal Antitumor Activity in HER2+ Breast Cancer Cells. 2014 , 55-80 | |
| 1120 | Addition of the Akt inhibitor triciribine overcomes antibody resistance in cells from ErbB2/Neu-positive/PTEN-deficient mammary tumors. 2014 , 44, 1277-83 | 7 |
| 1119 | Normalized ImQCM: An Algorithm for Detecting Weak Quasi-Cliques in Weighted Graph with Applications in Gene Co-Expression Module Discovery in Cancers. 2014 , 13, 137-46 | 22 |
| 1118 | Phosphorylation of NTRK1 at Y674/Y675 induced by TP53-dependent repression of PTPN6 expression: a potential novel prognostic marker for breast cancer. 2014 , 27, 361-74 | 12 |
| 1117 | eEF2K--a new target in breast cancers with combined inactivation of p53 and PTEN. 2014 , 6, 1512-4 | 4 |
| 1116 | Normal cell-type epigenetics and breast cancer classification: a case study of cell mixture-adjusted analysis of DNA methylation data from tumors. 2014 , 13, 53-64 | 12 |
| 1115 | Classification of Breast Cancer Subtypes by combining Gene Expression and DNA Methylation Data. 2014 , 11, 1-14 | 30 |
| 1114 | Modeling the altered expression levels of genes on signaling pathways in tumors as causal bayesian networks. 2014 , 13, 77-84 | 9 |
| 1113 | RAD51B Activity and Cell Cycle Regulation in Response to DNA Damage in Breast Cancer Cell Lines. 2014 , 8, 135-44 | 8 |
| 1112 | A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data. 2014 , 13, 109-17 | 17 |
| 1111 | Tumor antigens as proteogenomic biomarkers in invasive ductal carcinomas. 2014 , 7 Suppl 3, S2 | 11 |
| 1110 | The biological and clinical challenge of liver cancer heterogeneity. 2014 , 1, 349-353 | 26 |
| 1109 | Abundant circulating microRNAs in breast cancer patients fluctuate considerably during neoadjuvant chemotherapy. 2014 , 8, 845-848 | 20 |

| | | |
|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1108 | Integrated RNA and DNA sequencing improves mutation detection in low purity tumors. 2014 , 42, e107 | 59 |
| 1107 | The Hippo transducers TAZ and YAP in breast cancer: oncogenic activities and clinical implications. 2015 , 17, e14 | 55 |
| 1106 | ALK alteration is a frequent event in aggressive breast cancers. 2015 , 17, 127 | 19 |
| 1105 | Comparison of targeted next-generation sequencing and Sanger sequencing for the detection of PIK3CA mutations in breast cancer. 2015 , 15, 20 | 43 |
| 1104 | Classic Ras Proteins Promote Proliferation and Survival via Distinct Phosphoproteome Alterations in Neurofibromin-Null Malignant Peripheral Nerve Sheath Tumor Cells. 2015 , 74, 568-86 | 11 |
| 1103 | Integration and comparison of different genomic data for outcome prediction in cancer. 2015 , 8, 32 | 10 |
| 1102 | Modern reproductive patterns associated with estrogen receptor positive but not negative breast cancer susceptibility. 2014 , 2015, 52-74 | 19 |
| 1101 | A multi-omic analysis of human naïve CD4+ T cells. 2015 , 9, 75 | 30 |
| 1100 | The Emerging Role of ABL Kinases in Solid Tumors. 2015 , 1, 110-123 | 45 |
| 1099 | Identification of gene signatures for classifying of breast cancer subtypes using protein interaction database and support vector machines. 2015 , | 1 |
| 1098 | Appraisal of the technologies and review of the genomic landscape of ductal carcinoma in situ of the breast. 2015 , 17, 80 | 5 |
| 1097 | MEK and PI3K inhibition in solid tumors: rationale and evidence to date. 2015 , 7, 170-80 | 84 |
| 1096 | Delineating transcriptional networks of prognostic gene signatures refines treatment recommendations for lymph node-negative breast cancer patients. 2015 , 282, 3455-73 | 9 |
| 1095 | HER2 as a target in invasive urothelial carcinoma. 2015 , 4, 844-52 | 31 |
| 1094 | Molecular portrait of breast cancer in China reveals comprehensive transcriptomic likeness to Caucasian breast cancer and low prevalence of luminal A subtype. 2015 , 4, 1016-30 | 24 |
| 1093 | Identifying Etiologically Distinct Sub-Types of Cancer: A Demonstration Project Involving Breast Cancer. 2015 , 4, 1432-9 | 14 |
| 1092 | Identification of several potential chromatin binding sites of HOXB7 and its downstream target genes in breast cancer. 2015 , 137, 2374-83 | 23 |
| 1091 | Inherited CHST11/MIR3922 deletion is associated with a novel recessive syndrome presenting with skeletal malformation and malignant lymphoproliferative disease. 2015 , 3, 413-23 | 8 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1090 | Breast cancer heterogeneity: parallel evolution or conscious uncoupling?. 2015 , 237, 1-3 | 2 |
| 1089 | Pharmacodynamic assays to facilitate preclinical and clinical development of pre-mRNA splicing modulatory drug candidates. 2015 , 3, e00158 | 10 |
| 1088 | Prognostic role of PIK3CA mutations of cell-free DNA in early-stage triple negative breast cancer. 2015 , 106, 1582-9 | 46 |
| 1087 | The importance of molecular markers for diagnosis and selection of targeted treatments in patients with cancer. 2015 , 278, 545-70 | 38 |
| 1086 | Phosphoproteomic profiling of tumor tissues identifies HSP27 Ser82 phosphorylation as a robust marker of early ischemia. 2015 , 5, 13660 | 11 |
| 1085 | Divergent Synthesis of Chondroitin Sulfate Disaccharides and Identification of Sulfate Motifs that Inhibit Triple Negative Breast Cancer. 2015 , 5, 14355 | 25 |
| 1084 | Highly informative marker sets consisting of genes with low individual degree of differential expression. 2015 , 5, 14967 | 21 |
| 1083 | Genomic alterations in DNA repair and chromatin remodeling genes in estrogen receptor-positive metastatic breast cancer patients with exceptional responses to capecitabine. 2015 , 4, 1289-93 | 6 |
| 1082 | Inhibition of focal adhesion kinase induces apoptosis in bladder cancer cells via Src and the phosphatidylinositol 3-kinase/Akt pathway. 2015 , 10, 1725-1731 | 33 |
| 1081 | Tumor Heterogeneity in Breast Cancer. 2015 , 22, 294-302 | 8 |
| 1080 | Minimax estimation in sparse canonical correlation analysis. 2015 , 43, | 22 |
| 1079 | Developmental genes significantly afflicted by aberrant promoter methylation and somatic mutation predict overall survival of late-stage colorectal cancer. 2015 , 5, 18616 | 10 |
| 1078 | Cancer Pharmacogenomics. 2015 , 1, 164-191 | |
| 1077 | TP53 supports basal-like differentiation of mammary epithelial cells by preventing translocation of deltaNp63 into nucleoli. 2014 , 4, 4663 | 7 |
| 1076 | Novel genes associated with lymph node metastasis in triple negative breast cancer. 2015 , 5, 15832 | 31 |
| 1075 | Targeted Therapy for Breast Cancer. 2015 , 190-192 | |
| 1074 | Ethnicity-Dependent and -Independent Heterogeneity in Healthy Normal Breast Hierarchy Impacts Tumor Characterization. 2015 , 5, 13526 | 31 |
| 1073 | Integrative investigation on breast cancer in ER, PR and HER2-defined subgroups using mRNA and miRNA expression profiling. 2014 , 4, 6566 | 50 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1072 | Egln2 associates with the NRF1-PGC1 β complex and controls mitochondrial function in breast cancer. 2015 , 34, 2953-70 | 42 |
| 1071 | A potential prognostic long non-coding RNA signature to predict metastasis-free survival of breast cancer patients. 2015 , 5, 16553 | 81 |
| 1070 | Deciphering Genomic Underpinnings of Quantitative MRI-based Radiomic Phenotypes of Invasive Breast Carcinoma. 2015 , 5, 17787 | 108 |
| 1069 | Identifying ultrasound and clinical features of breast cancer molecular subtypes by ensemble decision. 2015 , 5, 11085 | 41 |
| 1068 | Characterization of DNA variants in the human kinome in breast cancer. 2015 , 5, 14736 | 1 |
| 1067 | Cancer type-dependent genetic interactions between cancer driver alterations indicate plasticity of epistasis across cell types. 2015 , 11, 824 | 47 |
| 1066 | Combined Mapping of Multiple clUsteriNg ALgorithms (COMMUNAL): A Robust Method for Selection of Cluster Number, K. 2015 , 5, 16971 | 13 |
| 1065 | Systematically Prioritizing Functional Differentially Methylated Regions (fDMRs) by Integrating Multi-omics Data in Colorectal Cancer. 2015 , 5, 12789 | 4 |
| 1064 | Exploratory Methods to Integrate Multisource Data. 242-268 | |
| 1063 | Analyzing Combinations of Somatic Mutations in Cancer Genomes. 337-361 | |
| 1062 | TP53 Mutational Analysis Enhances the Prognostic Accuracy of IHC4 and PAM50 Assays. 2015 , 5, 17879 | 7 |
| 1061 | HER2-Mutated Breast Cancer Responds to Treatment With Single-Agent Neratinib, a Second-Generation HER2/EGFR Tyrosine Kinase Inhibitor. 2015 , 13, 1061-4 | 57 |
| 1060 | The influence of cancer tissue sampling on the identification of cancer characteristics. 2015 , 5, 15474 | 11 |
| 1059 | Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation. 2015 , 13, 1066-70 | 25 |
| 1058 | Targeting Breast Cancer Metastasis. 2015 , 9, 23-34 | 87 |
| 1057 | Endogenous antibodies for tumor detection. 2014 , 4, 5088 | 6 |
| 1056 | Reference-free inference of tumor phylogenies from single-cell sequencing data. 2015 , 16 Suppl 11, S7 | 6 |
| 1055 | An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. 2015 , 16 Suppl 12, S2 | 6 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 1054 | Enhancing cancer clonality analysis with integrative genomics. 2015 , 16 Suppl 13, S7 | 3 |
| 1053 | Somatic mutations in leukocytes infiltrating primary breast cancers. 2015 , 1, 15005 | 18 |
| 1052 | Mammary Stem Cell Self-Renewal Is Regulated by Slit2/Robo1 Signaling through SNAI1 and mINSC. 2015 , 13, 290-301 | 35 |
| 1051 | Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib. 2015 , 33, 526-32 | 9 |
| 1050 | Context-Specific Effects of TGF- β /SMAD3 in Cancer Are Modulated by the Epigenome. 2015 , 13, 2480-2490 | 27 |
| 1049 | A computational method for clinically relevant cancer stratification and driver mutation module discovery using personal genomics profiles. 2015 , 16 Suppl 7, S6 | 10 |
| 1048 | Bioinformatics analysis of thousands of TCGA tumors to determine the involvement of epigenetic regulators in human cancer. 2015 , 16 Suppl 8, S5 | 22 |
| 1047 | Computational methods and resources for the interpretation of genomic variants in cancer. 2015 , 16 Suppl 8, S7 | 11 |
| 1046 | Leveraging global gene expression patterns to predict expression of unmeasured genes. 2015 , 16, 1065 | 2 |
| 1045 | PTK6 inhibition promotes apoptosis of Lapatinib-resistant Her2(+) breast cancer cells by inducing Bim. 2015 , 17, 86 | 30 |
| 1044 | Cancer classification in the genomic era: five contemporary problems. 2015 , 9, 27 | 35 |
| 1043 | Enhancing the discovery and development of immunotherapies for cancer using quantitative and systems pharmacology: Interleukin-12 as a case study. 2015 , 3, 27 | 15 |
| 1042 | Induction of proto-oncogene BRF2 in breast cancer cells by the dietary soybean isoflavone daidzein. 2015 , 15, 905 | 24 |
| 1041 | TGF- β isoforms and receptors mRNA expression in breast tumours: prognostic value and clinical implications. 2015 , 15, 1010 | 19 |
| 1040 | Shared kernel Bayesian screening. 2015 , 102, 829-842 | 7 |
| 1039 | Ectopic expression of RNF168 and 53BP1 increases mutagenic but not physiological non-homologous end joining. 2015 , 43, 4950-61 | 18 |
| 1038 | Novel syngeneic mouse mammary carcinoma cell lines from aggressive ErbB2/Neu-overexpressing/PTEN-deficient tumors. 2015 , 33, 179-84 | 1 |
| 1037 | Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases. 2015 , 15, 699 | 9 |

| | | |
|------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1036 | A co-culture genome-wide RNAi screen with mammary epithelial cells reveals transmembrane signals required for growth and differentiation. 2015 , 17, 4 | 20 |
| 1035 | Chromatin interaction analysis reveals changes in small chromosome and telomere clustering between epithelial and breast cancer cells. 2015 , 16, 214 | 123 |
| 1034 | Inferring synthetic lethal interactions from mutual exclusivity of genetic events in cancer. 2015 , 10, 57 | 33 |
| 1033 | The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. 2015 , 7, 57 | 56 |
| 1032 | Understanding drugs in breast cancer through drug sensitivity screening. 2015 , 4, 611 | 9 |
| 1031 | Comprehensive data resources and analytical tools for pathological association of aminoacyl tRNA synthetases with cancer. 2015 , 2015, | 3 |
| 1030 | Concurrent DNA Copy-Number Alterations and Mutations in Genes Related to Maintenance of Genome Stability in Uninvolved Mammary Glandular Tissue from Breast Cancer Patients. 2015 , 36, 1088-99 | 6 |
| 1029 | The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study. 2015 , 237, 166-78 | 42 |
| 1028 | Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance. 2015 , 237, 363-78 | 72 |
| 1027 | Integrative network-based approach identifies key genetic elements in breast invasive carcinoma. 2015 , 16 Suppl 5, S2 | 27 |
| 1026 | Detection of miRNA regulatory effect on triple negative breast cancer transcriptome. 2015 , 16, S4 | 11 |
| 1025 | Partial PTEN deletion is linked to poor prognosis in breast cancer. 2015 , 15, 963 | 27 |
| 1024 | The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype. 2015 , 15, 791 | 23 |
| 1023 | The treatment patterns, efficacy, and safety of nab (®)-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. 2015 , 15, 1019 | 18 |
| 1022 | Integrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potential. 2015 , 9, 62 | 34 |
| 1021 | Assessing breast cancer cell lines as tumour models by comparison of mRNA expression profiles. 2015 , 17, 114 | 42 |
| 1020 | Multipotent luminal mammary cancer stem cells model tumor heterogeneity. 2015 , 17, 137 | 32 |
| 1019 | Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion. 2015 , 17, 128 | 34 |

| | | |
|------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1018 | CoMEt: a statistical approach to identify combinations of mutually exclusive alterations in cancer. 2015 , 16, 160 | 132 |
| 1017 | Tools for translational epigenetic studies involving formalin-fixed paraffin-embedded human tissue: applying the Infinium HumanMethylation450 Beadchip assay to large population-based studies. 2015 , 8, 543 | 14 |
| 1016 | DNA methylation in ductal carcinoma in situ related with future development of invasive breast cancer. 2015 , 7, 75 | 36 |
| 1015 | Transgelin gene is frequently downregulated by promoter DNA hypermethylation in breast cancer. 2015 , 7, 104 | 25 |
| 1014 | The integrative epigenomic-transcriptomic landscape of ER positive breast cancer. 2015 , 7, 126 | 17 |
| 1013 | GATA family transcriptional factors: emerging suspects in hematologic disorders. 2015 , 4, 28 | 39 |
| 1012 | Integrative genomic analysis reveals functional diversification of APOBEC gene family in breast cancer. 2015 , 9, 34 | 14 |
| 1011 | Overcoming Phosphatidylinositol 3-Kinase (PI3K) Activation in Breast Cancer: Emerging PI3K Inhibitors. 2015 , 3, 27-39 | 2 |
| 1010 | Breast cancer subtype intertumor heterogeneity: MRI-based features predict results of a genomic assay. 2015 , 42, 1398-406 | 97 |
| 1009 | Are acinic cell carcinomas of the breast and salivary glands distinct diseases?. 2015 , 67, 529-37 | 25 |
| 1008 | Advances in the Molecular Analysis of Breast Cancer: Pathway Toward Personalized Medicine. 2015 , 22, 211-9 | 21 |
| 1007 | Hereditary Breast Cancer Syndromes: Molecular Pathogenesis and Diagnostics. 2015 , 1-16 | 1 |
| 1006 | Genetic subtypes of invasive bladder cancer. 2015 , 25, 449-58 | 28 |
| 1005 | Science and Ethics in Dialogue: Ethical Research Conduct and Genetic Information Application. 2015 , 4, 1-163 | |
| 1004 | Impact of allele-specific peptides in proteome quantification. 2015 , 9, 432-6 | 1 |
| 1003 | Runx1 is associated with breast cancer progression in MMTV-PyMT transgenic mice and its depletion in vitro inhibits migration and invasion. 2015 , 230, 2522-32 | 50 |
| 1002 | MRI phenotype of breast cancer: Kinetic assessment for molecular subtypes. 2015 , 42, 920-4 | 55 |
| 1001 | MAP2K1 and MAP3K1 mutations in Langerhans cell histiocytosis. 2015 , 54, 361-8 | 131 |

| | | |
|------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 1000 | GATA3 in Breast Cancer: Tumor Suppressor or Oncogene?. 2015 , 16, 163-8 | 58 |
| 999 | Detection of novel germline mutations for breast cancer in non-BRCA1/2 families. 2015 , 282, 3424-37 | 31 |
| 998 | MicroRNA-Based Therapeutic Strategies for Targeting Mutant and Wild Type RAS in Cancer. 2015 , 76, 328-42 | 8 |
| 997 | The Role of MicroRNAs in the Chemoresistance of Breast Cancer. 2015 , 76, 368-74 | 51 |
| 996 | Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy. 2015 , 13, 623-7 | 3 |
| 995 | Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer. 2015 , 39, 1026-34 | 27 |
| 994 | Cd11b(+) myeloid cells support hepatic metastasis through down-regulation of angiopoietin-like 7 in cancer cells. 2015 , 62, 521-33 | 33 |
| 993 | Functional screening identifies MCT4 as a key regulator of breast cancer cell metabolism and survival. 2015 , 237, 152-65 | 55 |
| 992 | The SWI/SNF ATPases Are Required for Triple Negative Breast Cancer Cell Proliferation. 2015 , 230, 2683-94 | 46 |
| 991 | Triple-negative Breast Carcinoma: Morphologic and Molecular Subtypes. 2015 , 22, 306-13 | 11 |
| 990 | Clinical Trials of Precision Medicine through Molecular Profiling: Focus on Breast Cancer. 2015 , e183-90 | 15 |
| 989 | Precision medicine for metastatic breast cancer. 2015 , e2-7 | 13 |
| 988 | Prognostic and predictive value of PDL1 expression in breast cancer. 2015 , 6, 5449-64 | 313 |
| 987 | New and emerging factors in tumorigenesis: an overview. 2015 , 7, 225-39 | 24 |
| 986 | Reverse phase protein arrays in signaling pathways: a data integration perspective. 2015 , 9, 3519-27 | 32 |
| 985 | PTEN insufficiency modulates ER+ breast cancer cell cycle progression and increases cell growth in vitro and in vivo. 2015 , 9, 4631-8 | 4 |
| 984 | Comparative genomic analysis reveals bilateral breast cancers are genetically independent. 2015 , 6, 31820-9 | 15 |
| 983 | Dual HER2 blockade in the neoadjuvant and adjuvant treatment of HER2-positive breast cancer. 2015 , 7, 321-35 | 11 |

| | | |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 982 | Targeting SOD1 induces synthetic lethal killing in BLM- and CHEK2-deficient colorectal cancer cells. 2015 , 6, 27907-22 | 28 |
| 981 | Targeted pathways in breast cancer: molecular and protein markers guiding therapeutic decisions. 2014 , 7, 4-21 | 21 |
| 980 | Incidence and clinical significance of ESR1 mutations in heavily pretreated metastatic breast cancer patients. 2015 , 8, 3323-8 | 34 |
| 979 | Computational characterisation of cancer molecular profiles derived using next generation sequencing. 2015 , 19, A78-91 | 4 |
| 978 | Whole-Exome Sequencing Identifies Novel Somatic Mutations in Chinese Breast Cancer Patients. 2015 , 9, | 15 |
| 977 | Identification of Copy Number Aberrations in Breast Cancer Subtypes Using Persistence Topology. 2015 , 4, 339-69 | 12 |
| 976 | Age and the means of bypassing stasis influence the intrinsic subtype of immortalized human mammary epithelial cells. 2015 , 3, 13 | 22 |
| 975 | Effects of age on the detection and management of breast cancer. 2015 , 7, 908-29 | 180 |
| 974 | Pyrosequencing-Based Assays for Rapid Detection of HER2 and HER3 Mutations in Clinical Samples Uncover an E332E Mutation Affecting HER3 in Retroperitoneal Leiomyosarcoma. 2015 , 16, 19447-57 | 2 |
| 973 | Analysis of Reverse Phase Protein Array Data: From Experimental Design towards Targeted Biomarker Discovery. 2015 , 4, 520-39 | 12 |
| 972 | Chemoprevention of Breast Cancer by Dietary Polyphenols. 2015 , 20, 22578-620 | 67 |
| 971 | Mutant p53 - Heat Shock Response Oncogenic Cooperation: A New Mechanism of Cancer Cell Survival. 2015 , 6, 53 | 20 |
| 970 | Role of IGF1R in Breast Cancer Subtypes, Stemness, and Lineage Differentiation. 2015 , 6, 59 | 87 |
| 969 | Estrogen-Related Receptors in Breast Cancer and Prostate Cancer. 2015 , 6, 83 | 43 |
| 968 | A Network-Based Model of Oncogenic Collaboration for Prediction of Drug Sensitivity. 2015 , 6, 341 | 5 |
| 967 | Putative Breast Cancer Driver Mutations in TBX3 Cause Impaired Transcriptional Repression. 2015 , 5, 244 | 15 |
| 966 | Cancer stem cell-driven efficacy of trastuzumab (Herceptin): towards a reclassification of clinically HER2-positive breast carcinomas. 2015 , 6, 32317-38 | 26 |
| 965 | Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: treating cancer like an infectious disease. 2015 , 6, 4569-84 | 309 |

| | | |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------|
| 964 | Ganetespib: research and clinical development. 2015 , 8, 1849-58 | 50 |
| 963 | A Comprehensive Outline of Trastuzumab Resistance Biomarkers in HER2 Overexpressing Breast Cancer. 2015 , 15, 665-83 | 31 |
| 962 | SPARCoC: a new framework for molecular pattern discovery and cancer gene identification. 2015 , 10, e0117135 | 5 |
| 961 | Anaplastic lymphoma kinase gene copy number gain in inflammatory breast cancer (IBC): prevalence, clinicopathologic features and prognostic implication. 2015 , 10, e0120320 | 12 |
| 960 | The invadopodia scaffold protein Tks5 is required for the growth of human breast cancer cells in vitro and in vivo. 2015 , 10, e0121003 | 46 |
| 959 | HP1 is a biomarker for breast cancer prognosis and PARP inhibitor therapy. 2015 , 10, e0121207 | 25 |
| 958 | AGR3 in breast cancer: prognostic impact and suitable serum-based biomarker for early cancer detection. 2015 , 10, e0122106 | 30 |
| 957 | Bone marrow stromal antigen 2 (BST-2) DNA is demethylated in breast tumors and breast cancer cells. 2015 , 10, e0123931 | 16 |
| 956 | Development and validation of a novel platform-independent metastasis signature in human breast cancer. 2015 , 10, e0126631 | 11 |
| 955 | Revealing the Molecular Portrait of Triple Negative Breast Tumors in an Understudied Population through Omics Analysis of Formalin-Fixed and Paraffin-Embedded Tissues. 2015 , 10, e0126762 | 14 |
| 954 | Network-Based Integration of Disparate Omic Data To Identify "Silent Players" in Cancer. 2015 , 11, e1004595 | 50 |
| 953 | The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. 2015 , 19, A68-77 | 1337 |
| 952 | Comparison of the Prognostic Utility of the Diverse Molecular Data among lncRNA, DNA Methylation, microRNA, and mRNA across Five Human Cancers. 2015 , 10, e0142433 | 7 |
| 951 | Genome Modeling System: A Knowledge Management Platform for Genomics. 2015 , 11, e1004274 | 59 |
| 950 | A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces. 2015 , 11, e1004518 | 79 |
| 949 | Identification of High-Impact cis-Regulatory Mutations Using Transcription Factor Specific Random Forest Models. 2015 , 11, e1004590 | 16 |
| 948 | Canine spontaneous head and neck squamous cell carcinomas represent their human counterparts at the molecular level. 2015 , 11, e1005277 | 26 |
| 947 | Annexin A1 Preferentially Predicts Poor Prognosis of Basal-Like Breast Cancer Patients by Activating mTOR-S6 Signaling. 2015 , 10, e0127678 | 23 |

| | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 946 | Lymphangioliomyomatosis Biomarkers Linked to Lung Metastatic Potential and Cell Stemness. 2015 , 10, e0132546 | 10 |
| 945 | Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration. 2015 , 10, e0133503 | 18 |
| 944 | Context Sensitive Modeling of Cancer Drug Sensitivity. 2015 , 10, e0133850 | 12 |
| 943 | Comparative Gene Expression Analyses Identify Luminal and Basal Subtypes of Canine Invasive Urothelial Carcinoma That Mimic Patterns in Human Invasive Bladder Cancer. 2015 , 10, e0136688 | 43 |
| 942 | RelA-Induced Interferon Response Negatively Regulates Proliferation. 2015 , 10, e0140243 | 13 |
| 941 | Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer. 2015 , 10, e0141763 | 63 |
| 940 | Profiling of Discrete Gynecological Cancers Reveals Novel Transcriptional Modules and Common Features Shared by Other Cancer Types and Embryonic Stem Cells. 2015 , 10, e0142229 | 38 |
| 939 | Evaluating Serum Markers for Hormone Receptor-Negative Breast Cancer. 2015 , 10, e0142911 | 2 |
| 938 | Intra-Genome DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers. 2015 , 10, e0143178 | 10 |
| 937 | Mutation Screening of 1,237 Cancer Genes across Six Model Cell Lines of Basal-Like Breast Cancer. 2015 , 10, e0144528 | 5 |
| 936 | Development of breast cancer therapy: biomarker-driven and response-guided approaches in a neoadjuvant setting. 2015 , 30, e252-3 | 2 |
| 935 | Contextualizing the Genes Altered in Bladder Neoplasms in Pediatric and Teen Patients Allows Identifying Two Main Classes of Biological Processes Involved and New Potential Therapeutic Targets. 2016 , 17, 33-61 | 2 |
| 934 | Molecular Imaging-Guided Interventional Hyperthermia in Treatment of Breast Cancer. 2015 , 2015, 505269 | 4 |
| 933 | Deciphering the Correlation between Breast Tumor Samples and Cell Lines by Integrating Copy Number Changes and Gene Expression Profiles. 2015 , 2015, 901303 | 6 |
| 932 | Whole Exome- and mRNA-Sequencing of an AT/RT Case Reveals Few Somatic Mutations and Several Deregulated Signalling Pathways in the Context of SMARCB1 Deficiency. 2015 , 2015, 862039 | 5 |
| 931 | Effect of tumor size on breast cancer-specific survival stratified by joint hormone receptor status in a SEER population-based study. 2015 , 6, 22985-95 | 12 |
| 930 | Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?. 2015 , 6, 12890-908 | 80 |
| 929 | . 2015 , | 2 |

| | | |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 928 | Triple-negative breast cancer: molecular subtypes and new targets for therapy. 2015 , e31-9 | 83 |
| 927 | Hypoxia in breast cancer. 2015 , 66, 337-46 | 8 |
| 926 | Deletion of the BMP receptor BMPR1a impairs mammary tumor formation and metastasis. 2015 , 6, 22890-904 | 25 |
| 925 | Cyr61 as mediator of Src signaling in triple negative breast cancer cells. 2015 , 6, 13520-38 | 22 |
| 924 | Treatment-induced cell cycle kinetics dictate tumor response to chemotherapy. 2015 , 6, 7040-52 | 12 |
| 923 | Molecular oncology update: Breast cancer gene expression profiling. 2015 , 01, 065-072 | 4 |
| 922 | Identifying core gene modules in glioblastoma based on multilayer factor-mediated dysfunctional regulatory networks through integrating multi-dimensional genomic data. 2015 , 43, 1997-2007 | 26 |
| 921 | Genomic profiling of breast cancers. 2015 , 27, 34-9 | 16 |
| 920 | A RING to rule them all? Insights into the Map3k1 PHD motif provide a new mechanistic understanding into the diverse roles of Map3k1. 2015 , 22, 540-8 | 22 |
| 919 | Inhibition of BMP signaling suppresses metastasis in mammary cancer. 2015 , 34, 2437-49 | 71 |
| 918 | Personalized Therapies for Cancer Treatment. 2015 , 317-346 | |
| 917 | BRCA1-like signature in triple negative breast cancer: Molecular and clinical characterization reveals subgroups with therapeutic potential. 2015 , 9, 1528-38 | 45 |
| 916 | Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. 2015 , 7, 1034-47 | 284 |
| 915 | Redox-Mediated Suberoylanilide Hydroxamic Acid Sensitivity in Breast Cancer. 2015 , 23, 15-29 | 11 |
| 914 | TFmiR: a web server for constructing and analyzing disease-specific transcription factor and miRNA co-regulatory networks. 2015 , 43, W283-8 | 43 |
| 913 | Frequency and distribution of Notch mutations in tumor cell lines. 2015 , 15, 311 | 14 |
| 912 | Exome sequencing of contralateral breast cancer identifies metastatic disease. 2015 , 151, 319-24 | 18 |
| 911 | The relevance of EMT in breast cancer metastasis: Correlation or causality?. 2015 , 589, 1577-87 | 143 |

| | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 910 | Challenges in the management of advanced, ER-positive, HER2-negative breast cancer. 2015 , 12, 541-52 | 80 |
| 909 | HER2-mTOR signaling-driven breast cancer cells require ER-associated degradation to survive. 2015 , 8, ra52 | 16 |
| 908 | Targeting ADAM-17 with an inhibitory monoclonal antibody has antitumour effects in triple-negative breast cancer cells. 2015 , 112, 1895-903 | 43 |
| 907 | The cancer cell map initiative: defining the hallmark networks of cancer. 2015 , 58, 690-8 | 89 |
| 906 | Next-Generation Sequencing for Cancer Biomarker Discovery. 2015 , 103-125 | 1 |
| 905 | From bench to bedside: What do we know about hormone receptor-positive and human epidermal growth factor receptor 2-positive breast cancer?. 2015 , 153, 45-53 | 34 |
| 904 | Two Isoforms of the RNA Binding Protein, Coding Region Determinant-binding Protein (CRD-BP/IGF2BP1), Are Expressed in Breast Epithelium and Support Clonogenic Growth of Breast Tumor Cells. 2015 , 290, 13386-400 | 34 |
| 903 | tmle.npvi: targeted, integrative search of associations between DNA copy number and gene expression, accounting for DNA methylation. 2015 , 31, 3054-6 | 3 |
| 902 | Predicting censored survival data based on the interactions between meta-dimensional omics data in breast cancer. 2015 , 56, 220-8 | 27 |
| 901 | Clinical applications of next generation sequencing in cancer: from panels, to exomes, to genomes. 2015 , 6, 215 | 60 |
| 900 | High level PHGDH expression in breast is predominantly associated with keratin 5-positive cell lineage independently of malignancy. 2015 , 9, 1636-54 | 28 |
| 899 | Undifferentiated State Induced by Rb-p53 Double Inactivation in Mouse Thyroid Neuroendocrine Cells and Embryonic Fibroblasts. 2015 , 33, 1657-69 | 18 |
| 898 | Epigenomic Biomarkers for the Advance of Personalized Medicine. 2015 , 187-217 | |
| 897 | Application of quantitative proteomics to the integrated analysis of the ubiquitylated and global proteomes of xenograft tumor tissues. 2015 , 12, 14 | 7 |
| 896 | Genome-wide analysis of alternative transcripts in human breast cancer. 2015 , 151, 295-307 | 16 |
| 895 | Targeting CD151 by lentivirus-mediated RNA interference inhibits luminal and basal-like breast cancer cell growth and invasion. 2015 , 407, 111-21 | 6 |
| 894 | Selection of a breast cancer subpopulation-specific antibody using phage display on tissue sections. 2015 , 62, 263-72 | 13 |
| 893 | MicroRNA-30c-2-3p negatively regulates NF- κ B signaling and cell cycle progression through downregulation of TRADD and CCNE1 in breast cancer. 2015 , 9, 1106-19 | 61 |

| | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 892 | Pathway-based personalized analysis of breast cancer expression data. 2015 , 9, 1471-83 | 26 |
| 891 | Down-regulation of programmed cell death 4 (PDCD4) is associated with aromatase inhibitor resistance and a poor prognosis in estrogen receptor-positive breast cancer. 2015 , 152, 29-39 | 47 |
| 890 | Dysfunction of the Reciprocal Feedback Loop between GATA3- and ZEB2-Nucleated Repression Programs Contributes to Breast Cancer Metastasis. 2015 , 27, 822-36 | 98 |
| 889 | Identifying aggressive forms of endometrioid-type endometrial cancer: new insights into molecular subtyping. 2015 , 15, 1-3 | 16 |
| 888 | SomnClust: detection of cancer genes based on somatic mutation patterns of inactivation and clustering. 2015 , 16, 125 | 23 |
| 887 | Identification of sample-specific regulations using integrative network level analysis. 2015 , 15, 319 | 9 |
| 886 | Enhanced anti-tumor immune responses and delay of tumor development in human epidermal growth factor receptor 2 mice immunized with an immunostimulatory peptide in poly(D,L-lactic-co-glycolic) acid nanoparticles. 2015 , 17, 48 | 13 |
| 885 | The impact of DNA input amount and DNA source on the performance of whole-exome sequencing in cancer epidemiology. 2015 , 24, 1207-13 | 18 |
| 884 | Development and Validation of a Novel Radiosensitivity Signature in Human Breast Cancer. 2015 , 21, 3667-77 | 86 |
| 883 | ATM has a major role in the double-strand break repair pathway dysregulation in sporadic breast carcinomas and is an independent prognostic marker at both mRNA and protein levels. 2015 , 112, 1059-66 | 36 |
| 882 | Anti-EFNA4 Calicheamicin Conjugates Effectively Target Triple-Negative Breast and Ovarian Tumor-Initiating Cells to Result in Sustained Tumor Regressions. 2015 , 21, 4165-73 | 58 |
| 881 | Personalized Therapy of Cancer. 2015 , 199-381 | 1 |
| 880 | INPP4B overexpression is associated with poor clinical outcome and therapy resistance in acute myeloid leukemia. 2015 , 29, 1485-95 | 34 |
| 879 | Association of PIK3CA Mutation Status before and after Neoadjuvant Chemotherapy with Response to Chemotherapy in Women with Breast Cancer. 2015 , 21, 4365-72 | 20 |
| 878 | Identification of E545k mutation in plasma from a PIK3CA wild-type metastatic breast cancer patient by array-based digital polymerase chain reaction: Circulating-free DNA a powerful tool for biomarker testing in advance disease. 2015 , 166, 783-7 | 7 |
| 877 | Systematic transcriptome analysis reveals tumor-specific isoforms for ovarian cancer diagnosis and therapy. 2015 , 112, E3050-7 | 51 |
| 876 | Functions of Fibroblast Growth Factor Receptors in cancer defined by novel translocations and mutations. 2015 , 26, 425-49 | 89 |
| 875 | Exome Capture and Capturing Technologies in Cancer Research. 2015 , 279-302 | |

| | | |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 874 | Computational and Statistical Epigenomics. 2015 , | 2 |
| 873 | Molecular Classification of Breast Carcinoma: From Traditional, Old-Fashioned Way to A New Age, and A New Way. 2015 , 11, 59-66 | 85 |
| 872 | Identification of differential splicing genes in gliomas using exon expression profiling. 2015 , 11, 843-50 | 15 |
| 871 | Progress of cancer genomics. 2015 , 6, 557-60 | |
| 870 | Triple Negative Breast Cancer: Nanosolutions for a Big Challenge. 2015 , 2, 1500053 | 27 |
| 869 | Feasibility of implementing molecular-guided therapy for the treatment of patients with relapsed or refractory neuroblastoma. 2015 , 4, 871-86 | 20 |
| 868 | Perturbations of PIP3 signalling trigger a global remodelling of mRNA landscape and reveal a transcriptional feedback loop. 2015 , 43, 9663-79 | 17 |
| 867 | A permutation approach for selecting the penalty parameter in penalized model selection. 2015 , 71, 1185-94 | 14 |
| 866 | Epidermal growth factor receptor and AKT1 gene copy numbers by multi-gene fluorescence in situ hybridization impact on prognosis in breast cancer. 2015 , 106, 642-9 | 14 |
| 865 | Drug Selection in the Genomic Age: Application of the Coexpression Extrapolation Principle for Drug Repositioning in Cancer Therapy. 2015 , 1, 17-21 | |
| 864 | An Optimization-Based Framework for the Transformation of Incomplete Biological Knowledge into a Probabilistic Structure and Its Application to the Utilization of Gene/Protein Signaling Pathways in Discrete Phenotype Classification. 2015 , 12, 1304-21 | 14 |
| 863 | Role of vascular density and normalization in response to neoadjuvant bevacizumab and chemotherapy in breast cancer patients. 2015 , 112, 14325-30 | 161 |
| 862 | Therapeutic targeting of casein kinase 1 in breast cancer. 2015 , 7, 318ra202 | 38 |
| 861 | Global transcription network incorporating distal regulator binding reveals selective cooperation of cancer drivers and risk genes. 2015 , 43, 5716-29 | 6 |
| 860 | Next generation sequencing of triple negative breast cancer to find predictors for chemotherapy response. 2015 , 17, 134 | 47 |
| 859 | Dual inhibition of Type I and Type III PI3 kinases increases tumor cell apoptosis in HER2+ breast cancers. 2015 , 17, 148 | 10 |
| 858 | Identification of Variant-Specific Functions of PIK3CA by Rapid Phenotyping of Rare Mutations. 2015 , 75, 5341-54 | 99 |
| 857 | Type 1 Insulin-Like Growth Factor Receptor/Insulin Receptor Substrate 1 Signaling Confers Pathogenic Activity on Breast Tumor Cells Lacking REST. 2015 , 35, 2991-3004 | 9 |

| | | |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 856 | BMX Negatively Regulates BAK Function, Thereby Increasing Apoptotic Resistance to Chemotherapeutic Drugs. 2015 , 75, 1345-55 | 22 |
| 855 | Plasma Autoantibodies Associated with Basal-like Breast Cancers. 2015 , 24, 1332-40 | 36 |
| 854 | Estrogen receptor- β directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. 2015 , 112, 15172-7 | 74 |
| 853 | A survey of disease connections for CD4+ T cell master genes and their directly linked genes. 2015 , 59 Pt B, 78-90 | 1 |
| 852 | The immortality two-step. 2015 , 14, 798 | 1 |
| 851 | Differential flux balance analysis of quantitative proteomic data on protein interaction networks. 2015 , | |
| 850 | Decreased CDK10 expression correlates with lymph node metastasis and predicts poor outcome in breast cancer patients - a short report. 2015 , 38, 485-91 | 17 |
| 849 | DNA methylation profiling to assess pathogenicity of BRCA1 unclassified variants in breast cancer. 2015 , 10, 1121-32 | 11 |
| 848 | . 2015 , | 0 |
| 847 | Anti-Müllerian hormone concentrations in premenopausal women and breast cancer risk. 2015 , 8, 528-34 | 21 |
| 846 | Elevated RNA Editing Activity Is a Major Contributor to Transcriptomic Diversity in Tumors. 2015 , 13, 267-76 | 198 |
| 845 | Patterns and functional implications of rare germline variants across 12 cancer types. 2015 , 6, 10086 | 170 |
| 844 | Signaling pathway models as biomarkers: Patient-specific simulations of JNK activity predict the survival of neuroblastoma patients. 2015 , 8, ra130 | 102 |
| 843 | Potential Therapeutic Targets in Triple Negative Breast Cancer. 2015 , 7, 215-223 | 1 |
| 842 | Translational cancer research comes of age in Latin America. 2015 , 7, 319fs50 | 8 |
| 841 | Breast Cancer: Molecular Mechanisms, Diagnosis, and Treatment. 2015 , 155-200 | 1 |
| 840 | Targeted Therapies Overcoming Endocrine Resistance in Hormone Receptor-Positive Breast Cancer. 2015 , 10, 168-72 | 19 |
| 839 | Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma. 2015 , 138, 656-62 | 43 |

| | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 838 | Beyond the one-locus-one-miRNA paradigm: microRNA isoforms enable deeper insights into breast cancer heterogeneity. 2015 , 43, 9158-75 | 107 |
| 837 | Thyroid genomics: refining diagnosis, prognosis and treatment. 2015 , 2, 105-107 | |
| 836 | Transformation of enriched mammary cell populations with polyomavirus middle T antigen influences tumor subtype and metastatic potential. 2015 , 17, 132 | 6 |
| 835 | Molecular segmentation of luminal breast: Reality in 2015?. 2015 , 24 Suppl 2, S41-3 | |
| 834 | Gemcitabine treatment enhances HER2 expression in low HER2-expressing breast cancer cells and enhances the antitumor effects of trastuzumab emtansine. 2015 , 34, 504-10 | 11 |
| 833 | Mitogen-activated protein kinase phosphatase 1 is involved in tamoxifen resistance in MCF7 cells. 2015 , 34, 2423-30 | 12 |
| 832 | Electrostatic study of Alanine mutational effects on transcription: application to GATA-3:DNA interaction complex. 2015 , 2015, 4005-8 | 1 |
| 831 | Upregulated Annexin A1 promotes cellular invasion in triple-negative breast cancer. 2015 , 33, 1064-70 | 28 |
| 830 | P2Y2 nucleotide receptor-mediated extracellular signal-regulated kinases and protein kinase C activation induces the invasion of highly metastatic breast cancer cells. 2015 , 34, 195-202 | 23 |
| 829 | Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer. 2015 , 7, 232-241 | |
| 828 | Widespread intron retention diversifies most cancer transcriptomes. 2015 , 7, 45 | 188 |
| 827 | HDAC6 activity is a non-oncogene addiction hub for inflammatory breast cancers. 2015 , 17, 149 | 29 |
| 826 | The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. 2015 , 149, 69-79 | 11 |
| 825 | A seven-gene signature can predict distant recurrence in patients with triple-negative breast cancers who receive adjuvant chemotherapy following surgery. 2015 , 136, 1976-84 | 14 |
| 824 | Identifying predictive features in drug response using machine learning: opportunities and challenges. 2015 , 55, 15-34 | 46 |
| 823 | Case records of the Massachusetts General Hospital. Case 1-2015. A 66-year-old woman with metastatic breast cancer after endocrine therapy. 2015 , 372, 162-70 | 2 |
| 822 | Detection of BRCA1 and BRCA2 germline mutations in Japanese population using next-generation sequencing. 2015 , 3, 121-9 | 48 |
| 821 | Construction and analysis of the NCI-EDRN breast cancer reference set for circulating markers of disease. 2015 , 24, 435-41 | 11 |

| | | |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----|
| 820 | Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial. 2015 , 33, 1340-7 | 88 |
| 819 | Therapeutic targeting of tumor suppressor genes. 2015 , 121, 1357-68 | 92 |
| 818 | HER2-family signalling mechanisms, clinical implications and targeting in breast cancer. 2015 , 149, 5-15 | 51 |
| 817 | Prognostic and predictive values of EGFR overexpression and EGFR copy number alteration in HER2-positive breast cancer. 2015 , 112, 103-11 | 75 |
| 816 | Targeted therapies in melanoma. 2015 , 24, 347-58 | 5 |
| 815 | Optimising translational oncology in clinical practice: strategies to accelerate progress in drug development. 2015 , 41, 129-35 | 14 |
| 814 | Triple positive breast cancer: a distinct subtype?. 2015 , 41, 69-76 | 56 |
| 813 | An assessment of computational methods for estimating purity and clonality using genomic data derived from heterogeneous tumor tissue samples. 2015 , 16, 232-41 | 51 |
| 812 | Buparlisib , an oral pan-PI3K inhibitor for the treatment of breast cancer. 2015 , 24, 421-31 | 23 |
| 811 | High HER2 expression correlates with response to the combination of lapatinib and trastuzumab. 2015 , 21, 569-76 | 58 |
| 810 | PTEN Loss Is Associated with Worse Outcome in HER2-Amplified Breast Cancer Patients but Is Not Associated with Trastuzumab Resistance. 2015 , 21, 2065-74 | 47 |
| 809 | Mutant p53 Amplifies Epidermal Growth Factor Receptor Family Signaling to Promote Mammary Tumorigenesis. 2015 , 13, 743-54 | 29 |
| 808 | Decarbamoyl mitomycin C (DMC) activates p53-independent ataxia telangiectasia and rad3 related protein (ATR) chromatin eviction. 2015 , 14, 744-54 | 7 |
| 807 | Signaling-mediated regulation of MicroRNA processing. 2015 , 75, 783-91 | 40 |
| 806 | Somatic Diseases (Cancer): Whole Exome and Whole Genome Sequencing. 2015 , 343-360 | |
| 805 | mTOR Signaling in Endometrial Cancer: From a Molecular and Therapeutic Point of View. 2015 , 4, 1-10 | 10 |
| 804 | Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast Cancer. 2015 , 15, 197-203 | 12 |
| 803 | Tyrosine kinase discoidin domain receptors DDR1 and DDR2 are coordinately deregulated in triple-negative breast cancer. 2015 , 150, 9-18 | 49 |

| | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 802 | Patient-derived xenograft models of breast cancer and their predictive power. 2015 , 17, 17 | 195 |
| 801 | Triple-negative breast cancer in African-American women: disparities versus biology. 2015 , 15, 248-54 | 223 |
| 800 | Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer. 2015 , 33, 304-11 | 435 |
| 799 | Lipid nanocarriers of a lipid-conjugated estrogenic derivative inhibit tumor growth and enhance cisplatin activity against triple-negative breast cancer: pharmacokinetic and efficacy evaluation. 2015 , 12, 1105-20 | 46 |
| 798 | Cancer genomics: why rare is valuable. 2015 , 93, 369-81 | 7 |
| 797 | Loss of the Notch effector RBPJ promotes tumorigenesis. 2015 , 212, 37-52 | 39 |
| 796 | PIK3CA mutations are associated with decreased benefit to neoadjuvant human epidermal growth factor receptor 2-targeted therapies in breast cancer. 2015 , 33, 1334-9 | 164 |
| 795 | Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. 2015 , 9, 772-82 | 29 |
| 794 | The antitumorigenic function of EGFR in metastatic breast cancer is regulated by expression of Mig6. 2015 , 17, 124-33 | 26 |
| 793 | Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer. 2015 , 11, 823-34 | 2 |
| 792 | CLK2 Is an Oncogenic Kinase and Splicing Regulator in Breast Cancer. 2015 , 75, 1516-26 | 51 |
| 791 | Gene expression-based classifications of fibroadenomas and phyllodes tumours of the breast. 2015 , 9, 1081-90 | 25 |
| 790 | Tamoxifen resistance: from cell culture experiments towards novel biomarkers. 2015 , 211, 189-97 | 47 |
| 789 | Omics Pipe: a community-based framework for reproducible multi-omics data analysis. 2015 , 31, 1724-8 | 53 |
| 788 | ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathways. 2015 , 31, 1745-53 | 24 |
| 787 | The chemistry and pharmacology of privileged pyrroloquinazolines. 2015 , 6, 510-520 | 6 |
| 786 | Inferring biological tasks using Pareto analysis of high-dimensional data. 2015 , 12, 233-5, 3 p following 235 | 93 |
| 785 | Evaluation of melanoma antigen (MAGE) gene expression in human cancers using The Cancer Genome Atlas. 2015 , 208, 25-34 | 14 |

| | | |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-----|
| 784 | Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression. 2015 , 27, 211-22 | 548 |
| 783 | Methylation profiling of 48 candidate genes in tumor and matched normal tissues from breast cancer patients. 2015 , 149, 767-79 | 46 |
| 782 | Markers for the identification of late breast cancer recurrence. 2015 , 17, 10 | 46 |
| 781 | Decreased mRNA Expression in Human Breast Cancer is Associated with Estrogen Receptor-Negative Subtypes and Poor Prognosis. 2015 , 2, 255-263 | 74 |
| 780 | Co-targeting BRAF and cyclin dependent kinases 4/6 for BRAF mutant cancers. 2015 , 149, 139-49 | 20 |
| 779 | Metabolic Signatures of Human Breast Cancer. 2015 , 2, | 42 |
| 778 | S100 proteins in cancer. 2015 , 15, 96-109 | 416 |
| 777 | The characteristics and clinical significance of atypical mitosis in breast cancer.. 2022 , | 0 |
| 776 | The Importance of RTK Signaling Genes and their Inhibitors in Breast Cancer. 2022 , 7, 258-271 | |
| 775 | Molecular Progression of Breast Cancer and Personalized Medicine in Terms of Clinical Trials. 2022 , 367-401 | |
| 774 | OVOL1 inhibits breast cancer cell invasion by enhancing the degradation of TGF- β type I receptor.. 2022 , 7, 126 | 0 |
| 773 | Distinct clinical and somatic mutational features of breast tumors with high-, low-, or non-expressing human epidermal growth factor receptor 2 status.. 2022 , 20, 142 | 2 |
| 772 | Non-canonical genomic driver mutations of urethane carcinogenesis.. 2022 , 17, e0267147 | |
| 771 | Gene expression signatures in early Breast Cancer: better together with clinicopathological features.. 2022 , 103708 | 0 |
| 770 | Amino Acid Metabolism-Related lncRNA Signature Predicts the Prognosis of Breast Cancer. 2022 , 13, | 0 |
| 769 | Triple-Negative Breast Cancer: the Current Aspects of Pathogenesis and Therapies. 1 | 0 |
| 768 | Proteogenomic characterization of 2002 human cancers reveals pan-cancer molecular subtypes and associated pathways.. 2022 , 13, 2669 | 3 |
| 767 | Breaking the Immune Complexity of the Tumor Microenvironment Using Single-Cell Technologies. 2022 , 13, | 0 |

- 766 Regulation of protein complex partners as a compensatory mechanism in aneuploid tumors.. **2022**, 11, 0
- 765 PRMT inhibition induces a viral mimicry response in triple-negative breast cancer.. **2022**, 3
- 764 Investigation of the effects of overexpression of jumping translocation breakpoint (JTB) protein in MCF7 cells for potential use as a biomarker in breast cancer.. **2022**, 12, 1784-1823
- 763 Natural Compound-Based Nanoparticles to Target Free Radicals in Cancer. **2022**, 1-14
- 762 SlideGraph+: Whole Slide Image Level Graphs to Predict HER2 Status in Breast Cancer. **2022**, 102486 0
- 761 Whole-transcriptomic profiling of human cerebral cortex tissues reveals microglia-associated molecular subtypes.
- 760 The Applications of Plasma Cell-free DNA in Cancer Detection: Implications in the Management of Breast Cancer Patients. **2022**, 103725
- 759 The AKT1E17K Allele Promotes Breast Cancer in Mice. **2022**, 14, 2645
- 758 Real World Evaluation of the Prosigna/PAM50 Test in a Node-Negative Postmenopausal Swedish Population: A Multicenter Study. **2022**, 14, 2615 2
- 757 Comprehensive Analysis of Gene Expression Profiles to Identify Differential Prognostic Factors of Primary and Metastatic Breast Cancer. **2022**, 103318 0
- 756 Wnt Signaling in the Breast: From Development to Disease. **2022**, 10, 1
- 755 Kindlin-2 promotes Src-mediated tyrosine phosphorylation of androgen receptor and contributes to breast cancer progression. **2022**, 13, 0
- 754 A human breast atlas integrating single-cell proteomics and transcriptomics. **2022**, 1
- 753 Hydrogel Nanoarchitectonics: An Evolving Paradigm for Ultrasensitive Biosensing. 2107571 2
- 752 Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers. **2022**, 29, 107327482211062
- 751 Dihydroconiferyl Ferulate Isolated from *Dendropanax morbiferus* H.L.V. Suppresses Stemness of Breast Cancer Cells via Nuclear EGFR/c-Myc Signaling. **2022**, 15, 664
- 750 ROS1 altered breast cancers ▯ distinctive molecular subtype of PR- metastatic breast cancers: Expanding the scope of targeted therapeutics. **2022**, 41, 295-301
- 749 Integration of multi-omics data shows downregulation of mismatch repair, purin, and tublin pathways in AR-negative triple-negative chemotherapy-resistant breast tumors.

| | | |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 748 | Reassessment of Reliability and Reproducibility for Triple-Negative Breast Cancer Subtyping. 2022 , 14, 2571 | 0 |
| 747 | Clinical Relevance of Estrogen Reactivity in the Breast Cancer Microenvironment. 12, | 0 |
| 746 | Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification. | |
| 745 | mTOR pathway gene expression in association with race and clinicopathological characteristics in Black and White breast cancer patients. 2022 , 13, | 1 |
| 744 | Cytokeratins 5 and 17 maintain an aggressive epithelial state in basal-like breast cancer. | |
| 743 | Mechanisms of miR-3189-3p-mediated inhibition of c-MYC translation in triple negative breast cancer. 2022 , 22, | 1 |
| 742 | Fatty acid oxidation protects cancer cells from apoptosis by increasing mitochondrial membrane lipids. 2022 , 39, 110870 | 2 |
| 741 | Dysregulation and therapeutic targeting of RNA splicing in cancer. 2022 , 3, 536-546 | 3 |
| 740 | ESR2 Drives Mesenchymal-to-Epithelial Transition in Triple-Negative Breast Cancer and Tumorigenesis In Vivo. 12, | |
| 739 | Familiäre Krebserkrankungen. | |
| 738 | Hormonal and Genetic Regulatory Events in Breast Cancer and Its Therapeutics: Importance of the Steroidogenic Acute Regulatory Protein. 2022 , 10, 1313 | 0 |
| 737 | Proteomic analysis reveals stage-specific reprogramed metabolism for the primary breast cancer cell lines MGSO-3 and MACL-1. 2200095 | 1 |
| 736 | Kinase inhibitors for precision therapy of triple-negative breast cancer: Progress, challenges, and new perspectives on targeting this heterogeneous disease. 2022 , 215775 | 0 |
| 735 | SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. 2022 , 132, | 0 |
| 734 | Development and Verification of a Prognostic Ferroptosis-Related Gene Model in Triple-Negative Breast Cancer. 12, | 0 |
| 733 | Fulvestrant plus capivasertib versus placebo after relapse or progression on an aromatase inhibitor in metastatic, oestrogen receptor-positive, HER2-negative breast cancer (FAKTION): overall survival, updated progression-free survival, and expanded biomarker analysis from a randomised, phase 2 trial. 2022 , | 4 |
| 732 | Focal Adhesion Kinase (FAK)-Hippo/YAP transduction signaling mediates the stimulatory effects exerted by S100A8/A9-RAGE system in triple-negative breast cancer (TNBC). 2022 , 41, | 2 |
| 731 | Live-attenuated poliovirus-induced extrinsic apoptosis through Caspase 8 within breast cancer cell lines expressing CD155. | |

- 730 Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines. **2022**, 29, 4020-4033
- 729 A pro-metastatic tRNA fragment drives Nucleolin oligomerization and stabilization of its bound metabolic mRNAs. **2022**, 1
- 728 5-miR-183-5p|+2 elicits tumor suppressor activity in a negative feedback loop with E2F1. **2022**, 41,
- 727 Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in ER (+) and/or PR (+) and HER2 (±) Breast Cancer. **2022**, 13, 1
- 726 Glycoproteomics Identifies Plexin-B3 as Targetable Cell Surface Protein Required for Growth and Invasion of Triple Negative Breast Cancer Cells.
- 725 Case Report: Extensive Tumor Profiling in Primary Neuroendocrine Breast Cancer Cases as a Role Model for Personalized Treatment in Rare and Aggressive Cancer Types. **2022**, 9, 0
- 724 Targeting LIPA independent of its lipase activity is a therapeutic strategy in solid tumors via induction of endoplasmic reticulum stress. 0
- 723 Interplay between Caveolin-1 and body and tumor size affects clinical outcomes in breast cancer. **2022**, 22, 101464 0
- 722 A Multiomics Signature Highlights Alterations Underlying Homologous Recombination Deficiency in Triple-Negative Breast Cancer. 0
- 721 Common Cancers and Their Genetic Alterations. **2022**, 317-354
- 720 How to Compare Various Clustering Outcomes? Metrics to Investigate Breast Cancer Patient Subpopulations Based on Proteomic Profiles. **2022**, 309-318
- 719 Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications.
- 718 Comparisons of Knowledge Graphs and Entity Extraction in Breast Cancer Subtyping Biomedical Text Analysis. **2022**, 249-259
- 717 Transcriptome-wide prediction of prostate cancer gene expression from histopathology images using co-expression-based convolutional neural networks. 1
- 716 Genome-wide cross-cancer analysis illustrates the critical role of bimodal miRNA in patient survival and drug responses to PI3K inhibitors. **2022**, 18, e1010109
- 715 Serial Tumor Molecular Profiling of Newly Diagnosed HER2-Negative Breast Cancers During Chemotherapy in Combination with Angiogenesis Inhibitors. **2022**, 17, 355-368
- 714 Update on prognostic and predictive biomarkers of breast cancer. **2022**, 0
- 713 Updates on Management of Hereditary Breast Cancer: New Data on PARP Inhibitors Change Recommendations Regarding the Multidisciplinary Care of Breast Cancer Patients with BRCA Mutations.

| | | |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 712 | The risk variant rs11836367 contributes to breast cancer onset and metastasis by attenuating Wnt signaling via regulating NTN4 expression. 2022 , 8, | 0 |
| 711 | Gene signature for predicting homologous recombination deficiency in triple-negative breast cancer. | |
| 710 | Homologous Recombination Deficiency in Ovarian, Breast, Colorectal, Pancreatic, Non-Small Cell Lung and Prostate Cancers, and the Mechanisms of Resistance to PARP Inhibitors. 12, | 1 |
| 709 | Breast Cancer Genomics: Primary and Most Common Metastases. 2022 , 14, 3046 | |
| 708 | Classification of triple negative breast cancer by epithelial mesenchymal transition and the tumor immune microenvironment. 2022 , 12, | 0 |
| 707 | MALAT1-dependent hsa_circ_0076611 regulates translation rate in triple-negative breast cancer. 2022 , 5, | 2 |
| 706 | Breast carcinomas with osteoclast-like giant cells: a comprehensive clinico-pathological and molecular portrait and evidence of RANK-L expression. | 0 |
| 705 | Analysis of Omics Data Reveals Nucleotide Excision Repair-Related Genes Signature in Highly-Grade Serous Ovarian Cancer to Predict Prognosis. 10, | 0 |
| 704 | Combined analysis of receptor expression reflects inter-and intra-tumor heterogeneity in HR+/HER2+ breast cancer. | 0 |
| 703 | GRHL2 motif is associated with intratumor heterogeneity of cis-regulatory elements in luminal breast cancer. 2022 , 8, | 0 |
| 702 | Vaccines for immunoprevention of DNA mismatch repair deficient cancers. 2022 , 10, e004416 | 3 |
| 701 | Extracellular sialyltransferase st6gal1 in breast tumor cell growth and invasiveness. | 1 |
| 700 | BRCA1, BRCA2, TP53, PIK3CA, PTEN and AKT1 genes mutations in Burkina Faso breast cancer patients: prevalence, spectrum and novel variant. | 1 |
| 699 | High Expression of a Cancer Stemness-Related Gene, Chromobox 8 (CBX8), in Normal Tissue Adjacent to the Tumor (NAT) Is Associated with Poor Prognosis of Colorectal Cancer Patients. 2022 , 11, 1852 | |
| 698 | Cancer-associated fibroblasts suppress CD8+ T cell infiltration and confer resistance to immune checkpoint blockade. | 2 |
| 697 | RhoBTB3 Regulates Proliferation and Invasion of Breast Cancer Cells via Col1a1. 2022 , | 1 |
| 696 | Luminal progenitors undergo partial epithelial-to-mesenchymal transition at the onset of basal-like breast tumorigenesis. | |
| 695 | NR2F1, a Tumor Dormancy Marker, Is Expressed Predominantly in Cancer-Associated Fibroblasts and Is Associated with Suppressed Breast Cancer Cell Proliferation. 2022 , 14, 2962 | 1 |

| | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 694 | Stem Cell Theory of Cancer: Origin of Metastasis and Sub-clonality. 2022 , | |
| 693 | Prognostic significance of RNA-based TP53 pathway function among estrogen receptor positive and negative breast cancer cases. 2022 , 8, | 0 |
| 692 | Recent insights into the effects of metabolism on breast cancer cell dormancy. | 0 |
| 691 | Deep reinforcement learning for personalized treatment recommendation. | 0 |
| 690 | Nanotechnological Approaches for the Treatment of Triple-Negative Breast Cancer: A Comprehensive Review. 2022 , 23, | 0 |
| 689 | Exome sequencing identifies novel susceptibility genes and defines the contribution of coding variants to breast cancer risk. | 0 |
| 688 | Epigenetic Mechanisms Influencing Therapeutic Response in Breast Cancer. 12, | 1 |
| 687 | Activation Versus Inhibition of IGF1R: A Dual Role in Breast Tumorigenesis. 13, | 0 |
| 686 | Antiprogestins reduce epigenetic field cancerization in breast tissue of young healthy women. 2022 , 14, | 1 |
| 685 | Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Httle cell carcinoma. 2022 , 8, | 0 |
| 684 | Drug Repurposing by Tumor Tissue Editing. 12, | 0 |
| 683 | DNA methylation changes in response to neoadjuvant chemotherapy are associated with breast cancer survival. 2022 , 24, | 3 |
| 682 | Breast Cancer Subtypes And Prognosis: Answers To Subgroup Classification Questions, Identifying The Worst Subgroup In Our Single-Center Series. | |
| 681 | A hierarchical spike-and-slab model for pan-cancer survival using pan-omic data. 2022 , 23, | |
| 680 | Linking histology and molecular state across human tissues. | |
| 679 | Integrative multi-omic analysis identifies genetically influenced DNA methylation biomarkers for breast and prostate cancers. 2022 , 5, | |
| 678 | Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status. 2022 , 14, 3003 | |
| 677 | Cytoplasmic p53 Isoforms Are Associated with Worse Disease-Free Survival in Breast Cancer. 2022 , 23, 6670 | 0 |

| | | |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 676 | Replication Stress Defines Distinct Molecular Subtypes Across Cancers. 2022 , 2, 503-517 | 0 |
| 675 | Heterogeneity of triple-negative breast cancer: understanding the Daedalian labyrinth and how it could reveal new drug targets. 1-17 | 1 |
| 674 | omicsGAT: Graph Attention Network for Cancer Subtype Analyses. | |
| 673 | Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity. 2022 , 23, 6547 | 0 |
| 672 | Unsupervised Representation Learning for Tissue Segmentation in Histopathological Images: From Global to Local Contrast. 2022 , 1-1 | 0 |
| 671 | Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer. 2022 , 13, | 1 |
| 670 | Role of germline variants in the metastasis of breast carcinomas. 2022 , 13, 843-862 | |
| 669 | High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex sequencing. 2022 , 8, | 0 |
| 668 | Functional screening reveals HORMAD1-driven gene dependencies associated with translesion synthesis and replication stress tolerance. | 1 |
| 667 | Genomic Markers of CDK 4/6 Inhibitor Resistance in Hormone Receptor Positive Metastatic Breast Cancer. 2022 , 14, 3159 | 0 |
| 666 | Chemokine receptors differentially expressed by race category and molecular subtype in the breast cancer TCGA cohort. 2022 , 12, | 1 |
| 665 | Enrichment of breast cancer stem cells following cytotoxic chemotherapy is mediated by hypoxia-inducible factors. | 1 |
| 664 | Alpelisib monotherapy for PI3K-altered, pre-treated advanced breast cancer: a phase 2 study. | 1 |
| 663 | Know thy cells: commonly used triple-negative human breast cancer cell lines carry mutations in RAS and effectors. 2022 , 24, | 1 |
| 662 | A deep learning model to classify neoplastic state and tissue origin from transcriptomic data. 2022 , 12, | 1 |
| 661 | Expression of DNA Helicase Genes Was Correlated with Homologous Recombination Deficiency in Breast Cancer. 2022 , 2022, 1-7 | 0 |
| 660 | BMI1 promotes the proliferation and inhibits autophagy of breast cancer cells by activating COPZ1. | 1 |
| 659 | In vivo multidimensional CRISPR screens identify Lgals2 as an immunotherapy target in triple-negative breast cancer. 2022 , 8, | 1 |

- 658 Multiomics technologies: role in disease biomarker discoveries and therapeutics.
- 657 Focal Adhesion Kinase Provides a Collateral Vulnerability That Can Be Leveraged to Improve mTORC1 Inhibitor Efficacy. **2022**, 14, 3374
- 656 Multimodal Prediction of Breast Cancer Recurrence Assays and Risk of Recurrence. 0
- 655 A deep learning approach for improved detection of homologous recombination deficiency from shallow genomic profiles.
- 654 The Link Between the Microbiota and HER2+ Breast Cancer: The New Challenge of Precision Medicine. 12, 1
- 653 Long-term outcomes of non-metastatic breast cancer patients by molecular subtypes. **2022**, 22, 0
- 652 Multi-Omics and Artificial Intelligence-Guided Drug Repositioning: Prospects, Challenges, and Lessons Learned from COVID-19. **2022**, 26, 361-371 2
- 651 Intratumoral PDGFB gene predominantly expressed in endothelial cells is associated with angiogenesis and lymphangiogenesis, but not with metastasis in breast cancer.
- 650 From Immunohistochemistry to New Digital Ecosystems: A State-of-the-Art Biomarker Review for Precision Breast Cancer Medicine. **2022**, 14, 3469 1
- 649 Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor Benefit. **2022**, 1
- 648 Statins inhibit proliferation and induce apoptosis in triple-negative breast cancer cells. **2022**, 39, 1
- 647 MicroRNA-21 is immunosuppressive and pro-metastatic via separate mechanisms. **2022**, 11, 1
- 646 Comparisons of Metastatic Patterns, Survival Outcomes and Tumor Immune Microenvironment Between Young and Non-Young Breast Cancer Patients. 10, 1
- 645 EBF1 promotes triple-negative breast cancer progression by surveillance of the HIF1 β pathway. **2022**, 119, 1
- 644 Immune checkpoint blockade in hormone receptor-positive breast cancer: Resistance mechanisms and future perspectives. **2022**, 1
- 643 Comparative Analysis of Gene Correlation Networks of Breast Cancer Patients Based on Mutations in TP53. **2022**, 12, 979 1
- 642 Addition of Capecitabine to Adjuvant Chemotherapy May be the Most Effective Strategy for Patients With Early-Stage Triple-Negative Breast Cancer: A Network Meta-Analysis of 9 Randomized Controlled Trials. 13, 1
- 641 Hippo-TAZ signaling is the master regulator of the onset of triple-negative basal-like breast cancers. **2022**, 119, 0

| | | |
|-----|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 640 | CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. 2022 , 14, 3361 | 1 |
| 639 | ANKHD1 contributes to the malignant phenotype of triple-negative breast cancer cells. | |
| 638 | Integrated DNA and RNA Sequencing Reveals Drivers of Endocrine Resistance in Estrogen Receptor Positive Breast Cancer. OF1-OF12 | 1 |
| 637 | Rethinking breast cancer follow-up based on individual risk and recurrence management. 2022 , 102434 | 1 |
| 636 | A randomized phase 3 trial of Gemcitabine or Nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer. 2022 , 13, | 1 |
| 635 | Impact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancer. 2022 , 8, | 0 |
| 634 | Mutational landscape of pan-cancer patients with PIK3CA alterations in Chinese population. 2022 , 15, | 0 |
| 633 | Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis. 2022 , | 1 |
| 632 | Hypoxia induces HIF1 α -dependent epigenetic vulnerability in triple negative breast cancer to confer immune effector dysfunction and resistance to anti-PD-1 immunotherapy. 2022 , 13, | 3 |
| 631 | Combined Dusp4 and p53 loss with Dbf4 amplification drives tumorigenesis via cell cycle restriction and replication stress escape in breast cancer. 2022 , 24, | |
| 630 | Clinical trials of immunotherapy in triple-negative breast cancer. | 1 |
| 629 | Breast Cancer Stem Cells: Signaling Pathways, Cellular Interactions, and Therapeutic Implications. 2022 , 14, 3287 | 2 |
| 628 | Comparison of actionable events detected in cancer genomes by whole-genome sequencing, in silico whole-exome and mutation panels. 2022 , 7, 100540 | 1 |
| 627 | Functional mechanisms of TRPS1 in disease progression and its potential role in personalized medicine. 2022 , 237, 154022 | 1 |
| 626 | Capturing the latent space of an Autoencoder for multi-omics integration and cancer subtyping. 2022 , 148, 105832 | 0 |
| 625 | Perioperative Care of the Cancer Patient: Breast Procedures. 2023 , 262-281 | |
| 624 | Carrier-free nanoprodrug for p53-mutated tumor therapy via concurrent delivery of zinc-manganese dual ions and ROS. 2023 , 20, 404-417 | 1 |
| 623 | Inflammation-Driven Regulation of PD-L1 and PD-L2, and Their Cross-Interactions with Protective Soluble TNF Receptors in Human Triple-Negative Breast Cancer. 2022 , 14, 3513 | 0 |

- 622 Association of Pathway Mutations With Survival in Taiwanese Breast Cancers. 12, 1
- 621 Comprehensive Analysis of the Immunogenomics of Triple-Negative Breast Cancer Brain Metastases From LCCC1419. 12, 0
- 620 Tumor immune microenvironment of self-identified African American and non-African American triple negative breast cancer. **2022**, 8, 0
- 619 Mutant p53-microRNA-200c-ZEB2-Axis-Induced CPT1C Elevation Contributes to Metabolic Reprogramming and Tumor Progression in Basal-Like Breast Cancers. 12, 0
- 618 Immunometabolism characteristics and a potential prognostic risk model associated with TP53 mutations in breast cancer. 13, 0
- 617 Emerging Trends in Bioinformatics for Breast Cancer Molecular Research. **2022**, 86-108
- 616 Multi-Omics Binary Integration via Lasso Ensembles (MOBILE) for identification of context-specific networks and new regulatory mechanisms. 0
- 615 The role of obesity and bariatric surgery-induced weight loss in breast cancer. 0
- 614 Contrast Subgraphs Allow Comparing Homogeneous and Heterogeneous Networks Derived from Omics Data. 0
- 613 Tumor cell-derived extracellular vesicles for breast cancer specific delivery of therapeutic P53. **2022**, 349, 606-616 1
- 612 Pozotinib Inhibits HER2-Mutant-Driven Therapeutic Resistance and Multiorgan Metastasis in Breast Cancer. **2022**, 82, 2928-2939 0
- 611 Multi-Gene Mutation Profiling by Targeted Next-Generation Sequencing in Premenopausal Breast Cancer. **2022**, 13, 1362 1
- 610 Comparison of endocrine therapy and chemotherapy as different systemic treatment modes for metastatic luminal HER2-negative breast cancer patients: A retrospective study. 12, 1
- 609 Navigating the HER2-Low Paradigm in Breast Oncology: New Standards, Future Horizons. OF1-OF5 0
- 608 IL-6: The Link Between Inflammation, Immunity and Breast Cancer. 12, 2
- 607 Identifying the Antitumor Effects of Curcumin on Lung Adenocarcinoma Using Comprehensive Bioinformatics Analysis. Volume 16, 2365-2382
- 606 Firmas gēnicas en el cāncer de mama. **2022**, 35, S67-S86
- 605 GenoPPML: A framework for genomic privacy-preserving machine learning. **2022**, 1

| | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 604 | Glycoproteomics Identifies Plexin-B3 as a Targetable Cell Surface Protein Required for the Growth and Invasion of Triple-Negative Breast Cancer Cells. | 0 |
| 603 | Prospective Clinical Genomic Profiling of Ewing Sarcoma: ERF and FGFR1 Mutations as Recurrent Secondary Alterations of Potential Biologic and Therapeutic Relevance. 2022, | 1 |
| 602 | A high-throughput drug screen reveals means to differentiate triple-negative breast cancer. | 2 |
| 601 | TGFBR3 supports anoikis through suppressing ATF4 signaling. | |
| 600 | An Overview Regarding Pharmacogenomics And Biomarkers Discovery: Focus On Breast Cancer. 2022, 22, | 0 |
| 599 | Adaptation to Hypoxia May Promote Therapeutic Resistance to Androgen Receptor Inhibition in Triple-Negative Breast Cancer. 2022, 23, 8844 | 1 |
| 598 | Molecular Subtyping of Invasive Breast Cancer Using a PAM50-Based Multigene Expression Test-Comparison with Molecular-Like Subtyping by Tumor Grade/Immunohistochemistry and Influence on Oncologist's Decision on Systemic Therapy in a Real-World Setting. 2022, 23, 8716 | 1 |
| 597 | SUPREME: A cancer subtype prediction methodology integrating multiomics data using Graph Convolutional Neural Network. | 0 |
| 596 | PTPRD and CNTNAP2 as markers of tumor aggressiveness in oligodendrogliomas. 2022, 12, | |
| 595 | Integration of multi-omics data shows downregulation of mismatch repair, purin, and tubulin pathways in triple-negative chemotherapy-resistant breast tumors. | |
| 594 | Relationship between metabolic reprogramming and drug resistance in breast cancer. 12, | 1 |
| 593 | Early triple negative breast cancers in a Singapore cohort exhibit high PIK3CA mutation rates associated with low PD-L1 expression. | |
| 592 | Programmed death-ligand 1 (PD-L1) expression predicts response to neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis. 1-9 | 0 |
| 591 | Network Pharmacology Analysis, Molecular Docking, and In Vitro Verification Reveal the Action Mechanism of <i>Prunella vulgaris</i> L. in Treating Breast Cancer. 2022, 2022, 1-19 | 0 |
| 590 | Breast Cancer-Delivered Exosomal miRNA as Liquid Biopsy Biomarkers for Metastasis Prediction: A Focus on Translational Research with Clinical Applicability. 2022, 23, 9371 | 3 |
| 589 | PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer. 2022, 11, 2508 | 4 |
| 588 | Prädiktive molekulare Diagnostik beim Mammakarzinom. 2022, 43, 388-398 | 0 |
| 587 | High miR-99b expression is associated with cell proliferation and worse patient outcomes in breast cancer. | |

- 586 Predicting the molecular subtypes of breast cancer using nomograms based on three-dimensional ultrasonography characteristics. 12,
- 585 HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer. **2022**, 104205 ○
- 584 Clonal evolution in primary breast cancers under sequential epirubicin and docetaxel monotherapy. **2022**, 14, ○
- 583 Predicting the Prognostic Value of POLI Expression in Different Cancers via a Machine Learning Approach. **2022**, 23, 8571 ○
- 582 Silencing of COL3A1 represses proliferation, migration, invasion, and immune escape of triple negative breast cancer cells via down-regulating PD-L1 expression. ○
- 581 Potential of histone deacetylase inhibitors in the control and regulation of prostate, breast and ovarian cancer. 10, ○
- 580 PACT promotes the metastasis of basal-like breast cancer through Rac1 SUMOylation and activation. ○
- 579 Comparative Efficacy and safety of new targeted therapies and immunotherapies for metastatic triple negative breast cancer: a network meta-analysis.
- 578 Risk Stratification for Breast Cancer Patient by Simultaneous Learning of Molecular Subtype and Survival Outcome Using Genetic Algorithm-Based Gene Set Selection. **2022**, 14, 4120
- 577 Loss of PTEN Expression, PIK3CA Mutations, and Breast Cancer Survival in the Nurses' Health Studies.
- 576 Ovo Like Zinc Finger 2 (OVOL2) Suppresses Breast Cancer Stem Cell Traits and Correlates with Immune Cells Infiltration. Volume 14, 211-227
- 575 Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer. 13, ○
- 574 Triple negative breast cancer: Pitfalls and progress. **2022**, 8, 8
- 573 FAK-SFK Signaling Integrates ECM Rigidity Sensing and Engagement of ERBB2 to Activate YAP and Promote Invasive Growth and Metastasis in Breast Cancer.
- 572 A benchmark study of deep learning-based multi-omics data fusion methods for cancer. **2022**, 23, 3
- 571 Accurate determination of CRISPR-mediated gene fitness in transplantable tumours. **2022**, 13,
- 570 Breast cancer cell-derived microRNA-155 suppresses tumor progression via enhancing immune cell recruitment and anti-tumor function. ○
- 569 Identification of Lethal Inhibitors and Inhibitor Combinations for Mono-Driver versus Multi-Driver Triple-Negative Breast Cancer Cells. **2022**, 14, 4027

568 Breast cancer stage prediction: a computational approach guided by transcriptome analysis.

567 A Distinct Chromatin State Drives Therapeutic Resistance in Invasive Lobular Breast Cancer. 1

566 Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities. 9, 2

565 Connecting omics signatures and revealing biological mechanisms with iLINCS. 2022, 13, 1

564 Exome sequencing reveals a distinct somatic genomic landscape in breast cancer from women with germline PTEN variants. 2022, 109, 1520-1533

563 Subtype and cell type specific expression of lncRNAs provide insight into breast cancer. 2022, 5, 2

562 Recent Advances of Utilizing Artificial Intelligence in Lab on a Chip for Diagnosis and Treatment. 2203169 3

561 Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents. 2022, 14, 4064 0

560 The Pyroptosis-Related Risk Genes APOBEC3D, TNFRSF14, and RAC2 Were Used to Evaluate Prognosis and as Tumor Suppressor Genes in Breast Cancer. 2022, 2022, 1-14 0

559 Glycosphingolipids are mediators of cancer plasticity through independent signaling pathways. 2022, 40, 111181 1

558 Fate decisions of breast cancer stem cells in cancer progression. 12,

557 Precision Breast Cancer Medicine: Early Stage Triple Negative Breast Cancer—A Review of Molecular Characterisation, Therapeutic Targets and Future Trends. 12, 3

556 CDK4/6 inhibitors versus PI3K/AKT/mTOR inhibitors in women with hormone receptor-positive, HER2-negative metastatic breast cancer: An updated systematic review and network meta-analysis of 28 randomized controlled trials. 12, 0

555 Temporal profiling of the breast tumour microenvironment reveals collagen XII as a driver of metastasis. 2022, 13, 2

554 Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine.

553 Comparative analysis of the molecular subtype landscape in canine and human mammary gland tumors. 0

552 Loss of genes in chromosome arms 5q and 16q in breast cancer. 2022, 41, 331-341

551 Triple-negative breast cancer influences a mixed M1/M2 macrophage phenotype associated with tumor aggressiveness. 2022, 17, e0273044 2

| | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 550 | A deep learning approach with subregion partition in MRI image analysis for metastatic brain tumor. 16, | |
| 549 | Association between adrenal-restrictive HSD3B1 inheritance and hormone independent subtypes of endometrial and breast cancer. | 1 |
| 548 | Noncanonical Wnt/Ror2 signaling regulates cell-matrix adhesion to prompt directional tumor cell invasion in breast cancer. | |
| 547 | Targeted therapy for breast cancer: An overview of drug classes and outcomes. 2022, 204, 115209 | 2 |
| 546 | The current staging and classification systems of breast cancer and their pitfalls: Is it possible to integrate the complexity of this neoplasm into a unified staging system?. 2022, 178, 103781 | 1 |
| 545 | BET inhibition induces vulnerability to MCL1 targeting through upregulation of fatty acid synthesis pathway in breast cancer. 2022, 40, 111304 | 0 |
| 544 | Homoharringtonine demonstrates a cytotoxic effect against triple-negative breast cancer cell lines and acts synergistically with paclitaxel. 2022, 12, | 0 |
| 543 | Breast Cancer Subtypes and Prognosis: Answers to Subgroup Classification Questions, Identifying the Worst Subgroup in Our Single-Center Series. Volume 14, 259-280 | 0 |
| 542 | Connexins orchestrate progression of breast cancer metastasis to the brain by promoting FAK activation. 2022, 14, | 0 |
| 541 | ACACB is a novel metabolism-related biomarker in the prediction of response to cetuximab therapy in metastatic colorectal cancer. 2022, | 0 |
| 540 | Genomic Classification of HER2-Positive Patients With 80-Gene and 70-Gene Signatures Identifies Diversity in Clinical Outcomes With HER2-Targeted Neoadjuvant Therapy. 2022, | 1 |
| 539 | Redefining normal breast cell populations using long noncoding RNAs. | 0 |
| 538 | Sustained potentiation of bystander killing via PTEN-loss driven macropinocytosis targeted peptide-drug conjugate therapy in metastatic triple-negative breast cancer. 2022, 289, 121783 | 0 |
| 537 | Integration of differential expression and network structure for omics data analysis. 2022, 150, 106133 | 0 |
| 536 | Advancement of cell-penetrating peptides in combating triple-negative breast cancer. 2022, 27, 103353 | 0 |
| 535 | Mesenchymal stem/stromal cells in breast cancer development and management. 2022, 86, 81-92 | 1 |
| 534 | The inhibition of centromere protein K causes anticancer effects in breast carcinoma via effects on the FAK/PI3K/AKT/mTOR pathway. 2022, 454, 116232 | 0 |
| 533 | Artificial Intelligence Enhanced Breast MRI and DWI: Current Status and Future Applications. 2023 , 162-175 | 0 |

| | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 532 | Biomarkers, Prognosis, and Prediction Factors. 2023 , 49-70 | 0 |
| 531 | Natural Compound-Based Nanoparticles to Target Free Radicals in Cancer. 2022 , 745-758 | 0 |
| 530 | Breast cancer: introduction. 2022 , 3-26 | 0 |
| 529 | Construction of Gene Network Based on Inter-tumor Heterogeneity for Tumor Type Identification. 2022 , 345-355 | 0 |
| 528 | Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role. 2022 , 14, 175883592211136 | 1 |
| 527 | End-to-End Learning for Image-Based Detection of Molecular Alterations in Digital Pathology. 2022 , 88-98 | 0 |
| 526 | Estrogen Receptor Alpha and ESR1 Mutations in Breast Cancer. 2022 , 171-194 | 0 |
| 525 | Conjugation of tetracycline and penicillin with Sb(v) and Ag(i) against breast cancer cells. 2022 , 45, 152-168 | 1 |
| 524 | Analysis of Breast Cancer Classification with Machine Learning based Algorithms. 2022 , | 0 |
| 523 | Survival analysis for the identified cancer gene subtype from the co-clustering algorithm. 2022 , | 0 |
| 522 | Clustering Molecular Subtypes in Breast Cancer, Immunohistochemical Parameters and Risk of Axillary Nodal Involvement. 2022 , 12, 1404 | 1 |
| 521 | Lidocaine promotes apoptosis in breast cancer cells by affecting VDAC1 expression. 2022 , 22, | 0 |
| 520 | The role of artificial intelligence in accurate interpretation of HER2 IHC 0 and 1+ in breast cancers. | 0 |
| 519 | Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer. 2022 , 14, 4220 | 0 |
| 518 | Mechano-Sensing Channel PIEZO2 Enhances Invasive Phenotype in Triple-Negative Breast Cancer. 2022 , 23, 9909 | 0 |
| 517 | LINC00511/hsa-miR-573 axis-mediated high expression of Gasdermin C associates with dismal prognosis and tumor immune infiltration of breast cancer. 2022 , 12, | 0 |
| 516 | Development and testing of a polygenic risk score for breast cancer aggressiveness. | 0 |
| 515 | The Multi-Omic Landscape of Primary Breast Tumors and Their Metastases: Expanding the Efficacy of Actionable Therapeutic Targets. 2022 , 13, 1555 | 1 |

| | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 514 | Cancer cell histone density links global histone acetylation, mitochondrial proteome and histone acetylase inhibitor sensitivity. 2022 , 5, | 1 |
| 513 | The Molecular Predictive and Prognostic Biomarkers in Metastatic Breast Cancer: The Contribution of Molecular Profiling. 2022 , 14, 4203 | 0 |
| 512 | Endocrine therapy resistance: what we know and future directions. 480-496 | 0 |
| 511 | Applying artificial intelligence technology to assist with breast cancer diagnosis and prognosis prediction. 12, | 2 |
| 510 | Systematic analysis of the expression profile and prognostic significance of m6A regulators and PD-L1 in hepatocellular carcinoma. | 0 |
| 509 | Rational Approach to Finding Genes Encoding Molecular Biomarkers: Focus on Breast Cancer. 2022 , 13, 1538 | 0 |
| 508 | SDC4-rs1981429 and ATM-rs228590 may provide early biomarkers of breast cancer risk. | 0 |
| 507 | Roles of activator protein-2 gamma in breast cancer: A narrative review (SANRA). 2022 , 101, e30587 | 0 |
| 506 | The role of HER2 alterations in clinicopathological and molecular characteristics of breast cancer and HER2-targeted therapies: a comprehensive review. 2022 , 39, | 0 |
| 505 | The C-terminus of Gain-of-Function Mutant p53 R273H Is Required for Association with PARP1 and Poly-ADP-Ribose. OF1-OF12 | 0 |
| 504 | omicsGAT: Graph Attention Network for Cancer Subtype Analyses. 2022 , 23, 10220 | 0 |
| 503 | Utilization of cytologic cell blocks for targeted sequencing of solid tumors. | 0 |
| 502 | Divergence of mutational signatures in association with breast cancer subtype. | 1 |
| 501 | Heterogeneity of triple negative breast cancer: Current advances in subtyping and treatment implications. 2022 , 41, | 4 |
| 500 | PIK3CA mutation status, progression and survival in advanced HR + /HER2- breast cancer: a meta-analysis of published clinical trials. 2022 , 22, | 0 |
| 499 | BRCA1 transports the DNA damage signal for CDDP -induced centrosome amplification through the centrosomal Aurora A. | 0 |
| 498 | Attention-based GCN Integrates Multi-omics Data for Breast Cancer Subtype Classification and Patient-specific Gene Marker Identification. | 0 |
| 497 | AR Expression Correlates with Distinctive Clinicopathological and Genomic Features in Breast Cancer Regardless of ESR1 Expression Status. 2022 , 23, 11468 | 0 |

| | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 496 | Breast cancer: an up-to-date review and future perspectives. | 3 |
| 495 | Super-enhancer-controlled positive feedback loop BRD4/ERβ/ERβ promotes ERβ-positive breast cancer. | 0 |
| 494 | Recent advances in photothermal therapy-based multifunctional nanoplatforms for breast cancer. 10, | 1 |
| 493 | Targeting Mutant p53 for Cancer Treatment: Moving Closer to Clinical Use?. 2022 , 14, 4499 | 0 |
| 492 | TP53-positive clones are responsible for drug-tolerant persisters and recurrence of HER2-positive breast cancer. | 0 |
| 491 | Identification of cuproptosis-related patterns and construction of a scoring system for predicting prognosis, tumor microenvironment-infiltration characteristics, and immunotherapy efficacy in breast cancer. 12, | 0 |
| 490 | Genomic mapping of copy number variations influencing immune response in breast cancer. 12, | 0 |
| 489 | Macrophages Upregulate Estrogen Receptor Expression in the Model of Obesity-Associated Breast Carcinoma. 2022 , 11, 2844 | 1 |
| 488 | Circulating Tumor DNA After Neoadjuvant Chemotherapy in Breast Cancer Is Associated With Disease Relapse. 2022 , | 1 |
| 487 | Expression, Localization and Prognosis Association of MEP50 in Breast Cancer. 2022 , 14, 4766 | 0 |
| 486 | GraphBio: A shiny web app to easily perform popular visualization analysis for omics data. 13, | 0 |
| 485 | Sources of Cancer Neoantigens beyond Single-Nucleotide Variants. 2022 , 23, 10131 | 1 |
| 484 | Molecular Classification of Breast Cancer. 2022 , | 0 |
| 483 | Recursive integration of synergised graph representations of multi-omics data for cancer subtypes identification. 2022 , 12, | 0 |
| 482 | Trilaciclib prior to gemcitabine plus carboplatin for metastatic triple-negative breast cancer: phase III PRESERVE 2. | 0 |
| 481 | Network approaches for omics studies of neurodegenerative diseases. 13, | 0 |
| 480 | Trophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer. 2022 , 22, | 1 |
| 479 | Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. | 0 |

| | | |
|-----|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 478 | Deep Learning and Machine Learning with Grid Search to Predict Later Occurrence of Breast Cancer Metastasis Using Clinical Data. 2022 , 11, 5772 | 2 |
| 477 | Spatiotemporal control of ERK pulse frequency coordinates fate decisions during mammary acinar morphogenesis. 2022 , 57, 2153-2167.e6 | 2 |
| 476 | Immune depletion of the methylated phenotype of colon cancer is closely related to resistance to immune checkpoint inhibitors. 13, | 0 |
| 475 | MicroRNA-570 targets the HSP chaperone network, increases proteotoxic stress and inhibits mammary tumor cell migration. 2022 , 12, | 0 |
| 474 | A-to-I nonsynonymous RNA editing was significantly enriched in the ubiquitination site and correlated with clinical features and immune response. 2022 , 12, | 0 |
| 473 | Association of adenosine signaling gene signature with estrogen receptor-positive breast and prostate cancer bone metastasis. 9, | 1 |
| 472 | Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies. 12, | 0 |
| 471 | Expression Pattern and Clinical Significance of E2F Transcription Factors in Skin Cutaneous Melanoma. | 0 |
| 470 | Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer. 2022 , 29, 6847-6863 | 1 |
| 469 | Conducive target range of breast cancer: Hypoxic tumor microenvironment. 12, | 0 |
| 468 | IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target. 2022 , 39, | 0 |
| 467 | Interpretation of the role of germline and somatic non-coding mutations in cancer: expression and chromatin conformation informed analysis. 2022 , 14, | 0 |
| 466 | TP53mutation-associated and copy number-dependent KDM7A-DT expression affects DNA repair and promotes invasive breast cancer progression. | 0 |
| 465 | The effect of delayed treatment in breast cancer patients: How much is too late? An experience of a single-center study effect of surgery delay in survival. 2022 , 44, 101854 | 0 |
| 464 | Effect of Previous Cancer History on Survival of Patients with Different Subtypes of Breast Cancer. 2022 , 2022, 1-15 | 0 |
| 463 | PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond. 2022 , 14, 4332 | 2 |
| 462 | Synthesis, docking studies, biological activity of carbon monoxide release molecules based on coumarin derivatives. 10, | 1 |
| 461 | Impact of TP53 mutations in Triple Negative Breast Cancer. 2022 , 6, | 0 |

- 460 TP53 mutation-associated and copy number-dependent KDM7A-DT expression affects DNA repair and promotes invasive breast cancer progression. ○
- 459 Investigation of the Role of PUFA Metabolism in Breast Cancer Using a Rank-Based Random Forest Algorithm. **2022**, 14, 4663 ○
- 458 A comprehensive genomic and transcriptomic dataset of triple-negative breast cancers. **2022**, 9, ○
- 457 Association of androgen receptor expression with glucose metabolic features in triple-negative breast cancer. **2022**, 17, e0275279 ○
- 456 Comprehensive analysis identifies as a critical prognostic prediction gene in breast cancer. Publish Ahead of Print, ○
- 455 Hypoxia Triggers TAZ Phosphorylation in Basal A Triple Negative Breast Cancer Cells. **2022**, 23, 10119 ○
- 454 Current Molecular Combination Therapies Used for the Treatment of Breast Cancer. **2022**, 23, 11046 1
- 453 Artificial intelligence in histopathology: enhancing cancer research and clinical oncology. **2022**, 3, 1026-1038 4
- 452 Noninvasive assessment of breast cancer molecular subtypes on multiparametric MRI using convolutional neural network with transfer learning. ○
- 451 Exploring approaches for predictive cancer patient digital twins: Opportunities for collaboration and innovation. 4, ○
- 450 Genome engineering for estrogen receptor mutations reveals differential responses to anti-estrogens and new prognostic gene signatures for breast cancer. ○
- 449 Copper chelation inhibits TGF- β pathways and suppresses epithelial-mesenchymal transition in cancer. ○
- 448 Prognosis of lasso-like penalized Cox models with tumor profiling improves prediction over clinical data alone and benefits from bi-dimensional pre-screening. **2022**, 22, 1
- 447 Loss of the MLL3 tumor suppressor accelerates breast tumor onset via HIF1 α -induced CCL2-mediated recruitment of CCR2+ regulatory T cells. ○
- 446 A joint transcriptome-wide association study across multiple tissues identifies new candidate susceptibility genes for breast cancer. ○
- 445 Multiomic characterization and drug testing establish circulating tumor cells as an ex vivo tool for personalized medicine. **2022**, 25, 105081 ○
- 444 Metabolites of medicine food homology-derived endophytic fungi and their activities. **2022**, ○
- 443 Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers. **2022**, 5, ○

- 442 The prognostic and predictive values of differential expression of exosomal receptor tyrosine kinases and associated with the PI3K/AKT/mTOR signaling in breast cancer patients undergoing neoadjuvant chemotherapy. 0
- 441 ERK activation modulates invasiveness and Reactive Oxygen Species (ROS) production in triple negative breast cancer cell lines. **2022**, 110487 0
- 440 Proxalutamide in patients with AR-positive metastatic breast cancer: Results from an open-label multicentre phase Ib study and biomarker analysis. **2022**, 176, 1-12 0
- 439 A systematic review exploring the role of modern radiation for the treatment of Hereditary or Familial Breast Cancer. **2022**, 176, 59-67 0
- 438 Somatic Mutations of TP53 Identified by Targeted Next-Generation Sequencing Are Poor Prognostic Factors for Primary Operable Breast Cancer: A Single-Center Study. **2022**, 25, 379 3
- 437 A Hormone Immunotherapy (HIT) Combination in Advanced Breast Cancer. **2022**, 0
- 436 AKT Regulation of ORAI1-Mediated Calcium Influx in Breast Cancer Cells. **2022**, 14, 4794 0
- 435 UBE2T promotes breast cancer tumor growth by suppressing DNA replication stress. **2022**, 4, 1
- 434 HSPB1 facilitates chemoresistance through inhibiting ferroptotic cancer cell death and regulating NF- κ B signaling pathway in breast cancer. 0
- 433 A genome-wide cell-free DNA methylation analysis identifies an episcapature associated with metastatic luminal B breast cancer. 10, 0
- 432 Spatial transcriptomic analysis of a diverse patient cohort reveals a conserved architecture in triple-negative breast cancer. 0
- 431 Is the TCH-P regimen active in early or locally advanced HER2-positive breast cancer? Results of a retrospective study. 1-6 0
- 430 NSMCE2, a novel super-enhancer-regulated gene, is linked to poor prognosis and therapy resistance in breast cancer. **2022**, 22, 1
- 429 AKT-mTORC1 reactivation is the dominant resistance driver for PI3K/AKT inhibitors in PTEN-null breast cancer and can be overcome by combining with Mcl-1 inhibitors. 1
- 428 Identification and analysis of dysregulated fatty acid metabolism genes in breast cancer subtypes. **2022**, 39, 1
- 427 Comprehensive analysis of prognostic significance of cadherin (CDH) gene family in breast cancer. **2022**, 8498-8567 0
- 426 Inferring time-aware models of cancer progression using Timed Hazard Networks. 0
- 425 Alterations in the p53 isoform ratio govern breast cancer cell fate in response to DNA damage. **2022**, 13, 0

| | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 424 | Beyond the β Ps α A critical appraisal of the non-endocrine manifestations of multiple endocrine neoplasia type 1. 13, | o |
| 423 | Cancer Genomics and Evolution. 1-30 | o |
| 422 | Jewel 2.0: An Improved Joint Estimation Method for Multiple Gaussian Graphical Models. 2022 , 10, 3983 | o |
| 421 | Synthesis and Structure-Activity Relationship Studies of Novel Aryl Sulfonamides and Their Activity against Human Breast Cancer Cell Lines.. | o |
| 420 | Prognosis and stratification of breast cancer immune infiltration status based on a mitochondria-related gene signature.. | o |
| 419 | Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021. 2022 , 15, | 1 |
| 418 | The Present and Future of Clinical Management in Metastatic Breast Cancer. 2022 , 11, 5891 | o |
| 417 | STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. | o |
| 416 | Multi-view confounder detection for biomedical studies. | o |
| 415 | A combination of novel NSC small molecule inhibitor along with doxorubicin inhibits proliferation of triple-negative breast cancer through metabolic reprogramming. | o |
| 414 | A Transcriptome- and Interactome-Based Analysis Identifies Repurposable Drugs for Human Breast Cancer Subtypes. 2022 , 14, 2230 | o |
| 413 | PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer. | o |
| 412 | Increased Aurora B expression reduces substrate phosphorylation and induces chromosomal instability. 10, | 1 |
| 411 | A genomic and transcriptomic study toward breast cancer. 13, | o |
| 410 | Learning to distinguish progressive and non-progressive ductal carcinoma in situ. | o |
| 409 | Genomic instability, origin and evolution of cancer, and personalized immunotherapy. 2022 , | o |
| 408 | Inhibition of Wnt signaling in colon cancer cells via an oral drug that facilitates TNIK degradation. | o |
| 407 | The Predictive and Prognostic Role of RAS/RAF/MEK/ERK Pathway Alterations in Breast Cancer: Revision of the Literature and Comparison with the Analysis of Cancer Genomic Datasets. 2022 , 14, 5306 | o |

| | | |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 406 | PIK3CAMutations in Breast Cancer Subtypes Other Than HR-Positive/HER2-Negative. 2022 , 12, 1793 | 0 |
| 405 | Core promoter in TNBC is highly mutated with rich ethnic signature. | 0 |
| 404 | Identification of miRNA biomarkers for breast cancer by combining ensemble regularized multinomial logistic regression and Cox regression. 2022 , 23, | 0 |
| 403 | Molecular Mechanisms of Anti-Estrogen Therapy Resistance and Novel Targeted Therapies. 2022 , 14, 5206 | 1 |
| 402 | Comprehensive analysis of clinicopathologic features and p53 mutation in neuroendocrine neoplasms of the breast: experience from a large academic center. 2022 , 196, 463-469 | 0 |
| 401 | A cellular and transcriptomic dissection of the human breast for studying mechanisms of cell and tissue function. | 0 |
| 400 | PIK3CA-mutations in breast cancer. 2022 , 196, 483-493 | 0 |
| 399 | Anti-Hormonal Therapy in Breast Cancer and Its Effect on the Blood-Brain Barrier. 2022 , 14, 5132 | 0 |
| 398 | Identifying enhancer-driven subtype-specific prognostic markers in breast cancer based on multi-omics data. 13, | 0 |
| 397 | Identification and verification of the prognostic value of CUL7 in colon adenocarcinoma. 13, | 0 |
| 396 | Systems Biology and Genomics. 1-11 | 0 |
| 395 | Long noncoding RNA-mediated activation of PROTOR1/PRR5-AKT signaling shunt downstream of PI3K in triple-negative breast cancer. 2022 , 119, | 0 |
| 394 | Development and validation of an AI/ML platform for the discovery of splice-switching oligonucleotide targets. | 0 |
| 393 | Biological Hallmarks of Cancer. 1-10 | 0 |
| 392 | Cerulein suppresses ErbB2-overexpressing breast cancer by targeting ErbB2/PKM2 pathway. 2023 , 40, | 0 |
| 391 | K-RAS Associated Gene-Mutation-Based Algorithm for Prediction of Treatment Response of Patients with Subtypes of Breast Cancer and Especially Triple-Negative Cancer. 2022 , 14, 5322 | 0 |
| 390 | Ferroptosis heterogeneity in triple-negative breast cancer reveals an innovative immunotherapy combination strategy. 2022 , | 1 |
| 389 | Neoplasms of the Breast. 1-62 | 0 |

| | | |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 388 | Identification of a prognostic risk-scoring model and risk signatures based on glycosylation-associated cluster in breast cancer. 13, | 0 |
| 387 | Integrated bioinformatic analysis to understand the association between phthalate exposure and breast cancer progression. 2022 , 116296 | 0 |
| 386 | Clinical Efficacy and Whole-Exome Sequencing of Liquid Biopsies in a Phase IB/II Study of Bazedoxifene and Palbociclib in Advanced Hormone Receptor Positive Breast Cancer. OF1-OF13 | 1 |
| 385 | The Renaissance of CDK Inhibitors in Breast Cancer Therapy: An Update on Clinical Trials and Therapy Resistance. 2022 , 14, 5388 | 0 |
| 384 | PIK3CA mutations are associated with pathologic complete response rate to neoadjuvant pyrotinib and trastuzumab plus chemotherapy for HER2-positive breast cancer. | 0 |
| 383 | Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape. | 0 |
| 382 | MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling. 2022 , 13, | 2 |
| 381 | Identification and Validation of a Novel Glycolysis-Related Gene Signature for Predicting the Prognosis and Therapeutic Response in Triple-Negative Breast Cancer. | 0 |
| 380 | Multi-regional Sequencing Analysis Reveals Extensive Genetic Heterogeneity in Gastric Tumors from Latinos. | 0 |
| 379 | Acinic cell carcinoma of the breast: A comprehensive review. 2022 , 66, 208-216 | 0 |
| 378 | Targeting hypoxia-inducible factor-1alpha: A new strategy for triple-negative breast cancer therapy. 2022 , 156, 113861 | 0 |
| 377 | Hsa_circ_0000851 promotes PDK1/p-AKT-mediated cell proliferation and migration by regulating miR-1183 in triple-negative breast cancer. 2023 , 101, 110494 | 0 |
| 376 | A semi-supervised multi-task learning framework for cancer classification with weak annotation in whole-slide images. 2023 , 83, 102652 | 0 |
| 375 | Multivariate Analysis with the R Package mixOmics. 2023 , 333-359 | 0 |
| 374 | Translational proteomics and phosphoproteomics: Tissue to extracellular vesicles. 2022 , | 0 |
| 373 | Promoter hypomethylation and overexpression of TSTD1 mediate poor treatment response in breast cancer. 12, | 0 |
| 372 | Improving Infinium MethylationEPIC data processing: re-annotation of enhancers and long noncoding RNA genes and benchmarking of normalization methods. 2022 , 17, 2434-2454 | 0 |
| 371 | Voltage imaging reveals the dynamic electrical signatures of human breast cancer cells. 2022 , 5, | 0 |

| | | |
|-----|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 370 | lncRNASNP v3: an updated database for functional variants in long non-coding RNAs. | 1 |
| 369 | Reconstructing mutational lineages in breast cancer by multi-patient-targeted single-cell DNA sequencing. 2022 , 100215 | 0 |
| 368 | Integrin $\beta 4$ signals through DNA damage response pathway to sensitize breast cancer cells to cisplatin. 2022 , 12, | 0 |
| 367 | Development of a novel BRCAness score that predicts response to PARP inhibitors. 2022 , 10, | 0 |
| 366 | A synthetic lethal dependency on casein kinase 2 in response to replication-perturbing drugs in RB1-deficient ovarian and breast cancer cells. | 0 |
| 365 | Androgen receptor function and targeted therapeutics across breast cancer subtypes. 2022 , 24, | 2 |
| 364 | Grace-AKO: a novel and stable knockoff filter for variable selection incorporating gene network structures. 2022 , 23, | 0 |
| 363 | Breast cancer mutations HER2V777L and PIK3CAH1047R activate the p21-CDK4/6 Cyclin D1 axis driving tumorigenesis and drug resistance. | 0 |
| 362 | Personalized genome assembly for accurate cancer somatic mutation discovery using tumor-normal paired reference samples. 2022 , 23, | 0 |
| 361 | Proficiency testing of PIK3CA mutations in HR+/HER2-breast cancer on liquid biopsy and tissue. | 0 |
| 360 | Cell-Free DNA Fragmentomics: A Promising Biomarker for Diagnosis, Prognosis and Prediction of Response in Breast Cancer. 2022 , 23, 14197 | 2 |
| 359 | Association of body mass index and inflammatory dietary pattern with breast cancer pathologic and genomic immunophenotype in the nurses'health study. 2022 , 24, | 0 |
| 358 | Estrogen-Inducible LncRNA BNAT1 Functions as a Modulator for Estrogen Receptor Signaling in Endocrine-Resistant Breast Cancer Cells. 2022 , 11, 3610 | 0 |
| 357 | DNA barcoding reveals ongoing immunoeediting of clonal cancer populations during metastatic progression and immunotherapy response. 2022 , 13, | 0 |
| 356 | Interactive effects of molecular subtypes with tumor size and extracranial metastatic pattern on risk of brain metastasis in breast cancer patients: A population-based study. | 0 |
| 355 | Multi-omics Data Fusion using Adaptive GTO guided Non-negative Matrix Factorization for Cancer Subtype Discovery. 2022 , 107246 | 0 |
| 354 | Endoplasmic reticulum stress targeted therapy for breast cancer. 2022 , 20, | 1 |
| 353 | Loss of transcription factor TFEB dysregulates the G1/S transition and DNA replication in mammary epithelial cells. 2022 , 102692 | 0 |

- 352 Single-cell imaging based prognosis prediction identifies new breast cancer survival subtypes. ○
- 351 Genetic ancestry inference from cancer-derived molecular data across genomic and transcriptomic platforms. ○
- 350 Molecular differences between younger versus older ER-positive and HER2-negative breast cancers. **2022**, 8, 1
- 349 Loss of Brca1 and Trp53 in adult mouse mammary ductal epithelium results in development of hormone receptor-positive or hormone receptor-negative tumors, depending on inactivation of Rb family proteins. **2022**, 24, ○
- 348 Identification of a minority population of LMO2 + breast cancer cells that integrate into the vasculature and initiate metastasis. **2022**, 8, ○
- 347 Obesity and metabolic syndrome are associated with short-term endocrine therapy resistance in early ER + breast cancer. ○
- 346 Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers. **2022**, 24, ○
- 345 A highly potent small-molecule antagonist of exportin-1 selectively eliminates CD44+CD24-enriched breast cancer stem-like cells. **2022**, 100903 1
- 344 Future Role of Molecular Profiling in Small Breast Samples and Personalised Medicine. **2022**, 895-915 ○
- 343 Screening for Physical Activity Levels in Non-Metastatic Breast Cancer Patients Undergoing Surgery: An Observational Study. **2022**, 21, 153473542211403 ○
- 342 Less Common Triple-Negative Breast Cancers. **2022**, 463-573 ○
- 341 Eosinophilia in cancer and its regulation by sex hormones. **2023**, 34, 5-20 1
- 340 Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. **2023**, 112, 102496 ○
- 339 3?-epi-12#hydroxyfroside-mediated autophagy degradation of RIPK1/RIPK3 necrosomes leads to anergy of immunogenic cell death in triple-negative breast cancer cells. **2023**, 187, 106613 ○
- 338 Molecular targets that sensitize cancer to radiation killing: From the bench to the bedside. **2023**, 158, 114126 ○
- 337 The Clinical Utility of ESR1 Mutations in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer. **2023**, 37, 169-181 ○
- 336 Triple-Negative/Basal-Like Breast Carcinomas. **2022**, 445-462 ○
- 335 Clearance of ctDNA in triple-negative and HER2-positive breast cancer patients during neoadjuvant treatment is correlated with pathologic complete response. **2022**, 14, 175883592211396 ○

- 334 Somatic Mutations in Breast Cancer: The Tip of the Iceberg. 25, ○
- 333 microRNAs in Therapy Resistance of Breast Cancer. 103-112 ○
- 332 RUNX Proteins as Epigenetic Modulators in Cancer. **2022**, 11, 3687 ○
- 331 Preoperative Computed Tomography Radiomics Analysis for Predicting Receptors Status and Ki-67 Levels in Breast Cancer. **2022**, 45, 526-533 ○
- 330 Computational Pipeline to Identify Gene signatures that Define Cancer Subtypes. ○
- 329 Biomarkers of Response and Resistance to CDK4/6 Inhibitors in Breast Cancer: Hints from Liquid Biopsy and microRNA Exploration. **2022**, 23, 14534 ○
- 328 Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations. **2022**, ○
- 327 A Case Report of HER2-Amplification in the Breast Without Histological Abnormality. 106689692211375 ○
- 326 Circulating tumor DNA profile and its clinical significance in patients with hormone receptor-positive and HER2-negative mBC. 13, ○
- 325 Evaluation of alpelisib-induced hyperglycemia prophylaxis and associated risk factors in PIK3CA-mutated hormone-receptor positive, human epidermal growth factor-2 negative advanced breast cancer. ○
- 324 Pathway-level mutation analysis in primary high-grade serous ovarian cancer and matched brain metastases. **2022**, 12, ○
- 323 Exploring the Role of the Inhibitor of Apoptosis BIRC6 in Breast Cancer: A Database Analysis. **2022**, ○
- 322 High SURF4 expression is associated with poor prognosis of breast cancer. **2022**, 14, 9317-9337 ○
- 321 Checkpoint Kinase 1 (CHK1) Functions as Both a Diagnostic Marker and a Regulator of Epithelial-to-Mesenchymal Transition (EMT) in Triple-Negative Breast Cancer. **2022**, 44, 5848-5865 ○
- 320 Staging Breast Cancer with MRI, the T. A Key Role in the Neoadjuvant Setting. **2022**, 14, 5786 1
- 319 Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis. **2022**, ○
- 318 Systematic analysis of the expression profile and prognostic significance of m6A regulators and PD-L1 in hepatocellular carcinoma. **2022**, 13, ○
- 317 Bioinformatics driven discovery of small molecule compounds that modulate the FOXM1 and PPARA pathway activities in breast cancer. ○

| | | |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 316 | Synthetic lethality between CCNE1 hyperactivity and PARG inhibition in breast cancer. | 0 |
| 315 | Breast cancer plasticity is restricted by a LATS1-NCOR1 repressive axis. 2022 , 13, | 0 |
| 314 | Inactivation of LATS1/2 drives luminal-basal plasticity to initiate basal-like mammary carcinomas. 2022 , 13, | 0 |
| 313 | Targeting TRAIL Death Receptors in Triple-Negative Breast Cancers: Challenges and Strategies for Cancer Therapy. 2022 , 11, 3717 | 1 |
| 312 | Choice of High-Throughput Proteomics Method Affects Data Integration with Transcriptomics and the Potential Use in Biomarker Discovery. 2022 , 14, 5761 | 0 |
| 311 | PADA-1 trial: ESR1 mutations in plasma ctDNA guide treatment switching. | 0 |
| 310 | MYC regulates a pan-cancer network of co-expressed oncogenic splicing factors. 2022 , 41, 111704 | 1 |
| 309 | Is it possible to identify subpopulations of triple negative breast cancer?. 2022 , 13, 352-360 | 0 |
| 308 | Vemurafenib inhibits immune escape biomarker BCL2A1 by targeting PI3K/AKT signaling pathway to suppress breast cancer. 12, | 0 |
| 307 | The Insulin-like Growth Factor Signaling Pathway in Breast Cancer: An Elusive Therapeutic Target. 2022 , 12, 1992 | 1 |
| 306 | Genomic alteration profile and PD-L1 expression among different breast cancer subtypes in Chinese population and their correlations. | 0 |
| 305 | The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022. 2022 , 31, 1203-1226 | 0 |
| 304 | Breast Cancer Survival Analysis with Molecular Subtypes: An Initial Step. 2022 , | 0 |
| 303 | Genomic profiling and network-level understanding uncover the potential genes and the pathways in hepatocellular carcinoma. 13, | 0 |
| 302 | Artificial intelligence to guide precision anticancer therapy with multitargeted kinase inhibitors. 2022 , 22, | 0 |
| 301 | COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis. | 0 |
| 300 | Clinical Implications of APOBEC3-mediated Mutagenesis in Breast Cancer. | 1 |
| 299 | Transcriptomics indicate nuclear division and cell adhesion not recapitulated in MCF7 and MCF10A compared to luminal A breast tumours. 2022 , 12, | 0 |

- 298 The Clinical Utility of Droplet Digital PCR for Profiling Circulating Tumor DNA in Breast Cancer Patients. **2022**, 12, 3042 ○
- 297 Ethnic and racial-specific differences in levels of centrosome-associated mitotic kinases, proliferative and epithelial-to-mesenchymal markers in breast cancers. **2022**, 17, ○
- 296 Efficacy evaluation of neoadjuvant chemotherapy in patients with HER2-low expression breast cancer: A real-world retrospective study. 12, ○
- 295 An Approach for Systems-Level Understanding of Prostate Cancer from High-Throughput Data Integration to Pathway Modeling and Simulation. **2022**, 11, 4121 ○
- 294 DNA methylation landscape of tumor-associated macrophages reveals pathways, transcription factors and prognostic value relevant to triple-negative breast cancer patients. 1
- 293 Transcriptomic pan-cancer analysis using rank-based Bayesian inference. ○
- 292 An integrated investigation of structural and pathway alteration caused by PIK3CA and TP53 mutations identified in cfDNA of metastatic breast cancer. ○
- 291 RNF126-Mediated MRE11 Ubiquitination Activates the DNA Damage Response and Confers Resistance of Triple-Negative Breast Cancer to Radiotherapy. 2203884 ○
- 290 Antibody reliability influences observed mRNA-protein correlations in tumour samples. ○
- 289 MicroRNAs within the Basal-like signature of Quadruple Negative Breast Cancer impact overall survival in African Americans. **2022**, 12, ○
- 288 Accurate cell type deconvolution in spatial transcriptomics using a batch effect-free strategy. ○
- 287 Anticancer Effects of Fucoxanthin through Cell Cycle Arrest, Apoptosis Induction, Angiogenesis Inhibition, and Autophagy Modulation. **2022**, 23, 16091 1
- 286 Why is survival with triple negative breast cancer so low? insights and talking points from preclinical and clinical research 1-20 ○
- 285 Succinate at the Crossroad of Metabolism and Angiogenesis: Roles of SDH, HIF1 β and SUCNR1. **2022**, 10, 3089 ○
- 284 Nf1 deficiency accelerates mammary development and promotes luminal-basal plasticity. ○
- 283 circAR-E2E4-miR-665-STAT3 axis is a potential regulatory network in triple-negative breast cancer. **2022**, e12654 ○
- 282 Metformin Inducing the Change of Functional and Exhausted Phenotypic Tumor-Infiltrated Lymphocytes and the Correlation with JNK Signal Pathway in Triple-Negative Breast Cancer. Volume 14, 391-403 ○
- 281 The Great Immune Escape: Understanding the Divergent Immune Response in Breast Cancer Subtypes. OF1-OF18 1

| | | |
|-----|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 280 | NARF is a hypoxia-induced coactivator for OCT4-mediated breast cancer stem cell specification. 2022 , 8, | 0 |
| 279 | Identification of a minimum number of genes to predict triple-negative breast cancer subgroups from gene expression profiles. 2022 , 16, | 1 |
| 278 | Identification of HMGA2 as a predictive biomarker of response to bintrafusp alfa in a phase 1 trial in patients with advanced triple-negative breast cancer. 12, | 0 |
| 277 | Genomics of breast cancer brain metastases: a meta-analysis and therapeutic implications. | 0 |
| 276 | Transcriptomic changes underlying EGFR inhibitor resistance in human and mouse models of basal-like breast cancer. 2022 , 12, | 0 |
| 275 | Newly Developed Targeted Therapies Against Androgen Receptor in Triple-Negative Breast Cancer: A Review. PHARMREV-AR-2022-000665 | 0 |
| 274 | Network-based approaches for modeling disease regulation and progression. 2022 , | 0 |
| 273 | Update on triple-negative breast cancers [highlighting subtyping update and treatment implication. 2023 , 82, 17-35 | 2 |
| 272 | Next-generation sequencing in breast pathology: real impact on routine practice over a decade since its introduction. 2023 , 82, 162-169 | 1 |
| 271 | The BRCAness Landscape of Cancer. 2022 , 11, 3877 | 1 |
| 270 | Genetic landscape and personalized tracking of tumor mutations in Vietnamese women with breast cancer. | 1 |
| 269 | Hypoxic activation of PFKFB4 in breast tumor microenvironment shapes metabolic and cellular plasticity to accentuate metastatic competence. 2022 , 41, 111756 | 0 |
| 268 | Determination of BRCAness Phenotype in Breast Tumors for the Appointment of Neoadjuvant Chemotherapy Based on Platinum and Taxanes. 2023 , 24, 207 | 0 |
| 267 | Lasp1 Expression Is Implicated in Embryonic Development of Zebrafish. 2023 , 14, 35 | 0 |
| 266 | Lipid Metabolism Heterogeneity and Crosstalk with Mitochondria Functions Drive Breast Cancer Progression and Drug Resistance. 2022 , 14, 6267 | 0 |
| 265 | Distinct niche structures and intrinsic programs of fallopian tube and ovarian surface epithelial cells. 2022 , 105861 | 0 |
| 264 | An integrated analysis of the cancer genome atlas data discovers a hierarchical association structure across thirty three cancer types. 2022 , 1, e0000151 | 0 |
| 263 | The role of lncRNAs in the tumor microenvironment and immunotherapy of melanoma. 13, | 0 |

| | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 262 | Clinical proteomics towards multiomics in cancer. | 1 |
| 261 | Overexpression of HMGB3 and its prognostic value in breast cancer. 12, | 0 |
| 260 | Genetic variants in African-American and Hispanic patients with breast cancer. 2022 , 25, | 0 |
| 259 | Tumor-Infiltrating Lymphocytes and Immune Response in HER2-Positive Breast Cancer. 2022 , 14, 6034 | 1 |
| 258 | Notch signaling pathway: a comprehensive prognostic and gene expression profile analysis in breast cancer. 2022 , 22, | 0 |
| 257 | Multiparametric and accurate functional analysis of genetic sequence variants using CRISPR-Select. 2022 , 54, 1983-1993 | 1 |
| 256 | AKTIP loss is enriched in ER-positive breast cancer for tumorigenesis and confers endocrine resistance. 2022 , 41, 111821 | 0 |
| 255 | Mre11 liberates cGAS from nucleosome sequestration during tumorigenesis. | 0 |
| 254 | Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Current and Future Trends. 2023 , 15, 51 | 0 |
| 253 | Incorporating RNA-based risk scores for genomic instability to predict breast cancer recurrence and immunogenicity in a diverse population. | 0 |
| 252 | Artificial intelligence in breast cancer imaging: risk stratification, lesion detection and classification, treatment planning and prognosis narrative review. 795-816 | 0 |
| 251 | Bromodomain Protein BRD4-Mediated Mutant p53 Transcription Promotes TNBC Progression. 2022 , 23, 15163 | 0 |
| 250 | HER2 classification in breast cancer cells: A new explainable machine learning application for immunohistochemistry. 2022 , 25, | 1 |
| 249 | Overrepresentation of human epidermal growth factor receptor 2 positive- and Luminal B breast cancer metastases in the eyes and orbit. | 0 |
| 248 | Repression of miR-146a in predicting poor treatment outcome in triple-negative breast cancer. 2022 , | 0 |
| 247 | Targeting estrogen-mediated CYP4F2/CYP4F11-20-HETE metabolic disorder decelerates tumorigenesis in ER+ breast cancer. | 0 |
| 246 | Blockade of Store-operated Calcium Entry Sensitizes Breast Cancer Cells to Cisplatin Therapy via Modulating Inflammatory Response. 2022 , | 0 |
| 245 | Definition of a novel breast tumor-specific classifier based on secretome analysis. 2022 , 24, | 0 |

| | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 244 | The FDA-Approved Drug Pyrvinium Selectively Targets ER+ Breast Cancer Cells with High INPP4B Expression. 2023 , 15, 135 | 0 |
| 243 | Upregulation of SCD1 by ErbB2 via LDHA promotes breast cancer cell migration and invasion. 2023 , 40, | 0 |
| 242 | MLL3 loss drives metastasis by promoting a hybrid epithelial-mesenchymal transition state. | 0 |
| 241 | A Clinical Cognizance of Molecular and Pathological Diagnostic Approach of TNBC. 2023 , 26-46 | 0 |
| 240 | A DNA methylation atlas of normal human cell types. 2023 , 613, 355-364 | 2 |
| 239 | Coding roles of long non-coding RNAs in breast cancer: Emerging molecular diagnostic biomarkers and potential therapeutic targets with special reference to chemotherapy resistance. 13, | 0 |
| 238 | Opportunities and Obstacles to the Development of Health Data Warehouses in Hospitals in France: The Recent Experience of Comprehensive Cancer Centers. 2023 , 20, 1645 | 0 |
| 237 | Recent Trends in Modalities and Deep Learning Methods for Breast Cancer Detection. 2022 , 416-434 | 0 |
| 236 | Breast cancer heterogeneity and its implication in personalized precision therapy. 2023 , 12, | 0 |
| 235 | Transcriptomic Analysis of Subtype-Specific Tyrosine Kinases as Triple Negative Breast Cancer Biomarkers. 2023 , 15, 403 | 0 |
| 234 | Identifying biomarkers of differential chemotherapy response in TNBC patient-derived xenografts with a CTD/WGCNA approach. 2023 , 26, 105799 | 2 |
| 233 | Single-cell Genome-and-Transcriptome sequencing without upfront whole-genome amplification reveals cell state plasticity of melanoma subclones. | 0 |
| 232 | Therapeutic effects of hAMSCs secretome on proliferation of MDA-MB-231 breast cancer cells by the cell cycle arrest in G1/S phase. | 0 |
| 231 | Functional impact of multi-omic interactions in breast cancer subtypes. 13, | 1 |
| 230 | Predictors of success in establishing orthotopic patient-derived xenograft models of triple negative breast cancer. 2023 , 9, | 0 |
| 229 | Etiological Insights into TNBC and their Related Catastrophic Risks. 2023 , 1-25 | 0 |
| 228 | Microbiome, immune system and cancer: three sides of the one medal. 2023 , 21, 131-144 | 0 |
| 227 | PAQR8 promotes breast cancer recurrence and confers resistance to multiple therapies. 2023 , 25, | 0 |

- 226 Targeting PI3K/AKT/mTOR Pathway in Breast Cancer: From Biology to Clinical Challenges. **2023**, 11, 109 1
- 225 Immunohistochemical HER2 Recognition and Analysis of Breast Cancer Based on Deep Learning. **2023**, 13, 263 0
- 224 Triple negative breast tumors contain heterogeneous cancer cells expressing distinct KRAS-dependent collective and disseminative invasion programs. 0
- 223 Molecular Alterations and Putative Therapeutic Targeting of Planar Cell Polarity Proteins in Breast Cancer. **2023**, 12, 411 0
- 222 Genomic patterns of malignant peripheral nerve sheath tumor (MPNST) evolution correlate with clinical outcome and are detectable in cell-free DNA. 0
- 221 STARD3: A New Biomarker in HER2-Positive Breast Cancer. **2023**, 15, 362 0
- 220 The Role of Artificial Intelligence in Accurate Interpretation of HER2 Immunohistochemical Scores 0 and 1+ in Breast Cancer. **2023**, 100054 0
- 219 Molecular Sub-Typing and Exploration of Key Signalling Pathways Involved in Complicating the Disease. **2023**, 47-72 0
- 218 Anti-colorectal cancer of *Ardisia gigantifolia* Stapf. and targets prediction via network pharmacology and molecular docking study. **2023**, 23, 0
- 217 p53 expression in luminal breast cancer correlates with TP53 mutation and primary endocrine resistance. **2023**, 100100 0
- 216 Bioinformatics and In silico approaches to identify novel biomarkers and key pathways for cancers that are linked to the progression of female infertility: A comprehensive approach for drug discovery. **2023**, 18, e0265746 0
- 215 On data normalization and batch-effect correction for tumor subtyping with microRNA data. **2023**, 5, 0
- 214 Fast, accurate, and racially unbiased pan-cancer tumor-only variant calling with tabular machine learning. **2023**, 7, 0
- 213 Early Triple-Negative Breast Cancers in a Singapore Cohort Exhibit High PIK3CA Mutation Rates Associated With Low PD-L1 Expression. **2023**, 100056 0
- 212 Breast cancer cells interact with tumor-derived extracellular matrix in a molecular subtype-specific manner. **2023**, 213301 0
- 211 Comprehensive analysis of the prognosis and immune infiltrates for the BET protein family reveals the significance of BRD4 in glioblastoma multiforme. 11, 0
- 210 Mammary-specific ectopic expression of mutant human GATA3 did not potentiate medroxyprogesterone acetate-driven mouse mammary tumorigenesis. 0
- 209 Impact of Molecular Subtype Definitions on AI Classification of Breast Cancer at MRI. 0

| | | |
|-----|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 208 | Lachnochromonin, a fungal metabolite from <i>Lachnum virgineum</i> , inhibits cell growth and promotes apoptosis in tumor cells through JAK/STAT3 signaling. 2023 , 110592 | 0 |
| 207 | Poison cassette exon splicing of SRSF6 regulates nuclear speckle dispersal and the response to hypoxia. | 0 |
| 206 | Pre-Clinical and Clinical Evidence of Recent Therapeutic Trends and Spotting Possibility of Cure in Near Future. 2023 , 73-98 | 0 |
| 205 | Comprehensive analysis of alfa defensin expression and prognosis in human colorectal cancer. 12, | 1 |
| 204 | ProNGF Expression and Targeting in Glioblastoma Multiforme. 2023 , 24, 1616 | 0 |
| 203 | Chinese medicine formula Baipuhuang Keli inhibits triple-negative breast cancer by hindering DNA damage repair via MAPK/ERK pathway. 2023 , 304, 116077 | 0 |
| 202 | Breast cancer sub-types display heterogeneity in gene amplification and mRNA expression of the anti-apoptotic members of BCL2 family. 2023 , 857, 147179 | 0 |
| 201 | Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences. 2023 , 159, 114183 | 0 |
| 200 | The Prognostic and Predictive Value of Genomic Assays in Guiding Adjuvant Breast Radiation Therapy. 2023 , 11, 98 | 0 |
| 199 | MOCSC: a multi-omics data based framework for cancer subtype classification. 2022 , | 0 |
| 198 | Network-based assessment of HDAC6 activity predicts preclinical and clinical responses to the HDAC6 inhibitor ricolinostat in breast cancer. | 1 |
| 197 | Multiomics in primary and metastatic breast tumors from the AURORA US network finds microenvironment and epigenetic drivers of metastasis. | 0 |
| 196 | Firocoxib as a Potential Neoadjuvant Treatment in Canine Patients with Triple-Negative Mammary Gland Tumors. 2023 , 13, 60 | 0 |
| 195 | Oncogenic HJURP is driven by P53/ E2F1/FOXM1-axis regulated enhancer and potentiates TNBC proliferation and invasion. | 0 |
| 194 | Transcriptomic profiles-based approach to decode the role of miR -122 in triple negative breast cancer. | 0 |
| 193 | Molecular hallmarks of breast multiparametric magnetic resonance imaging during neoadjuvant chemotherapy. | 0 |
| 192 | GRHL2 Regulation of Growth/Motility Balance in Luminal versus Basal Breast Cancer. 2023 , 24, 2512 | 0 |
| 191 | Multiplatform molecular analysis of vestibular schwannoma reveals two robust subgroups with distinct microenvironment. | 0 |

- 190 Colorectal cancer with low SLC35A3 is associated with immune infiltrates and poor prognosis. ○
- 189 Risk of seizures in a population of women with BRCA-positive metastatic breast cancer from an electronic health record database in the United States. **2023**, 23, ○
- 188 Genomic characterisation of hormone receptor-positive breast cancer arising in very young women. **2023**, ○
- 187 Tumor immunology. **2023**, 245-452 ○
- 186 MiR-526b targets lncRNA SLC16A1-AS1 to suppress cell proliferation in triple-negative breast cancer. ○
- 185 Radiogenomic association of deep MR imaging features with genomic profiles and clinical characteristics in breast cancer. **2023**, 11, ○
- 184 MIMESIS: minimal DNA-methylation signatures to quantify and classify tumor signals in tissue and cell-free DNA samples. ○
- 183 The Evolution of Ki-67 and Breast Carcinoma: Past Observations, Present Directions, and Future Considerations. **2023**, 15, 808 ○
- 182 Pan-Cancer landscape of protein activities identifies drivers of signalling dysregulation and patient survival. 1
- 181 Deep Learning-Based Multiomics Data Integration Methods for Biomedical Application. 2200247 ○
- 180 Clinical Evidence of Circulating Tumor DNA Application in Aggressive Breast Cancer. **2023**, 13, 470 ○
- 179 Nomograms for Predicting Disease-Free Survival Based on Core Needle Biopsy and Surgical Specimens in Female Breast Cancer Patients with Non-Pathological Complete Response to Neoadjuvant Chemotherapy. **2023**, 13, 249 ○
- 178 Gene Expression Profiles in Cancers and Their Therapeutic Implications. **2023**, 29, 9-14 ○
- 177 Potential Regulation of miRNA-29 and miRNA-9 by Estrogens in Neurodegenerative Disorders: An Insightful Perspective. **2023**, 13, 243 ○
- 176 Systemically Identifying Triple-Negative Breast Cancer Subtype-Specific Prognosis Signatures, Based on Single-Cell RNA-Seq Data. **2023**, 12, 367 ○
- 175 PIC recruitment by synthetic reader-actuators to polycomb-silenced genes blocks triple-negative breast cancer invasion. ○
- 174 HDAC inhibitors target IRS4 to enhance anti-androgen receptor (AR) therapy in AR-positive triple negative breast cancer. ○
- 173 SPEAR: a Sparse Supervised Bayesian Factor Model for Multi-omic Integration. ○

- 172 Near-Infrared Phototheranostic Iron Pyrite Nanocrystals Simultaneously Induce Dual Cell Death Pathways via Enhanced Fenton Reactions in Triple-Negative Breast Cancer. ○
- 171 Moanna: Multi-Omics Autoencoder-Based Neural Network Algorithm for Predicting Breast Cancer Subtypes. **2023**, 11, 10912-10924 ○
- 170 HER2-low expression in breast oncology: treatment implications in the smart chemotherapy era. **2023**, 32, 149-154 1
- 169 Neoadjuvant endocrine therapy with or without palbociclib in low-risk patients: a phase III randomized double-blind SAFIA trial. ○
- 168 GRHL2-controlled gene expression networks in luminal breast cancer. **2023**, 21, ○
- 167 Prognostic Factors for Triple-Negative Breast Cancer with Residual Disease after Neoadjuvant Chemotherapy. **2023**, 13, 190 ○
- 166 HER2-positive breast cancer progresses rapidly after pyrotinib resistance: acquired RET gene fusion and TP53 gene mutation are potential reasons. Publish Ahead of Print, ○
- 165 Co-drug development of gallic acid and metformin targeting the pro-inflammatory cytokines for the treatment of breast cancer. ○
- 164 MiXcan: a framework for cell-type-aware transcriptome-wide association studies with an application to breast cancer. **2023**, 14, ○
- 163 Signal Transducer and Activator of Transcription as a Potential Therapeutic Target in Breast Cancer. **2023**, ○
- 162 HER2 expression defines unique requirements for flotillin and c-Src for EGFR signaling. ○
- 161 Blood-Based mRNA Tests as Emerging Diagnostic Tools for Personalised Medicine in Breast Cancer. **2023**, 15, 1087 ○
- 160 Network Analysis Identifies Potential Small-Molecule Drugs Sensitizing Triple-Negative Breast Cancer to Tamoxifen. **2022**, ○
- 159 The tumor microenvironment and triple-negative breast cancer aggressiveness: shedding light on mechanisms and targeting. **2022**, 26, 1041-1056 ○
- 158 Introduction to Breast Cancer. **2023**, 1-22 ○
- 157 A Ribosome-Related Prognostic Signature of Breast Cancer Subtypes Based on Changes in Breast Cancer Patients' Immunological Activity. **2023**, 59, 424 ○
- 156 CRISPR screens identify gene targets at breast cancer risk loci. **2023**, 24, ○
- 155 Chromosomal Instability as Enabling Feature and Central Hallmark of Breast Cancer. Volume 15, 189-211 ○

- 154 Multi-omics integration method based on attention deep learning network for biomedical data classification. **2023**, 231, 107377 ○
- 153 Single cell lineage tracing reveals subclonal dynamics of anti-EGFR therapy resistance in triple negative breast cancer. ○
- 152 Genetic ancestry of 1.127 Brazilian breast cancer patients and its correlation with molecular subtype and geographic region. **2023**, ○
- 151 Deciphering breast cancer: from biology to the clinic. **2023**, 186, 1708-1728 ○
- 150 Integration of clinical features and deep learning on pathology for the prediction of breast cancer recurrence assays and risk of recurrence. **2023**, 9, ○
- 149 Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior. **2023**, 36, 100125 ○
- 148 Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. **2023**, 212, 115545 ○
- 147 Predicting gene mutation status via artificial intelligence technologies based on multimodal integration (MMI) to advance precision oncology. **2023**, 91, 1-15 ○
- 146 Familial CCM Genes Might Not Be Main Drivers for Pathogenesis of Sporadic CCMs-Genetic Similarity between Cancers and Vascular Malformations. **2023**, 13, 673 ○
- 145 Next generation immuno-oncology tumor profiling using a rapid, non-invasive, computational biophysics biomarker in early-stage breast cancer. 6, ○
- 144 Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis. **2023**, 8, 101214 ○
- 143 Alpelisib-induced thyroiditis in a patient with metastatic breast cancer: Is routine monitoring of thyroid function required?. **2023**, 9, 100219 ○
- 142 ABCB1 Amplicon Contains Cyclic AMP Response Element-Driven TRIP6 Gene in Taxane-Resistant MCF-7 Breast Cancer Sublines. **2023**, 14, 296 ○
- 141 A robust and lightweight deep attention multiple instance learning algorithm for predicting genetic alterations. **2023**, 105, 102189 ○
- 140 Pseudo-temporal dynamics of chemoresistant triple negative breast cancer cells reveal EGFR/HER2 inhibition as synthetic lethal during mid-neoadjuvant chemotherapy. **2023**, 26, 106064 ○
- 139 Searching for DNA methylation in patients triple-negative breast cancer: a liquid biopsy approach. **2023**, 23, 41-51 ○
- 138 Landscape of Genetic Alterations Underlying Hallmark Signature Changes in Cancer Reveals TP53 Aneuploidy-driven Metabolic Reprogramming. **2023**, 3, 281-296 ○
- 137 Dual-Aptamer-Assisted Ratiometric SERS Biosensor for Ultrasensitive and Precise Identification of Breast Cancer Exosomes. **2023**, 8, 875-883 2

- 136 Chromatin profile-based identification of a novel ER-positive breast cancer subgroup with reduced ER-responsive element accessibility. **2023**, 128, 1208-1222 ○
- 135 EstroGene database reveals diverse temporal, context-dependent and directional estrogen receptor regulomes in breast cancer. ○
- 134 Pan-cancer molecular subtypes of metastasis reveal distinct and evolving transcriptional programs. **2023**, 4, 100932 1
- 133 Lactate from glycolysis regulates inflammatory macrophage polarization in breast cancer. ○
- 132 Molecular genetic clusters of triple-negative breast cancer and their prognostic significance. **2023**, 104, 198-206 ○
- 131 Metastatic Breast Cancer to the Spine: Incidence of Somatic Gene Alterations and Association of Targeted Therapies With Overall Survival. **2023**, Publish Ahead of Print, ○
- 130 Docking and Molecular Dynamics Simulation Revealed the Potential Inhibitory Activity of Amygdalin in Triple-Negative Breast Cancer Therapeutics Targeting the BRCT Domain of BARD1 Receptor. ○
- 129 Integrating multi-type aberrations from DNA and RNA through dynamic mapping gene space for subtype-specific breast cancer driver discovery. 11, e14843 ○
- 128 Type of adjuvant endocrine therapy and disease-free survival in patients with early HR-positive/HER2-positive BC: analysis from the phase III randomized ShortHER trial. **2023**, 9, ○
- 127 The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies. **2023**, 24, 3226 ○
- 126 Evaluation of PIK3CA mutations in advanced ER+/HER2-breast cancer in Portugal \square -PIK Project. 10, ○
- 125 AXL upregulates c-Myc expression through AKT and ERK signaling pathways in breast cancers. **2023**, 18, ○
- 124 Parallelized multidimensional analytic framework applied to mammary epithelial cells uncovers regulatory principles in EMT. **2023**, 14, ○
- 123 MiR-4521 perturbs FOXM1-mediated DNA damage response in breast cancer. ○
- 122 Chemoresistome Mapping in Individual Breast Cancer Patients Unravels Diversity in Dynamic Transcriptional Adaptation. ○
- 121 PCDHA1 High Expression is Associated With Poor Prognosis and Correlated With Immune Cell Infiltration in Breast Cancer. **2023**, ○
- 120 DNMT3a-dermatopontin axis suppresses breast cancer malignancy via inactivating YAP. **2023**, 14, ○
- 119 c-MYC-Induced AP4 Attenuates DREAM-Mediated Repression by p53. **2023**, 15, 1162 ○

| | | |
|-----|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---|
| 118 | Unravelling homologous recombination repair deficiency and therapeutic opportunities in soft tissue and bone sarcoma. 2023 , 15, | 1 |
| 117 | Targeting CXCR4 abrogates resistance to trastuzumab by blocking cell cycle progression and synergizes with docetaxel in breast cancer treatment. | 0 |
| 116 | Case report: Response to endocrine therapy in triple-negative breast cancer metastases with altered hormone receptors. 13, | 0 |
| 115 | Lessons from other fields of medicine, Part 1: Breast cancer. 2023 , 101-118 | 0 |
| 114 | Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression. 2023 , 133, | 0 |
| 113 | How I treat endocrine-dependent metastatic breast cancer. 2023 , 8, 100882 | 0 |
| 112 | Tumor-Derived Oxidative Stress Triggers Ovarian Follicle Loss in Breast Cancer. 2023 , 193, 608-623 | 0 |
| 111 | Discovery of multi-state gene cluster switches determining the adaptive mitochondrial and metabolic landscape of breast cancer. | 0 |
| 110 | Excellent response to olaparib in metastatic HR-positive, HER2-negative breast cancer with BRIP1 mutation. 2023 , 34, 315-318 | 0 |
| 109 | Targeted Therapy and Mechanisms of Drug Resistance in Breast Cancer. 2023 , 15, 1320 | 0 |
| 108 | The prognostic value of tumor mutation burden (TMB) and its relationship with immune infiltration in breast cancer patients. 2023 , 28, | 0 |
| 107 | Characteristics and Prognosis of 8p11.23-Amplified Squamous Lung Carcinomas. 2023 , 12, 1711 | 0 |
| 106 | Wnt/ β -catenin signaling within multiple cell types dependent upon β -catenin regulates Drosophila intestinal stem cell proliferation. | 0 |
| 105 | Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment. 2023 , 42, 1117-1131 | 0 |
| 104 | Unlocking the Resistance to Anti-HER2 Treatments in Breast Cancer: The Issue of HER2 Spatial Distribution. 2023 , 15, 1385 | 0 |
| 103 | Single-cell dissection reveals the role of DNA damage response patterns in tumor microenvironment components contributing to colorectal cancer progression and immunotherapy. | 0 |
| 102 | The Relationship between PIK3CA Mutation and Hormone Receptor Positive and HER2 Negative Breast Cancer. 2023 , 13, 2724-2728 | 0 |
| 101 | Comprehensive analysis of the prognosis of S100 family members and their relationship with tumor-infiltrating immune cells in human pancreatic adenocarcinoma. 2023 , 102, e32976 | 0 |

- 100 Cross-platform normalization enables machine learning model training on microarray and RNA-seq data simultaneously. **2023**, 6, ○
- 99 Deep learning predicts HRD and platinum response from histology slides in breast and ovarian cancer. ○
- 98 Proteomic profiling and its applications in cancer research. **2023**, 121-153 ○
- 97 Drugging the PI3K/AKT/mTOR Pathway in ER+ Breast Cancer. **2023**, 24, 4522 ○
- 96 A Clinical Study of Cases in which <i>BRCA1/2</i> Genetic Tests were Performed after Insurance Coverage as Additional Indication and Future Problems. **2022**, 83, 1381-1392 ○
- 95 CRISPR/Cas9 screen uncovers functional translation of cryptic lncRNA-encoded open reading frames in human cancer. **2023**, 133, 1
- 94 Contrast subgraphs allow comparing homogeneous and heterogeneous networks derived from omics data. **2022**, 12, ○
- 93 Biochemical Studies of Systemic Lupus Erythematosus-Associated Mutations in Nonreceptor Tyrosine Kinases Ack1 and Brk. **2023**, 62, 1124-1137 ○
- 92 ANKLE1 cleaves mitochondrial DNA and contributes to cancer risk by promoting apoptosis resistance and metabolic dysregulation. **2023**, 6, ○
- 91 Identification of Kinase Targets for Enhancing the Antitumor Activity of Eribulin in Triple-Negative Breast Cell Lines. **2023**, 11, 735 ○
- 90 Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer. **2023**, 14, ○
- 89 Hereditary Breast Cancer and Pathogenic Germline Variants. **2023**, 45-59 ○
- 88 Molecular Profiling in Early ER + Breast Cancer to Aid Systemic Therapy Decisions. **2023**, 25, 491-500 ○
- 87 Notch3 regulates Mybl2 via HeyL to limit proliferation and tumor initiation in breast cancer. **2023**, 14, ○
- 86 Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification. ○
- 85 DNA methylation patterns associated with breast cancer prognosis that are specific to tumor subtype and menopausal status. 14, ○
- 84 Cdk4/Cdk6 Dysregulation in Estrogen-Positive Receptor Breast Cancers. **2023**, 211-232 ○
- 83 CDKs in Cell-Cycle Progression and Therapeutic Strategies in Human Breast Cancer. **2023**, 291-311 ○

- 82 CDK1 Dysregulation in Breast Cancer. **2023**, 195-210
- 81 Magnetic resonance imaging-based radiomics assesses the level of immune cell infiltration in the breast cancer tumor microenvironment.
- 80 Mechanisms of Resistance to CDK4/6 Inhibitors and Predictive Biomarkers of Response in HR+/HER2-Metastatic Breast Cancer: A Review of the Literature. **2023**, 13, 987
- 79 Human basal-like breast cancer is represented by one of the two mammary tumor subtypes in dogs.
- 78 Psychotic disorders as a framework for precision psychiatry.
- 77 Discovering Synergistic Compounds with BYL-719 in PI3K Overactivated Basal-like PDXs. **2023**, 15, 1582
- 76 Intercellular hif1 α reprograms mammary progenitors and myeloid immune evasion to drive high-risk breast lesions. **2023**, 133,
- 75 Overexpression of CHAF1A is associated with poor prognosis, tumor immunosuppressive microenvironment and treatment resistance. 14,
- 74 ER +, HER2 \pm advanced breast cancer treated with tasisib and fulvestrant: genomic landscape and associated clinical outcomes.
- 73 A degradome-based prognostic signature that correlates with immune infiltration and tumor mutation burden in breast cancer. 14,
- 72 The construction and analysis of a prognostic assessment model based on P53-related multi-genes in breast carcinoma. Publish Ahead of Print,
- 71 Genomics of Breast Cancer Brain Metastases: A Meta-Analysis and Therapeutic Implications. **2023**, 15, 1728
- 70 The role of Th-17 cells and IL-17 in the metastatic spread of breast cancer: As a means of prognosis and therapeutic target. 14,
- 69 Position paper on CDK4/6 inhibitors in early breast cancer.
- 68 The Hurdle of Precision Medicine in Cancer Immunotherapy: Personalization Now or Then?. **2023**, 1-32
- 67 Prognostic and Predictive Value of LIV1 Expression in Early Breast Cancer and by Molecular Subtype. **2023**, 15, 938
- 66 Prevalence of TP53 gene Pro72Arg (rs1042522) single nucleotide polymorphism among Egyptian breast cancer patients. **2023**, 24,
- 65 PD-1/LAG-3 Dysfunctionality Signatures in Human Cancers.

- 64 Timed hazard networks: Incorporating temporal difference for oncogenetic analysis. **2023**, 18, e0283004 ○
- 63 Statistical Methods for Integrative Clustering of Multi-omics Data. **2023**, 73-93 ○
- 62 Uncommon invasive lobular carcinoma with papillary architecture—clinicopathologic and molecular characterization with review of the literature. ○
- 61 Functional and Phenotypic Characterisations of Common Syngeneic Tumour Cell Lines as Estrogen Receptor-Positive Breast Cancer Models. **2023**, 24, 5666 ○
- 60 HER2 Testing in Breast and Gastric Cancer with CDH1 Germline Mutations. **2023**, 149-165 ○
- 59 Pathology and Somatic Alterations in Hereditary Lobular Breast Cancers. **2023**, 167-180 ○
- 58 Copy number alteration is an independent prognostic biomarker in triple-negative breast cancer patients. ○
- 57 Loss of Kmt2c in vivo leads to EMT, mitochondrial dysfunction and improved response to lapatinib in breast cancer. **2023**, 80, ○
- 56 PIK3CA copy number gain and inhibitors of the PI3K/AKT/mTOR pathway in triple-negative breast cancer. mcs.a006255 ○
- 55 Intratumoral heterogeneity, treatment response, and survival outcome of ER -positive HER2 -positive breast cancer. ○
- 54 Systemic therapy for hormone receptor-positive/human epidermal growth factor receptor 2-negative early stage and metastatic breast cancer. ○
- 53 GE11-antigen-loaded hepatitis B virus core antigen virus-like particles efficiently bind to TNBC tumor. 13, ○
- 52 MiR-4521 perturbs FOXM1-mediated DNA damage response in breast cancer. 10, ○
- 51 Anti-tumor effects of miR -34a by regulating immune cells in the tumor microenvironment. ○
- 50 Disparities in stage at diagnosis among breast cancer molecular subtypes in China. ○
- 49 Performance of a PLK1 -based immune risk model for prognosis and treatment response prediction in breast cancer. ○
- 48 Targeting Mitochondria with ClpP Agonists as a Novel Therapeutic Opportunity in Breast Cancer. **2023**, 15, 1936 ○
- 47 PIK3CA and PIK3R1 tumor mutational landscape in a pan-cancer patient cohort and its association with pathway activation and treatment efficacy. **2023**, 13, ○

- 46 Correlation of androgen receptor with ultrasound, clinicopathological features and clinical outcomes in breast cancer. **2023**, 14, ○
- 45 Understanding Head and Neck Cancer Evolution to Guide Therapeutic Approaches. **2023**, 63-81 ○
- 44 Molecular breast cancer subtype identification using photoacoustic spectral analysis and machine learning at the biomacromolecular level. **2023**, 30, 100483 ○
- 43 The G protein-coupled receptor TBXA2R activates ERMs to promote motility, invasion, and metastasis of triple-negative breast cancer cells. ○
- 42 The Metabolic Landscape of Breast Cancer and Its Therapeutic Implications. ○
- 41 GATA-3 expression in breast cancer is related to intratumoral M2 macrophage infiltration and tumor differentiation. **2023**, 18, e0283003 ○
- 40 LncRNA LITATS1 suppresses TGF- β -induced EMT and cancer cell plasticity by potentiating TR1 degradation. ○
- 39 RRM2 and CDC6 are novel effectors of XBP1-mediated endocrine resistance and predictive markers of tamoxifen sensitivity. **2023**, 23, ○
- 38 Upregulation of the ferroptosis-related STEAP3 gene is a specific predictor of poor triple-negative breast cancer patient outcomes. 13, ○
- 37 Somatic Super-Enhancer Epigenetic Signature for Overall Survival Prediction in Patients with Breast Invasive Carcinoma. **2023**, 17, 117793222311627 ○
- 36 Crosstalk between triple negative breast cancer and microenvironment. **2023**, 14, 284-293 ○
- 35 A mass balance study of [14C]SHR6390 (dalpiciclib), a selective and potent CDK4/6 inhibitor in humans. 14, ○
- 34 Comprehensive analysis of glycolysis mediated pattern clusters and immune infiltration characterization of tumor microenvironment in triple-negative breast cancer. **2023**, 9, e15175 ○
- 33 Advances in Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer. ○
- 32 Kernelized multiview signed graph learning for single-cell RNA sequencing data. **2023**, 24, ○
- 31 Molecular landscape and emerging therapeutic strategies in breast cancer brain metastasis. **2023**, 15, 175883592311659 ○
- 30 The prognostic value and biological functions of HFM1 in breast cancer. ○
- 29 Machine learning-based somatic variant calling in cell-free DNA of metastatic breast cancer patients using large NGS panels. ○

- 28 Proteolysis Targeting Chimera (PROTAC) as a promising novel therapeutic modality for the treatment of triple-negative breast cancer (TNBC). ○
- 27 The Role of RNA Epitranscriptomics and the RNA Fat Mass and Obesity-Associated Demethylase in Triple Negative Breast Cancer. **2023**, 12, 27-50 ○
- 26 Pertuzumab Plus Trastuzumab in Patients With Endometrial Cancer With ERBB2/3 Amplification, Overexpression, or Mutation: Results From the TAPUR Study. **2023**, ○
- 25 Recent Advances with Precision Medicine Treatment for Breast Cancer including Triple-Negative Sub-Type. **2023**, 15, 2204 ○
- 24 The role of LIN28B in tumor progression and metastasis in solid tumor entities. **2023**, 31, 101-115 ○
- 23 Advances in pharmacotherapies that target the cell cycle for treatment of breast cancer: where are we at today?. 1-14 ○
- 22 N-acetylcysteine overcomes NF1 loss-driven resistance to PI3K inhibition in breast cancer. **2023**, 4, 101002 ○
- 21 Multi-omic molecular profiling and network biology for precision anaesthesiology: a narrative review. **2023**, ○
- 20 Learning Vector Quantized Representation for Cancer Subtypes Identification. **2023**, 107543 ○
- 19 Breast cancer patient-derived microtumors resemble tumor heterogeneity and enable protein-based stratification and functional validation of individualized drug treatment. ○
- 18 Accelerating the understanding of cancer biology through the lens of genomics. **2023**, 186, 1755-1771 ○
- 17 Cancer heterogeneity is defined by normal cellular trade-offs. ○
- 16 BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience. 13, ○
- 15 How valuable can proteogenomics be in clinical breast cancer research?. 1-4 ○
- 14 Ensembles for improved detection of invasive breast cancer in histological images. ○
- 13 Ca²⁺/Calmodulin Dependent Protein Kinase Kinase-2 (CaMKK2) promotes Protein Kinase G (PKG)-dependent actin cytoskeletal assembly to increase tumor metastasis. ○
- 12 PRR15 deficiency facilitates malignant progression by mediating PI3K/Akt signaling and predicts clinical prognosis in triple-negative rather than non-triple-negative breast cancer. **2023**, 14, ○
- 11 Aspects biologiques, précliniques et cliniques de l'association de radiothérapie et d'inhibiteur de CDK 4/6. **2023**, ○

- 10 COMMD3 loss drives invasive breast cancer growth by modulating copper homeostasis. **2023**, 42,
- 9 Metaplastic Breast Cancer: Current Understanding and Future Directions. **2023**,
- 8 PI3K β controls immune evasion in PTEN-deficient breast tumours.
- 7 Comprehensive genomic evaluation of advanced and recurrent breast cancer patients for tailored precision treatments.
- 6 Defining triple-negative breast cancer with neuroendocrine differentiation (TNBC-NED).
- 5 Can Patients with HER2-Low Breast Cancer Benefit from Anti-HER2 Therapies? A Review. Volume 15, 281-294
- 4 Identification of circulating tumour DNA (ctDNA) from the liquid biopsy results: Findings from an observational cohort study. **2023**, 35, 100701
- 3 Beyond Skin Rash: Alpelisib-Induced Anaphylactic Reactions.
- 2 Characterization of clinicopathological features, treatment practices, and outcomes among Finnish advanced breast cancer patients in real-life clinical practice.
- 1 General aspects of cancer therapy. **2023**, 1-35